{"PMC7261809": [["General Concept ::: IntroductionIt has been shown that different pro-inflammatory cytokines such as interleukin\ufeff-1\u03b2 (IL-1\u03b2), IL-6, and tumor necrosis factor\ufeff-\u03b1 (TNF-\u03b1) are involved in both term and preterm labor.", [["necrosis", "DISEASE", 141, 149], ["preterm labor", "DISEASE", 198, 211], ["interleukin\ufeff-1\u03b2", "GENE_OR_GENE_PRODUCT", 100, 115], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 117, 122], ["IL-6", "GENE_OR_GENE_PRODUCT", 125, 129], ["tumor necrosis factor\ufeff-\u03b1", "GENE_OR_GENE_PRODUCT", 135, 159], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 161, 166], ["pro-inflammatory cytokines", "PROTEIN", 65, 91], ["interleukin\ufeff-1\u03b2 (IL-1\u03b2", "PROTEIN", 100, 122], ["IL-6", "PROTEIN", 125, 129], ["tumor necrosis factor\ufeff-\u03b1", "PROTEIN", 135, 159], ["TNF-\u03b1", "PROTEIN", 161, 166], ["different pro-inflammatory cytokines", "PROBLEM", 55, 91], ["interleukin\ufeff", "TEST", 100, 112], ["IL", "TEST", 117, 119], ["IL", "TEST", 125, 127], ["tumor necrosis factor\ufeff", "PROBLEM", 135, 157], ["preterm labor", "PROBLEM", 198, 211], ["tumor necrosis", "OBSERVATION", 135, 149], ["preterm labor", "OBSERVATION", 198, 211]]], ["The mentioned cytokines trigger the production of uterine activation proteins and chemokines, and therefore cause preterm parturition.24,25 As would be discussed, using some antibiotics in the absence of bacterial infection increases release of pro-inflammatory cytokines such as IL-1, IL-6, and TNF-\u03b1, all being capable of inducing preterm parturition through different pathways.", [["uterine", "ANATOMY", 50, 57], ["preterm parturition", "DISEASE", 114, 133], ["infection", "DISEASE", 214, 223], ["uterine activation proteins", "GENE_OR_GENE_PRODUCT", 50, 77], ["IL-1", "GENE_OR_GENE_PRODUCT", 280, 284], ["IL-6", "GENE_OR_GENE_PRODUCT", 286, 290], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 296, 301], ["cytokines", "PROTEIN", 14, 23], ["uterine activation proteins", "PROTEIN", 50, 77], ["chemokines", "PROTEIN", 82, 92], ["pro-inflammatory cytokines", "PROTEIN", 245, 271], ["IL-1, IL-6", "PROTEIN", 280, 290], ["TNF", "PROTEIN", 296, 299], ["The mentioned cytokines", "TREATMENT", 0, 23], ["uterine activation proteins", "TREATMENT", 50, 77], ["chemokines", "TREATMENT", 82, 92], ["preterm parturition", "PROBLEM", 114, 133], ["some antibiotics", "TREATMENT", 169, 185], ["bacterial infection", "PROBLEM", 204, 223], ["pro-inflammatory cytokines", "TREATMENT", 245, 271], ["IL", "TEST", 280, 282], ["preterm parturition", "PROBLEM", 333, 352], ["uterine", "ANATOMY", 50, 57], ["bacterial", "OBSERVATION_MODIFIER", 204, 213], ["infection", "OBSERVATION", 214, 223], ["pro-inflammatory cytokines", "OBSERVATION", 245, 271]]], ["Moreover, the cytokine release could be amplified by antibiotic-induced endotoxemia through activation of Toll-like receptors (TLRs).", [["endotoxemia", "DISEASE", 72, 83], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 106, 125], ["TLRs", "GENE_OR_GENE_PRODUCT", 127, 131], ["cytokine", "PROTEIN", 14, 22], ["Toll-like receptors", "PROTEIN", 106, 125], ["TLRs", "PROTEIN", 127, 131], ["the cytokine release", "TREATMENT", 10, 30], ["antibiotic", "TREATMENT", 53, 63]]], ["Thus, consumption of non-indicated antibiotics for non-infected pregnant women, especially those more prone to preterm parturition, may increase the risk of preterm parturition.Interleukin-1 ::: Pro-Inflammatory Cytokines and Preterm Labor ::: IntroductionIL-1\u03b2 is one of the most important members of the IL-1 family26 with affinity to its receptors; IL-1R1 and IL-1R2.26,27 As a major mediator of inflammation, IL-1\u03b2 is involved in different disorders such as infections, autoimmune, and degenerative diseases which affect a wide variety of organs and cells.", [["organs", "ANATOMY", 543, 549], ["cells", "ANATOMY", 554, 559], ["preterm parturition", "DISEASE", 111, 130], ["preterm parturition", "DISEASE", 157, 176], ["inflammation", "DISEASE", 399, 411], ["infections", "DISEASE", 462, 472], ["degenerative diseases", "DISEASE", 490, 511], ["women", "ORGANISM", 73, 78], ["Interleukin-1", "GENE_OR_GENE_PRODUCT", 177, 190], ["IntroductionIL-1\u03b2", "GENE_OR_GENE_PRODUCT", 244, 261], ["IL-1 family26", "GENE_OR_GENE_PRODUCT", 306, 319], ["IL-1R1", "GENE_OR_GENE_PRODUCT", 352, 358], ["IL-1R2.26,27", "GENE_OR_GENE_PRODUCT", 363, 375], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 413, 418], ["organs", "ORGAN", 543, 549], ["cells", "CELL", 554, 559], ["Interleukin-1", "PROTEIN", 177, 190], ["Pro-Inflammatory Cytokines", "PROTEIN", 195, 221], ["IntroductionIL-1\u03b2", "PROTEIN", 244, 261], ["IL-1 family26", "PROTEIN", 306, 319], ["IL", "PROTEIN", 352, 354], ["1R1", "PROTEIN", 355, 358], ["IL", "PROTEIN", 363, 365], ["IL-1\u03b2", "PROTEIN", 413, 418], ["women", "SPECIES", 73, 78], ["non-indicated antibiotics", "TREATMENT", 21, 46], ["preterm parturition", "PROBLEM", 157, 176], ["Pro-Inflammatory Cytokines", "PROBLEM", 195, 221], ["Preterm Labor", "PROBLEM", 226, 239], ["IntroductionIL", "TREATMENT", 244, 258], ["IL", "TEST", 352, 354], ["inflammation", "PROBLEM", 399, 411], ["different disorders", "PROBLEM", 434, 453], ["infections", "PROBLEM", 462, 472], ["autoimmune", "PROBLEM", 474, 484], ["degenerative diseases", "PROBLEM", 490, 511], ["preterm parturition", "OBSERVATION", 157, 176], ["Pro-Inflammatory Cytokines", "OBSERVATION", 195, 221], ["inflammation", "OBSERVATION", 399, 411], ["infections", "OBSERVATION", 462, 472], ["degenerative", "OBSERVATION_MODIFIER", 490, 502], ["diseases", "OBSERVATION", 503, 511]]], ["IL-1\u03b2 expresses from hematopoietic cells such as macrophages, monocytes, microglia, and dendritic cells.", [["hematopoietic cells", "ANATOMY", 21, 40], ["macrophages", "ANATOMY", 49, 60], ["monocytes", "ANATOMY", 62, 71], ["microglia", "ANATOMY", 73, 82], ["dendritic cells", "ANATOMY", 88, 103], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 0, 5], ["hematopoietic cells", "CELL", 21, 40], ["macrophages", "CELL", 49, 60], ["monocytes", "CELL", 62, 71], ["microglia", "CELL", 73, 82], ["dendritic cells", "CELL", 88, 103], ["IL-1\u03b2", "PROTEIN", 0, 5], ["hematopoietic cells", "CELL_TYPE", 21, 40], ["macrophages", "CELL_TYPE", 49, 60], ["monocytes", "CELL_TYPE", 62, 71], ["microglia", "CELL_TYPE", 73, 82], ["dendritic cells", "CELL_TYPE", 88, 103], ["IL", "TREATMENT", 0, 2], ["hematopoietic cells", "PROBLEM", 21, 40], ["macrophages", "PROBLEM", 49, 60], ["monocytes", "TEST", 62, 71], ["microglia", "PROBLEM", 73, 82], ["dendritic cells", "PROBLEM", 88, 103], ["hematopoietic cells", "OBSERVATION", 21, 40], ["macrophages", "ANATOMY", 49, 60], ["monocytes", "ANATOMY", 62, 71], ["microglia", "ANATOMY", 73, 82], ["dendritic cells", "OBSERVATION", 88, 103]]], ["This pro-inflammatory cytokine produces from the mentioned resources through different pathways such as TLR activation and pro-inflammatory cytokine activities (such as TNF-\u03b1 and even IL-1\u03b2 itself).27 IL-1\u03b2 is the first known pro-inflammatory cytokine involved in preterm parturition produced following the release of different other cytokines including TNF-\u03b1, IL-1\u03b1, and IL-1\u03b2 itself.25 The role of IL-1\u03b2 during parturition has been proved by being detected in the myometrium, cervix, and fetal membranes,28 especially in non-infective preterm parturition.29 In an invivo study in mice, it was shown that IL-1\u03b2 administration induces premature contractility of the myometrium.30 Moreover, in-vivo studies have determined that the administration of IL-1\u03b2 could induce preterm labor which, by the way, could be prevented using the antagonist of IL-1 receptor.31,32 Beside term parturition, studies have evaluated the role of IL-1\u03b2 in preterm labor.", [["myometrium", "ANATOMY", 466, 476], ["cervix", "ANATOMY", 478, 484], ["fetal membranes", "ANATOMY", 490, 505], ["myometrium", "ANATOMY", 666, 676], ["preterm parturition", "DISEASE", 537, 556], ["preterm labor", "DISEASE", 768, 781], ["preterm labor", "DISEASE", 933, 946], ["TLR", "GENE_OR_GENE_PRODUCT", 104, 107], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 169, 174], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 184, 189], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 201, 206], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 354, 359], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 361, 366], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 372, 377], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 400, 405], ["myometrium", "MULTI-TISSUE_STRUCTURE", 466, 476], ["cervix", "MULTI-TISSUE_STRUCTURE", 478, 484], ["fetal membranes", "MULTI-TISSUE_STRUCTURE", 490, 505], ["mice", "ORGANISM", 582, 586], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 606, 611], ["myometrium", "MULTI-TISSUE_STRUCTURE", 666, 676], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 749, 754], ["IL-1 receptor", "GENE_OR_GENE_PRODUCT", 844, 857], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 924, 929], ["pro-inflammatory cytokine", "PROTEIN", 5, 30], ["TLR", "PROTEIN", 104, 107], ["pro-inflammatory cytokine", "PROTEIN", 123, 148], ["TNF", "PROTEIN", 169, 172], ["\u03b1", "PROTEIN", 173, 174], ["IL", "PROTEIN", 184, 186], ["\u03b2", "PROTEIN", 188, 189], ["IL-1\u03b2", "PROTEIN", 201, 206], ["pro-inflammatory cytokine", "PROTEIN", 226, 251], ["cytokines", "PROTEIN", 334, 343], ["TNF", "PROTEIN", 354, 357], ["IL-1\u03b1", "PROTEIN", 361, 366], ["IL-1\u03b2", "PROTEIN", 372, 377], ["IL-1\u03b2", "PROTEIN", 400, 405], ["IL-1\u03b2", "PROTEIN", 606, 611], ["IL-1\u03b2", "PROTEIN", 749, 754], ["IL-1 receptor", "PROTEIN", 844, 857], ["IL-1\u03b2", "PROTEIN", 924, 929], ["mice", "SPECIES", 582, 586], ["mice", "SPECIES", 582, 586], ["TLR activation", "TREATMENT", 104, 118], ["pro-inflammatory cytokine activities", "PROBLEM", 123, 159], ["TNF", "TEST", 169, 172], ["even IL", "TREATMENT", 179, 186], ["preterm parturition", "PROBLEM", 264, 283], ["different other cytokines", "TREATMENT", 318, 343], ["TNF", "TREATMENT", 354, 357], ["IL", "TREATMENT", 361, 363], ["non-infective preterm parturition", "PROBLEM", 523, 556], ["an invivo study", "TEST", 563, 578], ["IL-1\u03b2 administration", "TREATMENT", 606, 626], ["premature contractility of the myometrium", "PROBLEM", 635, 676], ["the administration of IL", "TREATMENT", 727, 751], ["preterm labor", "PROBLEM", 768, 781], ["the antagonist of IL", "TREATMENT", 826, 846], ["Beside term parturition", "PROBLEM", 864, 887], ["preterm labor", "PROBLEM", 933, 946], ["pro-inflammatory cytokine", "OBSERVATION", 123, 148], ["pro-inflammatory cytokine", "OBSERVATION", 226, 251], ["myometrium", "ANATOMY", 466, 476], ["cervix", "ANATOMY", 478, 484], ["fetal membranes", "ANATOMY", 490, 505], ["myometrium", "ANATOMY", 666, 676], ["preterm labor", "OBSERVATION", 933, 946]]], ["According to the data, the IL-1\u03b2 concentration was increased in amniotic fluid (AF)33,34 and plasma35 of women with preterm labor.", [["amniotic fluid", "ANATOMY", 64, 78], ["preterm labor", "DISEASE", 116, 129], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 27, 32], ["amniotic fluid", "ORGANISM_SUBSTANCE", 64, 78], ["women", "ORGANISM", 105, 110], ["IL-1\u03b2", "PROTEIN", 27, 32], ["women", "SPECIES", 105, 110], ["the IL-1\u03b2 concentration", "TREATMENT", 23, 46], ["amniotic fluid", "TEST", 64, 78], ["preterm labor", "PROBLEM", 116, 129], ["increased", "OBSERVATION_MODIFIER", 51, 60], ["amniotic fluid", "OBSERVATION", 64, 78]]], ["Also, systemic administration of IL-1\u03b2 in pregnant rhesus monkeys was also proven to stimulate the uterine contractility as well as significantly increase the production of other pro-inflammatory cytokines such as IL-6 and TNF-\u03b1 along with different prostaglandins (PGs) including PGF2\u03b1 and PGE2.36 PGF2\u03b1, on the other hand, has been introduced as the most potent contractile prostanoid in parturition which acts through its receptor, PGF receptor (PTGFR).37 Furthermore, IL-1\u03b2 is able to activate prostaglandin H synthase 2 (PGHS-2; also known as cyclooxygenase-2 or COX-2) which is responsible for the synthesis of prostaglandins.38\u201340 As it has been shown, IL-1\u03b2 (targeting amnion epithelial cells) is able to increase matrix metalloproteinase\ufeff-9 (MMP-9) expression which leads to degradation of the amniochorionic membrane as well as cervical ripening.41Tumor Necrosis Factor-\u03b1 ::: Pro-Inflammatory Cytokines and Preterm Labor ::: IntroductionTNF-\u03b1 is a pro-inflammatory cytokine belonging to the TNF superfamily which couples to its specific receptors: TNF receptor-1 (TNFR1 or p55) and TNFR2 (p75).", [["uterine", "ANATOMY", 99, 106], ["amnion epithelial cells", "ANATOMY", 677, 700], ["amniochorionic membrane", "ANATOMY", 803, 826], ["cervical", "ANATOMY", 838, 846], ["prostaglandins", "CHEMICAL", 250, 264], ["PGs", "CHEMICAL", 266, 269], ["PGF2", "CHEMICAL", 281, 285], ["PGE2", "CHEMICAL", 291, 295], ["PGF2\u03b1", "CHEMICAL", 299, 304], ["prostaglandin H", "CHEMICAL", 498, 513], ["prostaglandins", "CHEMICAL", 617, 631], ["prostaglandins", "CHEMICAL", 250, 264], ["PGF2\u03b1", "CHEMICAL", 281, 286], ["PGE2", "CHEMICAL", 291, 295], ["PGF2\u03b1", "CHEMICAL", 299, 304], ["prostaglandin H", "CHEMICAL", 498, 513], ["prostaglandins", "CHEMICAL", 617, 631], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 33, 38], ["rhesus", "ORGANISM", 51, 57], ["monkeys", "ORGANISM", 58, 65], ["uterine", "ORGAN", 99, 106], ["IL-6", "GENE_OR_GENE_PRODUCT", 214, 218], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 223, 228], ["prostaglandins", "SIMPLE_CHEMICAL", 250, 264], ["PGs", "SIMPLE_CHEMICAL", 266, 269], ["PGF2\u03b1", "SIMPLE_CHEMICAL", 281, 286], ["PGE2.36 PGF2\u03b1", "SIMPLE_CHEMICAL", 291, 304], ["PGF receptor", "GENE_OR_GENE_PRODUCT", 435, 447], ["PTGFR", "GENE_OR_GENE_PRODUCT", 449, 454], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 472, 477], ["prostaglandin H synthase 2", "GENE_OR_GENE_PRODUCT", 498, 524], ["PGHS-2", "GENE_OR_GENE_PRODUCT", 526, 532], ["cyclooxygenase-2", "GENE_OR_GENE_PRODUCT", 548, 564], ["COX-2", "GENE_OR_GENE_PRODUCT", 568, 573], ["prostaglandins", "SIMPLE_CHEMICAL", 617, 631], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 660, 665], ["amnion epithelial cells", "CELL", 677, 700], ["matrix metalloproteinase\ufeff-9", "GENE_OR_GENE_PRODUCT", 722, 749], ["MMP-9", "GENE_OR_GENE_PRODUCT", 751, 756], ["amniochorionic membrane", "CELLULAR_COMPONENT", 803, 826], ["cervical", "ORGAN", 838, 846], ["IntroductionTNF-\u03b1", "GENE_OR_GENE_PRODUCT", 935, 952], ["TNF", "GENE_OR_GENE_PRODUCT", 1001, 1004], ["TNF receptor-1", "GENE_OR_GENE_PRODUCT", 1058, 1072], ["TNFR1", "GENE_OR_GENE_PRODUCT", 1074, 1079], ["p55", "GENE_OR_GENE_PRODUCT", 1083, 1086], ["TNFR2", "GENE_OR_GENE_PRODUCT", 1092, 1097], ["p75", "GENE_OR_GENE_PRODUCT", 1099, 1102], ["IL-1\u03b2", "PROTEIN", 33, 38], ["pro-inflammatory cytokines", "PROTEIN", 179, 205], ["IL-6", "PROTEIN", 214, 218], ["TNF", "PROTEIN", 223, 226], ["PGF receptor", "PROTEIN", 435, 447], ["PTGFR", "PROTEIN", 449, 454], ["IL-1\u03b2", "PROTEIN", 472, 477], ["prostaglandin H synthase 2", "PROTEIN", 498, 524], ["PGHS-2", "PROTEIN", 526, 532], ["cyclooxygenase", "PROTEIN", 548, 562], ["COX", "PROTEIN", 568, 571], ["IL-1\u03b2", "PROTEIN", 660, 665], ["amnion epithelial cells", "CELL_TYPE", 677, 700], ["matrix metalloproteinase\ufeff-9 (MMP-9", "PROTEIN", 722, 756], ["Pro-Inflammatory Cytokines", "PROTEIN", 886, 912], ["IntroductionTNF-\u03b1", "PROTEIN", 935, 952], ["pro-inflammatory cytokine", "PROTEIN", 958, 983], ["TNF superfamily", "PROTEIN", 1001, 1016], ["TNF receptor-1", "PROTEIN", 1058, 1072], ["TNFR1", "PROTEIN", 1074, 1079], ["p55", "PROTEIN", 1083, 1086], ["TNFR2", "PROTEIN", 1092, 1097], ["p75", "PROTEIN", 1099, 1102], ["rhesus monkeys", "SPECIES", 51, 65], ["rhesus monkeys", "SPECIES", 51, 65], ["systemic administration of IL", "TREATMENT", 6, 35], ["other pro-inflammatory cytokines", "PROBLEM", 173, 205], ["IL", "TEST", 214, 216], ["TNF", "TEST", 223, 226], ["different prostaglandins (PGs", "TREATMENT", 240, 269], ["PGF2", "TREATMENT", 281, 285], ["PGE2", "TREATMENT", 291, 295], ["prostaglandin H synthase", "TEST", 498, 522], ["PGHS", "TEST", 526, 530], ["cyclooxygenase", "TEST", 548, 562], ["COX", "TEST", 568, 571], ["the synthesis of prostaglandins", "TREATMENT", 600, 631], ["IL", "TEST", 660, 662], ["targeting amnion epithelial cells", "TREATMENT", 667, 700], ["matrix metalloproteinase\ufeff", "TEST", 722, 747], ["MMP", "TEST", 751, 754], ["degradation of the amniochorionic membrane", "PROBLEM", 784, 826], ["cervical ripening", "TREATMENT", 838, 855], ["Pro-Inflammatory Cytokines", "PROBLEM", 886, 912], ["Preterm Labor", "PROBLEM", 917, 930], ["a pro-inflammatory cytokine", "TREATMENT", 956, 983], ["the TNF superfamily", "TREATMENT", 997, 1016], ["TNF receptor", "TEST", 1058, 1070], ["TNFR2", "TEST", 1092, 1097], ["uterine", "ANATOMY", 99, 106], ["amnion epithelial", "ANATOMY", 677, 694], ["amniochorionic membrane", "ANATOMY", 803, 826], ["cervical", "ANATOMY", 838, 846], ["Necrosis", "OBSERVATION", 864, 872]]], ["This cytokine has a wide range of activity in different inflammatory and non-inflammatory situations such as cachexia, septic shock, inflammatory disorders, and autoimmune diseases. \ufeffThe same as IL-1\u03b2, TNF-\u03b1 is expressed by different cells such as macrophages, monocytes, dendritic cells, B and T cells, and activated natural killer cells.42,43 Similar to IL-1\u03b2, TNF-\u03b1 is another pro-inflammatory cytokine elevated in AF of women with preterm parturition.33 This cytokine is also involved in the regulation and stimulation of PG synthesis during preterm parturition, such as COX-2.", [["cachexia", "ANATOMY", 109, 117], ["cells", "ANATOMY", 234, 239], ["macrophages", "ANATOMY", 248, 259], ["monocytes", "ANATOMY", 261, 270], ["dendritic cells", "ANATOMY", 272, 287], ["B", "ANATOMY", 289, 290], ["T cells", "ANATOMY", 295, 302], ["natural killer cells", "ANATOMY", 318, 338], ["cachexia", "DISEASE", 109, 117], ["septic shock", "DISEASE", 119, 131], ["inflammatory disorders", "DISEASE", 133, 155], ["autoimmune diseases", "DISEASE", 161, 180], ["AF", "DISEASE", 418, 420], ["preterm parturition", "DISEASE", 435, 454], ["PG", "CHEMICAL", 526, 528], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 195, 200], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 202, 207], ["cells", "CELL", 234, 239], ["macrophages", "CELL", 248, 259], ["monocytes", "CELL", 261, 270], ["dendritic cells", "CELL", 272, 287], ["B", "CELL", 289, 290], ["T cells", "CELL", 295, 302], ["natural killer cells", "CELL", 318, 338], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 356, 361], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 363, 368], ["women", "ORGANISM", 424, 429], ["PG", "SIMPLE_CHEMICAL", 526, 528], ["COX-2", "GENE_OR_GENE_PRODUCT", 575, 580], ["cytokine", "PROTEIN", 5, 13], ["IL-1\u03b2", "PROTEIN", 195, 200], ["TNF-\u03b1", "PROTEIN", 202, 207], ["macrophages", "CELL_TYPE", 248, 259], ["monocytes", "CELL_TYPE", 261, 270], ["dendritic cells", "CELL_TYPE", 272, 287], ["B and T cells", "CELL_TYPE", 289, 302], ["activated natural killer cells", "CELL_TYPE", 308, 338], ["IL", "PROTEIN", 356, 358], ["TNF-\u03b1", "PROTEIN", 363, 368], ["pro-inflammatory cytokine", "PROTEIN", 380, 405], ["cytokine", "PROTEIN", 463, 471], ["COX", "PROTEIN", 575, 578], ["women", "SPECIES", 424, 429], ["different inflammatory and non-inflammatory situations", "PROBLEM", 46, 100], ["cachexia", "PROBLEM", 109, 117], ["septic shock", "PROBLEM", 119, 131], ["inflammatory disorders", "PROBLEM", 133, 155], ["autoimmune diseases", "PROBLEM", 161, 180], ["IL", "TEST", 195, 197], ["TNF", "TEST", 202, 205], ["macrophages", "TEST", 248, 259], ["monocytes", "TEST", 261, 270], ["dendritic cells", "PROBLEM", 272, 287], ["B and T cells", "PROBLEM", 289, 302], ["activated natural killer cells", "PROBLEM", 308, 338], ["IL", "TEST", 356, 358], ["TNF", "TEST", 363, 366], ["another pro-inflammatory cytokine elevated", "PROBLEM", 372, 414], ["preterm parturition", "PROBLEM", 435, 454], ["PG synthesis", "TREATMENT", 526, 538], ["preterm parturition", "PROBLEM", 546, 565], ["wide range", "OBSERVATION_MODIFIER", 20, 30], ["activity", "OBSERVATION_MODIFIER", 34, 42], ["different", "OBSERVATION_MODIFIER", 46, 55], ["inflammatory", "OBSERVATION_MODIFIER", 56, 68], ["non-inflammatory", "OBSERVATION_MODIFIER", 73, 89], ["cachexia", "OBSERVATION", 109, 117], ["septic shock", "OBSERVATION", 119, 131], ["inflammatory", "OBSERVATION_MODIFIER", 133, 145], ["autoimmune diseases", "OBSERVATION", 161, 180], ["macrophages", "ANATOMY", 248, 259], ["dendritic cells", "OBSERVATION", 272, 287], ["natural killer cells", "OBSERVATION", 318, 338], ["preterm parturition", "OBSERVATION", 435, 454]]], ["Also, TNF-\u03b1 and IL-1\u03b2 could decrease levels of chorionic prostaglandin 15-hydroxy dehydrogenase (PGDH) in cultured chorion and placental trophoblast cells.", [["chorion", "ANATOMY", 115, 122], ["placental trophoblast cells", "ANATOMY", 127, 154], ["prostaglandin 15-hydroxy", "CHEMICAL", 57, 81], ["prostaglandin 15-hydroxy", "CHEMICAL", 57, 81], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 6, 11], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 16, 21], ["chorionic prostaglandin 15-hydroxy dehydrogenase", "GENE_OR_GENE_PRODUCT", 47, 95], ["PGDH", "GENE_OR_GENE_PRODUCT", 97, 101], ["chorion", "CELL", 115, 122], ["placental trophoblast cells", "CELL", 127, 154], ["TNF", "PROTEIN", 6, 9], ["IL-1\u03b2", "PROTEIN", 16, 21], ["chorionic prostaglandin 15-hydroxy dehydrogenase", "PROTEIN", 47, 95], ["PGDH", "PROTEIN", 97, 101], ["placental trophoblast cells", "CELL_TYPE", 127, 154], ["TNF", "TEST", 6, 9], ["IL", "TEST", 16, 18], ["chorionic prostaglandin", "PROBLEM", 47, 70], ["hydroxy dehydrogenase (PGDH)", "PROBLEM", 74, 102], ["cultured chorion and placental trophoblast cells", "PROBLEM", 106, 154], ["placental trophoblast cells", "OBSERVATION", 127, 154]]], ["PGDH could inactivate the PGs through catalyzing them to natural substances.24 Moreover, it has been shown that topical administration of TNF-\u03b1 could stimulate cervical ripening.25 According to the data, knockout mice lacking receptors for both IL-1\u03b2 and TNF-\u03b1 had a significantly lower rate of preterm labor following intrauterine inoculation of killed Escherichia coli (E.\ufeffcoli) in comparison to the wild types.", [["cervical", "ANATOMY", 160, 168], ["intrauterine", "ANATOMY", 319, 331], ["PGDH", "CHEMICAL", 0, 4], ["TNF-\u03b1", "CHEMICAL", 138, 143], ["preterm labor", "DISEASE", 295, 308], ["PGDH", "CHEMICAL", 0, 4], ["PGDH", "SIMPLE_CHEMICAL", 0, 4], ["PGs", "SIMPLE_CHEMICAL", 26, 29], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 138, 143], ["cervical", "ORGAN", 160, 168], ["mice", "ORGANISM", 213, 217], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 245, 250], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 255, 260], ["intrauterine", "IMMATERIAL_ANATOMICAL_ENTITY", 319, 331], ["Escherichia coli", "ORGANISM", 354, 370], ["E.\ufeffcoli", "ORGANISM", 372, 379], ["TNF", "PROTEIN", 138, 141], ["IL-1\u03b2", "PROTEIN", 245, 250], ["TNF", "PROTEIN", 255, 258], ["mice", "SPECIES", 213, 217], ["Escherichia coli", "SPECIES", 354, 370], ["mice", "SPECIES", 213, 217], ["Escherichia coli", "SPECIES", 354, 370], ["PGDH", "PROBLEM", 0, 4], ["topical administration of TNF", "TREATMENT", 112, 141], ["cervical ripening", "PROBLEM", 160, 177], ["TNF", "PROBLEM", 255, 258], ["preterm labor", "PROBLEM", 295, 308], ["intrauterine inoculation", "PROBLEM", 319, 343], ["killed Escherichia coli (E.\ufeffcoli", "PROBLEM", 347, 379], ["cervical", "ANATOMY", 160, 168], ["Escherichia coli", "OBSERVATION", 354, 370]]], ["This result was accompanied by lower levels of COX-2 in the myometrial tissue in the knockout group in comparison to the controls.44 As it has been studied, inhibiting COX-2 in mice is associated with the prevention of inflammation-induced preterm parturition.45 Furthermore, in a study on rhesus monkeys, the release of bacterial-induced TNF-\u03b1 and IL-1\u03b2 led to more uterine contractility.46 Like IL-1\u03b2, TNF-\u03b1 could increase MMP-9 activity, expression, and activity and secretion in trophoblast, chorion cells, and amnion cells, respectively.41 Moreover, it has been shown that TNF-\u03b1 could induce mRNA expression of MMP-1, MMP-3, and MMP-9 in cervical smooth muscle cells after 24\u201348 h of administration.", [["myometrial tissue", "ANATOMY", 60, 77], ["uterine", "ANATOMY", 367, 374], ["trophoblast", "ANATOMY", 483, 494], ["chorion cells", "ANATOMY", 496, 509], ["amnion cells", "ANATOMY", 515, 527], ["cervical smooth muscle cells", "ANATOMY", 643, 671], ["inflammation", "DISEASE", 219, 231], ["preterm parturition", "DISEASE", 240, 259], ["COX-2", "GENE_OR_GENE_PRODUCT", 47, 52], ["myometrial tissue", "TISSUE", 60, 77], ["COX-2", "GENE_OR_GENE_PRODUCT", 168, 173], ["mice", "ORGANISM", 177, 181], ["rhesus", "ORGANISM", 290, 296], ["monkeys", "ORGANISM", 297, 304], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 339, 344], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 349, 354], ["uterine", "ORGAN", 367, 374], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 397, 402], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 404, 409], ["MMP-9", "GENE_OR_GENE_PRODUCT", 425, 430], ["trophoblast", "CELL", 483, 494], ["chorion cells", "CELL", 496, 509], ["amnion cells", "CELL", 515, 527], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 578, 583], ["MMP-1", "GENE_OR_GENE_PRODUCT", 616, 621], ["MMP-3", "GENE_OR_GENE_PRODUCT", 623, 628], ["MMP-9", "GENE_OR_GENE_PRODUCT", 634, 639], ["cervical smooth muscle cells", "CELL", 643, 671], ["COX-2", "PROTEIN", 47, 52], ["COX-2", "PROTEIN", 168, 173], ["TNF", "PROTEIN", 339, 342], ["IL-1\u03b2", "PROTEIN", 349, 354], ["IL", "PROTEIN", 397, 399], ["TNF", "PROTEIN", 404, 407], ["MMP", "PROTEIN", 425, 428], ["trophoblast, chorion cells", "CELL_TYPE", 483, 509], ["amnion cells", "CELL_TYPE", 515, 527], ["TNF", "PROTEIN", 578, 581], ["MMP-1", "PROTEIN", 616, 621], ["MMP-3", "PROTEIN", 623, 628], ["MMP-9", "PROTEIN", 634, 639], ["cervical smooth muscle cells", "CELL_TYPE", 643, 671], ["mice", "SPECIES", 177, 181], ["rhesus monkeys", "SPECIES", 290, 304], ["mice", "SPECIES", 177, 181], ["rhesus monkeys", "SPECIES", 290, 304], ["lower levels of COX", "PROBLEM", 31, 50], ["inflammation", "PROBLEM", 219, 231], ["preterm parturition", "PROBLEM", 240, 259], ["a study", "TEST", 279, 286], ["bacterial-induced TNF", "TREATMENT", 321, 342], ["IL", "TREATMENT", 349, 351], ["TNF", "TEST", 404, 407], ["MMP", "TEST", 425, 428], ["secretion in trophoblast, chorion cells", "TEST", 470, 509], ["TNF", "TEST", 578, 581], ["MMP", "TEST", 616, 619], ["MMP", "TEST", 623, 626], ["MMP", "TEST", 634, 637], ["COX", "OBSERVATION", 47, 50], ["myometrial tissue", "ANATOMY", 60, 77], ["inflammation", "OBSERVATION", 219, 231], ["preterm parturition", "OBSERVATION", 240, 259], ["uterine contractility", "ANATOMY", 367, 388], ["trophoblast", "ANATOMY", 483, 494], ["chorion cells", "ANATOMY", 496, 509], ["amnion cells", "ANATOMY", 515, 527], ["cervical", "ANATOMY", 643, 651], ["smooth muscle", "ANATOMY", 652, 665]]], ["This pattern is also seen in treatment with IL-1\u03b2.47Interleukin-6 ::: Pro-Inflammatory Cytokines and Preterm Labor ::: IntroductionThe IL-6 cytokine family consists of different cytokines such as IL-6, IL-11, IL-27, and leukemia inhibitory factor.48 IL-6, which is the most important pro-inflammatory cytokine in this family, plays a critical role in the inflammation cascade.", [["inflammation", "DISEASE", 355, 367], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 44, 49], ["Interleukin-6", "GENE_OR_GENE_PRODUCT", 52, 65], ["IL-6", "GENE_OR_GENE_PRODUCT", 135, 139], ["IL-6", "GENE_OR_GENE_PRODUCT", 196, 200], ["IL-11", "GENE_OR_GENE_PRODUCT", 202, 207], ["IL-27", "GENE_OR_GENE_PRODUCT", 209, 214], ["leukemia inhibitory factor", "GENE_OR_GENE_PRODUCT", 220, 246], ["IL-6", "GENE_OR_GENE_PRODUCT", 250, 254], ["IL-1\u03b2", "PROTEIN", 44, 49], ["Interleukin-6", "PROTEIN", 52, 65], ["Pro-Inflammatory Cytokines", "PROTEIN", 70, 96], ["IL-6 cytokine family", "PROTEIN", 135, 155], ["cytokines", "PROTEIN", 178, 187], ["IL-27", "PROTEIN", 209, 214], ["leukemia inhibitory factor", "PROTEIN", 220, 246], ["IL-6", "PROTEIN", 250, 254], ["pro-inflammatory cytokine", "PROTEIN", 284, 309], ["treatment with IL", "TREATMENT", 29, 46], ["Pro-Inflammatory Cytokines", "PROBLEM", 70, 96], ["Preterm Labor", "PROBLEM", 101, 114], ["The IL", "TREATMENT", 131, 137], ["different cytokines", "TREATMENT", 168, 187], ["IL", "TEST", 196, 198], ["IL", "TEST", 202, 204], ["IL", "TEST", 209, 211], ["leukemia inhibitory factor", "PROBLEM", 220, 246], ["the inflammation cascade", "TREATMENT", 351, 375], ["Pro-Inflammatory Cytokines", "OBSERVATION", 70, 96], ["leukemia inhibitory", "OBSERVATION", 220, 239], ["most important", "OBSERVATION_MODIFIER", 269, 283], ["pro-inflammatory cytokine", "OBSERVATION", 284, 309], ["inflammation", "OBSERVATION", 355, 367]]], ["This pro-inflammatory cytokine is involved in the pathogenesis of different autoimmune and inflammation\ufeff-dependent diseases and mostly acts through binding to its receptor, IL-6R.49 This pro-inflammatory cytokine has shown to be increased in preterm parturition even in asymptomatic women.50,51 Pregnant IL-6 knocked\ufeff-out mice have been demonstrated to have a delay in delivery compared to the wild types.", [["preterm parturition", "DISEASE", 242, 261], ["IL-6R.49", "GENE_OR_GENE_PRODUCT", 173, 181], ["women", "ORGANISM", 283, 288], ["IL-6", "GENE_OR_GENE_PRODUCT", 304, 308], ["mice", "ORGANISM", 322, 326], ["pro-inflammatory cytokine", "PROTEIN", 5, 30], ["IL", "PROTEIN", 173, 175], ["pro-inflammatory cytokine", "PROTEIN", 187, 212], ["women", "SPECIES", 283, 288], ["mice", "SPECIES", 322, 326], ["mice", "SPECIES", 322, 326], ["different autoimmune and inflammation\ufeff", "PROBLEM", 66, 104], ["dependent diseases", "PROBLEM", 105, 123], ["preterm parturition", "PROBLEM", 242, 261], ["Pregnant IL", "TEST", 295, 306], ["a delay in delivery", "PROBLEM", 358, 377], ["different", "OBSERVATION_MODIFIER", 66, 75], ["autoimmune", "OBSERVATION", 76, 86], ["dependent", "OBSERVATION_MODIFIER", 105, 114], ["diseases", "OBSERVATION", 115, 123], ["shown to be", "UNCERTAINTY", 217, 228], ["increased", "OBSERVATION_MODIFIER", 229, 238], ["preterm parturition", "OBSERVATION", 242, 261]]], ["This delay is proved to be accelerated through the administration of exogenous IL-6.", [["IL-6", "GENE_OR_GENE_PRODUCT", 79, 83], ["exogenous IL-6", "PROTEIN", 69, 83], ["exogenous IL", "TREATMENT", 69, 81]]], ["Moreover, after lipopolysaccharide (LPS) treatment, the IL-6 knocked\ufeff-out mice group showed lower prevalence of preterm parturition in comparison to the wild types.", [["lipopolysaccharide", "CHEMICAL", 16, 34], ["LPS", "CHEMICAL", 36, 39], ["preterm parturition", "DISEASE", 112, 131], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 16, 34], ["LPS", "SIMPLE_CHEMICAL", 36, 39], ["IL-6", "GENE_OR_GENE_PRODUCT", 56, 60], ["mice", "ORGANISM", 74, 78], ["IL-6", "PROTEIN", 56, 60], ["mice", "SPECIES", 74, 78], ["lipopolysaccharide (LPS) treatment", "TREATMENT", 16, 50], ["the IL", "TREATMENT", 52, 58], ["preterm parturition", "PROBLEM", 112, 131], ["lower prevalence", "OBSERVATION_MODIFIER", 92, 108], ["preterm parturition", "OBSERVATION", 112, 131]]], ["In the IL-6 knocked\ufeff-out mice, oxytocin receptor(Oxtr) mRNA expression was 73% lower than the wild type \ufeffon day 19.5 post coitus, which reached acomparable level with wild type with a 1-day delay.", [["oxytocin", "CHEMICAL", 31, 39], ["oxytocin", "CHEMICAL", 31, 39], ["IL-6", "GENE_OR_GENE_PRODUCT", 7, 11], ["mice", "ORGANISM", 25, 29], ["oxytocin receptor", "GENE_OR_GENE_PRODUCT", 31, 48], ["Oxtr", "GENE_OR_GENE_PRODUCT", 49, 53], ["oxytocin receptor(Oxtr) mRNA", "RNA", 31, 59], ["mice", "SPECIES", 25, 29], ["mice", "SPECIES", 25, 29], ["oxytocin receptor", "TREATMENT", 31, 48], ["mRNA expression", "TEST", 55, 70]]], ["Also, in the wild type group during day 19.5 post coitum to the labor time, PTGFR and prostaglandin-endoperoxide synthase 2(PTGS2) showed a 3.9 and 2.6 (respectively) fold increase.", [["prostaglandin-endoperoxide", "CHEMICAL", 86, 112], ["prostaglandin-endoperoxide", "CHEMICAL", 86, 112], ["PTGFR", "GENE_OR_GENE_PRODUCT", 76, 81], ["prostaglandin-endoperoxide synthase 2", "GENE_OR_GENE_PRODUCT", 86, 123], ["PTGS2", "GENE_OR_GENE_PRODUCT", 124, 129], ["PTGFR", "PROTEIN", 76, 81], ["prostaglandin-endoperoxide synthase 2", "PROTEIN", 86, 123], ["PTGS2", "PROTEIN", 124, 129], ["PTGFR and prostaglandin-endoperoxide synthase", "TEST", 76, 121], ["PTGS2", "TEST", 124, 129]]], ["On the other hand, the knocked\ufeff-out mice showed a similar increase in the expression of PTGFR and PTGS2 from day 20.5 post coitum.52 More interestingly, the amount of PTGFR, as the receptor of most important uterine contractile prostanoid (PGF-2\u03b1), was shown to increase in both term and preterm parturition.24 Also, it has been demonstrated that IL-6 is able to induce PGE2 production in amnion and decidual cells.53 According to the data, IL-6 is also responsible for an increase in MMP-9 and MMP-2 activity through targeting trophoblasts.41 Furthermore, data have cleared that IL-1\u03b2 and IL-6 are able to induce oxytocin secretion in human uterine smooth muscle cells.54 Considering the affirmed role of oxytocin and PGs in term and preterm parturition, it seems that they could be involved in the possible hypothesized molecular pathways caused by IL-6 and IL-1\u03b2 in preterm parturition.55 Furthermore, IL-1\u03b2 seems to be capable of increasing PGE2 production from human amnion cells.56 Some of the most important roles of pro-inflammatory cytokines in term/preterm labor have been provided in Table 1.", [["uterine", "ANATOMY", 208, 215], ["amnion", "ANATOMY", 389, 395], ["decidual cells", "ANATOMY", 400, 414], ["trophoblasts", "ANATOMY", 528, 540], ["uterine smooth muscle cells", "ANATOMY", 642, 669], ["amnion cells", "ANATOMY", 972, 984], ["PGE2", "CHEMICAL", 370, 374], ["oxytocin", "CHEMICAL", 614, 622], ["oxytocin", "CHEMICAL", 706, 714], ["preterm parturition", "DISEASE", 869, 888], ["PGE2", "CHEMICAL", 945, 949], ["preterm labor", "DISEASE", 1059, 1072], ["PGE2", "CHEMICAL", 370, 374], ["oxytocin", "CHEMICAL", 614, 622], ["oxytocin", "CHEMICAL", 706, 714], ["PGE2", "CHEMICAL", 945, 949], ["mice", "ORGANISM", 36, 40], ["PTGFR", "GENE_OR_GENE_PRODUCT", 88, 93], ["PTGS2", "GENE_OR_GENE_PRODUCT", 98, 103], ["PTGFR", "GENE_OR_GENE_PRODUCT", 167, 172], ["uterine contractile prostanoid", "GENE_OR_GENE_PRODUCT", 208, 238], ["PGF-2\u03b1", "GENE_OR_GENE_PRODUCT", 240, 246], ["IL-6", "GENE_OR_GENE_PRODUCT", 347, 351], ["PGE2", "SIMPLE_CHEMICAL", 370, 374], ["amnion", "CELL", 389, 395], ["decidual cells", "CELL", 400, 414], ["IL-6", "GENE_OR_GENE_PRODUCT", 441, 445], ["MMP-9", "GENE_OR_GENE_PRODUCT", 485, 490], ["MMP-2", "GENE_OR_GENE_PRODUCT", 495, 500], ["trophoblasts", "CELL", 528, 540], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 580, 585], ["IL-6", "GENE_OR_GENE_PRODUCT", 590, 594], ["oxytocin", "SIMPLE_CHEMICAL", 614, 622], ["human", "ORGANISM", 636, 641], ["uterine smooth muscle cells", "CELL", 642, 669], ["oxytocin", "SIMPLE_CHEMICAL", 706, 714], ["PGs", "SIMPLE_CHEMICAL", 719, 722], ["IL-6", "GENE_OR_GENE_PRODUCT", 851, 855], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 860, 865], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 905, 910], ["PGE2", "SIMPLE_CHEMICAL", 945, 949], ["human", "ORGANISM", 966, 971], ["amnion cells", "CELL", 972, 984], ["PTGFR", "PROTEIN", 88, 93], ["PTGS2", "PROTEIN", 98, 103], ["PTGFR", "PROTEIN", 167, 172], ["uterine contractile prostanoid (PGF-2\u03b1", "PROTEIN", 208, 246], ["IL-6", "PROTEIN", 347, 351], ["PGE2", "PROTEIN", 370, 374], ["amnion and decidual cells", "CELL_TYPE", 389, 414], ["IL-6", "PROTEIN", 441, 445], ["MMP", "PROTEIN", 485, 488], ["MMP", "PROTEIN", 495, 498], ["trophoblasts", "CELL_TYPE", 528, 540], ["IL-1\u03b2", "PROTEIN", 580, 585], ["IL-6", "PROTEIN", 590, 594], ["human uterine smooth muscle cells", "CELL_TYPE", 636, 669], ["IL-6", "PROTEIN", 851, 855], ["IL-1\u03b2", "PROTEIN", 860, 865], ["IL-1\u03b2", "PROTEIN", 905, 910], ["PGE2", "PROTEIN", 945, 949], ["human amnion cells", "CELL_TYPE", 966, 984], ["pro-inflammatory cytokines", "PROTEIN", 1024, 1050], ["mice", "SPECIES", 36, 40], ["human", "SPECIES", 636, 641], ["human", "SPECIES", 966, 971], ["mice", "SPECIES", 36, 40], ["human", "SPECIES", 636, 641], ["human", "SPECIES", 966, 971], ["PTGFR and PTGS2", "PROBLEM", 88, 103], ["PTGFR", "TREATMENT", 167, 172], ["preterm parturition", "PROBLEM", 288, 307], ["PGE2 production in amnion and decidual cells", "PROBLEM", 370, 414], ["MMP", "TEST", 485, 488], ["MMP", "TEST", 495, 498], ["IL", "TEST", 580, 582], ["oxytocin secretion in human uterine smooth muscle cells", "PROBLEM", 614, 669], ["oxytocin and PGs", "TREATMENT", 706, 722], ["preterm parturition", "PROBLEM", 869, 888], ["increasing PGE2 production", "PROBLEM", 934, 960], ["human amnion cells", "TREATMENT", 966, 984], ["pro-inflammatory cytokines", "TREATMENT", 1024, 1050], ["preterm labor", "PROBLEM", 1059, 1072], ["similar", "OBSERVATION_MODIFIER", 50, 57], ["increase", "OBSERVATION_MODIFIER", 58, 66], ["amount", "OBSERVATION_MODIFIER", 157, 163], ["contractile prostanoid", "OBSERVATION", 216, 238], ["increase", "OBSERVATION_MODIFIER", 262, 270], ["both term", "OBSERVATION_MODIFIER", 274, 283], ["preterm parturition", "OBSERVATION", 288, 307], ["amnion", "ANATOMY", 389, 395], ["decidual cells", "OBSERVATION", 400, 414], ["increase", "OBSERVATION_MODIFIER", 473, 481], ["human uterine", "ANATOMY", 636, 649], ["smooth muscle cells", "OBSERVATION", 650, 669], ["preterm parturition", "OBSERVATION", 869, 888], ["increasing", "OBSERVATION_MODIFIER", 934, 944], ["PGE2", "OBSERVATION", 945, 949], ["human amnion cells", "OBSERVATION", 966, 984], ["pro-inflammatory cytokines", "OBSERVATION", 1024, 1050]]]], "b721ffae53a4509f1abe6d463af00fa47dbaa2ca": [["IntroductionSialic acid, a monosaccharide with a nine-carbon backbone, is widely found in nature as a terminal sugar of animal and microbial glycoproteins and glycolipids.", [["IntroductionSialic acid", "CHEMICAL", 0, 23], ["IntroductionSialic acid", "CHEMICAL", 0, 23], ["monosaccharide", "CHEMICAL", 27, 41], ["carbon", "CHEMICAL", 54, 60], ["sugar", "CHEMICAL", 111, 116], ["IntroductionSialic acid", "SIMPLE_CHEMICAL", 0, 23], ["IntroductionSialic acid", "TREATMENT", 0, 23], ["a monosaccharide", "TREATMENT", 25, 41], ["a nine-carbon backbone", "TREATMENT", 47, 69], ["microbial glycoproteins", "TREATMENT", 131, 154], ["glycolipids", "TREATMENT", 159, 170]]], ["It plays important roles in animal development, cellular recognition processes and host-pathogen interactions (Schauer 2009) .", [["cellular", "ANATOMY", 48, 56], ["cellular", "CELL", 48, 56]]], ["A common modification of sialic acid is 9-O-acetylation, which has been implicated in sialoglycan recognition and ganglioside biology.", [["sialic acid", "CHEMICAL", 25, 36], ["9-O", "CHEMICAL", 40, 43], ["sialic acid", "CHEMICAL", 25, 36], ["9-O", "CHEMICAL", 40, 43], ["ganglioside", "CHEMICAL", 114, 125], ["sialic acid", "SIMPLE_CHEMICAL", 25, 36], ["sialoglycan", "SIMPLE_CHEMICAL", 86, 97], ["ganglioside", "SIMPLE_CHEMICAL", 114, 125], ["sialic acid", "TEST", 25, 36], ["acetylation", "TREATMENT", 44, 55], ["sialic acid", "OBSERVATION", 25, 36]]], ["The hemagglutinins or hemagglutinin-esterases of type C influenza viruses and certain nidoviruses specifically recognize the 9-O-acetylated form of sialic acid, and this form of sialic acid is required for the entry of these viruses into human cells.", [["cells", "ANATOMY", 244, 249], ["influenza viruses", "DISEASE", 56, 73], ["sialic acid", "CHEMICAL", 148, 159], ["sialic acid", "CHEMICAL", 178, 189], ["sialic acid", "CHEMICAL", 148, 159], ["sialic acid", "CHEMICAL", 178, 189], ["hemagglutinin-esterases", "GENE_OR_GENE_PRODUCT", 22, 45], ["type C influenza viruses", "ORGANISM", 49, 73], ["sialic acid", "SIMPLE_CHEMICAL", 148, 159], ["sialic acid", "SIMPLE_CHEMICAL", 178, 189], ["human", "ORGANISM", 238, 243], ["cells", "CELL", 244, 249], ["hemagglutinins or hemagglutinin-esterases", "PROTEIN", 4, 45], ["human cells", "CELL_TYPE", 238, 249], ["C influenza viruses", "SPECIES", 54, 73], ["human", "SPECIES", 238, 243], ["type C influenza viruses", "SPECIES", 49, 73], ["human", "SPECIES", 238, 243], ["The hemagglutinins", "TREATMENT", 0, 18], ["hemagglutinin-esterases", "TREATMENT", 22, 45], ["type C influenza viruses", "PROBLEM", 49, 73], ["certain nidoviruses", "TREATMENT", 78, 97], ["sialic acid", "TREATMENT", 148, 159], ["sialic acid", "TREATMENT", 178, 189]]], ["Although we had previously inferred a role for sialic acid 9-O-acetylation in regulating Siglec-2 (Cariappa et al. 2009 ), we have demonstrated that many of the phenotypes on the basis of which earlier conclusions were made, actually resulted from a mutation that was traceable to a commercially available C57BL/6 strain of mice (Mahajan et al. 2016) .IntroductionPrevious studies had shown that a biochemical sialate-O-acetyl transferase activity exists in Golgi preparations.", [["Golgi", "ANATOMY", 458, 463], ["sialic acid 9-O", "CHEMICAL", 47, 62], ["sialate-O-acetyl", "CHEMICAL", 410, 426], ["sialic acid", "CHEMICAL", 47, 58], ["O", "CHEMICAL", 61, 62], ["sialate", "CHEMICAL", 410, 417], ["O", "CHEMICAL", 418, 419], ["acetyl", "CHEMICAL", 420, 426], ["sialic acid", "SIMPLE_CHEMICAL", 47, 58], ["Siglec-2", "GENE_OR_GENE_PRODUCT", 89, 97], ["C57BL/6 strain", "ORGANISM", 306, 320], ["mice", "ORGANISM", 324, 328], ["sialate-O-acetyl transferase", "GENE_OR_GENE_PRODUCT", 410, 438], ["Golgi", "CELLULAR_COMPONENT", 458, 463], ["Siglec", "PROTEIN", 89, 95], ["acetyl transferase", "PROTEIN", 420, 438], ["mice", "SPECIES", 324, 328], ["mice", "SPECIES", 324, 328], ["sialic acid", "TEST", 47, 58], ["the phenotypes", "PROBLEM", 157, 171], ["a mutation", "PROBLEM", 248, 258], ["Previous studies", "TEST", 364, 380], ["a biochemical sialate", "TEST", 396, 417], ["acetyl transferase activity", "TREATMENT", 420, 447]]], ["Using knock-down and over-expression studies in a human cell line, Arming et al. (2011) showed that CASD1 contributed to the 7-O-acetylation of GD3.", [["cell line", "ANATOMY", 56, 65], ["human", "ORGANISM", 50, 55], ["cell line", "CELL", 56, 65], ["CASD1", "GENE_OR_GENE_PRODUCT", 100, 105], ["GD3", "GENE_OR_GENE_PRODUCT", 144, 147], ["human cell line", "CELL_LINE", 50, 65], ["CASD1", "PROTEIN", 100, 105], ["GD3", "PROTEIN", 144, 147], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 50, 55], ["a human cell line", "TREATMENT", 48, 65]]], ["Baumann et al. (2015) inactivated Casd1 in the near-haploid myeloid cell line HAP1 using CRISPR/Cas9 based genome editing and demonstrated the loss of 9-O-acetyl moieties from sialo-glyconjugates in HAP1 cells lacking CASD1.", [["myeloid cell line HAP1", "ANATOMY", 60, 82], ["HAP1 cells", "ANATOMY", 199, 209], ["9-O-acetyl", "CHEMICAL", 151, 161], ["sialo-glyconjugates", "CHEMICAL", 176, 195], ["9-O-acetyl", "CHEMICAL", 151, 161], ["Casd1", "GENE_OR_GENE_PRODUCT", 34, 39], ["myeloid cell line HAP1", "CELL", 60, 82], ["9-O-acetyl moieties", "SIMPLE_CHEMICAL", 151, 170], ["sialo-glyconjugates", "SIMPLE_CHEMICAL", 176, 195], ["HAP1 cells", "CELL", 199, 209], ["CASD1", "GENE_OR_GENE_PRODUCT", 218, 223], ["Casd1", "DNA", 34, 39], ["near-haploid myeloid cell line HAP1", "CELL_LINE", 47, 82], ["CRISPR", "DNA", 89, 95], ["Cas9", "DNA", 96, 100], ["sialo-glyconjugates", "PROTEIN", 176, 195], ["HAP1 cells", "CELL_LINE", 199, 209], ["CASD1", "PROTEIN", 218, 223], ["inactivated Casd1", "PROBLEM", 22, 39], ["the near-haploid myeloid cell line HAP1", "TREATMENT", 43, 82], ["CRISPR/Cas9", "TREATMENT", 89, 100], ["the loss", "PROBLEM", 139, 147], ["acetyl moieties", "TREATMENT", 155, 170], ["sialo", "TEST", 176, 181], ["haploid myeloid cell line", "OBSERVATION", 52, 77], ["HAP1 cells", "OBSERVATION", 199, 209]]], ["Their studies implicated CASD1 in directly transferring acetyl moieties from acetyl-CoA to CMP-sialic acid.", [["acetyl", "CHEMICAL", 56, 62], ["acetyl-CoA", "CHEMICAL", 77, 87], ["CMP-sialic acid", "CHEMICAL", 91, 106], ["acetyl", "CHEMICAL", 56, 62], ["acetyl-CoA", "CHEMICAL", 77, 87], ["CMP-sialic acid", "CHEMICAL", 91, 106], ["CASD1", "GENE_OR_GENE_PRODUCT", 25, 30], ["acetyl moieties", "SIMPLE_CHEMICAL", 56, 71], ["acetyl-CoA", "SIMPLE_CHEMICAL", 77, 87], ["CMP-sialic acid", "SIMPLE_CHEMICAL", 91, 106], ["CASD1", "PROTEIN", 25, 30], ["Their studies", "TEST", 0, 13], ["acetyl moieties", "TREATMENT", 56, 71], ["acetyl", "TREATMENT", 77, 83], ["CMP", "TEST", 91, 94], ["sialic acid", "TREATMENT", 95, 106]]], ["Whether CMP-sialic acid is the preferred substrate for the O-acetylation of sialic acid in vivo, however, remains to be established.", [["CMP-sialic acid", "CHEMICAL", 8, 23], ["sialic acid", "CHEMICAL", 76, 87], ["CMP-sialic acid", "CHEMICAL", 8, 23], ["sialic acid", "CHEMICAL", 76, 87], ["CMP-sialic acid", "SIMPLE_CHEMICAL", 8, 23], ["sialic acid", "SIMPLE_CHEMICAL", 76, 87], ["CMP", "TEST", 8, 11], ["sialic acid", "TREATMENT", 12, 23], ["the O-acetylation of sialic acid", "TREATMENT", 55, 87], ["sialic acid", "OBSERVATION", 12, 23]]], ["In this report, we describe a mouse strain in which Casd1 has been deleted in the germline.", [["mouse", "ORGANISM", 30, 35], ["Casd1", "GENE_OR_GENE_PRODUCT", 52, 57], ["Casd1", "PROTEIN", 52, 57], ["germline", "DNA", 82, 90], ["mouse", "SPECIES", 30, 35], ["mouse", "SPECIES", 30, 35], ["a mouse strain", "PROBLEM", 28, 42]]], ["Analysis of these mice demonstrated the loss of 9-Oacetylation of sialic acid on the surface of all hematopoietic cells examined.", [["surface", "ANATOMY", 85, 92], ["hematopoietic cells", "ANATOMY", 100, 119], ["sialic acid", "CHEMICAL", 66, 77], ["sialic acid", "CHEMICAL", 66, 77], ["mice", "ORGANISM", 18, 22], ["sialic acid", "SIMPLE_CHEMICAL", 66, 77], ["surface", "CELLULAR_COMPONENT", 85, 92], ["hematopoietic cells", "CELL", 100, 119], ["hematopoietic cells", "CELL_TYPE", 100, 119], ["mice", "SPECIES", 18, 22], ["mice", "SPECIES", 18, 22], ["these mice", "TEST", 12, 22], ["the loss of 9", "PROBLEM", 36, 49], ["sialic acid", "PROBLEM", 66, 77], ["loss", "OBSERVATION_MODIFIER", 40, 44], ["sialic acid", "OBSERVATION", 66, 77], ["all hematopoietic cells", "OBSERVATION", 96, 119]]], ["Based on the differential specificity of hemagglutinin esterases from influenza C and bovine coronavirus, we inferred that the murine erythroid lineage-specific epitope recognized by the TER-119 monoclonal antibody is comprised of a 7,9-di-O-acetyl sialic acid glycoform that is completely lost in Casd1-deficient mice.", [["erythroid lineage", "ANATOMY", 134, 151], ["7,9-di-O-acetyl sialic acid", "CHEMICAL", 233, 260], ["7,9-di-O-acetyl sialic acid", "CHEMICAL", 233, 260], ["hemagglutinin esterases", "GENE_OR_GENE_PRODUCT", 41, 64], ["influenza C", "ORGANISM", 70, 81], ["bovine coronavirus", "ORGANISM", 86, 104], ["murine", "ORGANISM", 127, 133], ["erythroid lineage", "CELL", 134, 151], ["TER", "GENE_OR_GENE_PRODUCT", 187, 190], ["7,9-di-O-acetyl sialic acid", "SIMPLE_CHEMICAL", 233, 260], ["Casd1", "GENE_OR_GENE_PRODUCT", 298, 303], ["mice", "ORGANISM", 314, 318], ["hemagglutinin esterases", "PROTEIN", 41, 64], ["murine erythroid lineage", "CELL_TYPE", 127, 151], ["TER-119 monoclonal antibody", "PROTEIN", 187, 214], ["Casd1", "PROTEIN", 298, 303], ["bovine", "SPECIES", 86, 92], ["coronavirus", "SPECIES", 93, 104], ["murine", "SPECIES", 127, 133], ["mice", "SPECIES", 314, 318], ["bovine coronavirus", "SPECIES", 86, 104], ["mice", "SPECIES", 314, 318], ["hemagglutinin esterases", "PROBLEM", 41, 64], ["influenza C", "PROBLEM", 70, 81], ["bovine coronavirus", "PROBLEM", 86, 104], ["the TER", "TEST", 183, 190], ["monoclonal antibody", "TEST", 195, 214], ["di-O-acetyl sialic acid glycoform", "TREATMENT", 237, 270], ["hemagglutinin esterases", "OBSERVATION", 41, 64], ["bovine coronavirus", "OBSERVATION", 86, 104], ["erythroid lineage", "OBSERVATION", 134, 151]]], ["The putative 7,9-di-O-acetyl sialic acid glycoform can be detected early in erythroid differentiation from the Ery-A and Ery-B stages onward.", [["erythroid", "ANATOMY", 76, 85], ["7,9-di-O-acetyl sialic acid", "CHEMICAL", 13, 40], ["7,9-di-O-acetyl sialic acid", "CHEMICAL", 13, 40], ["7,9-di-O-acetyl sialic acid", "SIMPLE_CHEMICAL", 13, 40], ["erythroid", "CELL", 76, 85], ["The putative", "TEST", 0, 12], ["di-O-acetyl sialic acid glycoform", "TREATMENT", 17, 50], ["erythroid differentiation", "OBSERVATION", 76, 101]]], ["We also observed that a distinct 9-O-acetyl sialic acid moiety also decorates cells of the erythroid lineage from the Ery-C stage onward including mature red blood cells.ResultsTargeted deletion of Casd1 in mice results in a loss of 9-O-acetyl sialic acid in mononuclear hematopoietic cells Prior in vitro studies have suggested that CASD1 is a sialic acid 9-O-acetyl transferase.", [["cells", "ANATOMY", 78, 83], ["erythroid lineage", "ANATOMY", 91, 108], ["red blood cells", "ANATOMY", 154, 169], ["mononuclear hematopoietic cells", "ANATOMY", 259, 290], ["9-O-acetyl sialic acid", "CHEMICAL", 33, 55], ["9-O-acetyl sialic acid", "CHEMICAL", 233, 255], ["sialic acid 9-O-acetyl", "CHEMICAL", 345, 367], ["9-O-acetyl sialic acid", "CHEMICAL", 33, 55], ["9-O-acetyl sialic acid", "CHEMICAL", 233, 255], ["sialic acid", "CHEMICAL", 345, 356], ["9-O-acetyl", "CHEMICAL", 357, 367], ["9-O-acetyl sialic acid", "SIMPLE_CHEMICAL", 33, 55], ["cells", "CELL", 78, 83], ["erythroid lineage", "CELL", 91, 108], ["red blood cells", "CELL", 154, 169], ["Casd1", "GENE_OR_GENE_PRODUCT", 198, 203], ["mice", "ORGANISM", 207, 211], ["9-O-acetyl sialic acid", "SIMPLE_CHEMICAL", 233, 255], ["mononuclear hematopoietic cells", "CELL", 259, 290], ["CASD1", "GENE_OR_GENE_PRODUCT", 334, 339], ["sialic acid 9-O-acetyl transferase", "GENE_OR_GENE_PRODUCT", 345, 379], ["erythroid lineage", "CELL_TYPE", 91, 108], ["mature red blood cells", "CELL_TYPE", 147, 169], ["Casd1", "DNA", 198, 203], ["mononuclear hematopoietic cells", "CELL_TYPE", 259, 290], ["CASD1", "PROTEIN", 334, 339], ["sialic acid 9-O-acetyl transferase", "PROTEIN", 345, 379], ["mice", "SPECIES", 207, 211], ["mice", "SPECIES", 207, 211], ["acetyl sialic acid moiety", "PROBLEM", 37, 62], ["the erythroid lineage", "PROBLEM", 87, 108], ["red blood cells", "TEST", 154, 169], ["acetyl sialic acid in mononuclear hematopoietic cells", "PROBLEM", 237, 290], ["vitro studies", "TEST", 300, 313], ["a sialic acid", "TEST", 343, 356], ["erythroid lineage", "OBSERVATION", 91, 108], ["red blood cells", "OBSERVATION", 154, 169], ["mononuclear hematopoietic cells", "OBSERVATION", 259, 290]]], ["To assess the function of 9-O-acetyl sialic acids in vivo, we generated Casd1-deficient mice ( Figure 1A) .", [["9-O-acetyl sialic acids", "CHEMICAL", 26, 49], ["9-O-acetyl sialic acids", "CHEMICAL", 26, 49], ["9-O-acetyl sialic acids", "SIMPLE_CHEMICAL", 26, 49], ["Casd1", "GENE_OR_GENE_PRODUCT", 72, 77], ["mice", "ORGANISM", 88, 92], ["Casd1", "PROTEIN", 72, 77], ["mice", "SPECIES", 88, 92], ["the function", "TEST", 10, 22], ["acetyl sialic acids", "TREATMENT", 30, 49]]], ["The influenza C hemagglutinin-esterase (CHE) that is known to be specific for 9-Oacetyl sialic acid was expressed as an Fc-fusion protein (CHE-Fc) (Muchmore and Varki 1987) .", [["CHE", "CHEMICAL", 40, 43], ["9-Oacetyl sialic acid", "CHEMICAL", 78, 99], ["9-Oacetyl sialic acid", "CHEMICAL", 78, 99], ["influenza C hemagglutinin-esterase", "GENE_OR_GENE_PRODUCT", 4, 38], ["CHE", "GENE_OR_GENE_PRODUCT", 40, 43], ["9-Oacetyl sialic acid", "SIMPLE_CHEMICAL", 78, 99], ["CHE-Fc", "GENE_OR_GENE_PRODUCT", 139, 145], ["influenza C hemagglutinin-esterase", "PROTEIN", 4, 38], ["CHE", "PROTEIN", 40, 43], ["Fc", "PROTEIN", 120, 122], ["fusion protein", "PROTEIN", 123, 137], ["CHE", "PROTEIN", 139, 142], ["Fc", "PROTEIN", 143, 145], ["influenza C hemagglutinin", "SPECIES", 4, 29], ["The influenza C hemagglutinin-esterase", "TEST", 0, 38], ["Oacetyl sialic acid", "TREATMENT", 80, 99], ["an Fc-fusion protein", "TEST", 117, 137]]], ["Inactivation of the esterase domain of CHE-Fc with diisopropyl fluorophosphate (DFP) yields CHE-FcD, which has been widely used as a specific probe of 9-O-acetyl sialic acid (Klein et al. 1994) .", [["CHE", "CHEMICAL", 39, 42], ["diisopropyl fluorophosphate", "CHEMICAL", 51, 78], ["DFP", "CHEMICAL", 80, 83], ["CHE-FcD", "CHEMICAL", 92, 99], ["9-O-acetyl sialic acid", "CHEMICAL", 151, 173], ["diisopropyl fluorophosphate", "CHEMICAL", 51, 78], ["DFP", "CHEMICAL", 80, 83], ["CHE-FcD", "CHEMICAL", 92, 99], ["9-O-acetyl sialic acid", "CHEMICAL", 151, 173], ["CHE-Fc", "GENE_OR_GENE_PRODUCT", 39, 45], ["diisopropyl fluorophosphate", "SIMPLE_CHEMICAL", 51, 78], ["DFP", "SIMPLE_CHEMICAL", 80, 83], ["CHE-FcD", "SIMPLE_CHEMICAL", 92, 99], ["9-O-acetyl sialic acid", "SIMPLE_CHEMICAL", 151, 173], ["esterase domain", "PROTEIN", 20, 35], ["CHE-Fc", "PROTEIN", 39, 45], ["the esterase domain", "TEST", 16, 35], ["CHE", "TEST", 39, 42], ["diisopropyl fluorophosphate (DFP", "TREATMENT", 51, 83], ["CHE-FcD", "TREATMENT", 92, 99], ["acetyl sialic acid", "TREATMENT", 155, 173]]], ["Using the CHE-FcD reagent, we evaluated the effect of Casd1 deficiency on sialic acid 9-O-acetylation in all hematopoietic lineages, focusing our analysis on the spleen, bone marrow and lymph nodes.ResultsWild-type myeloid cells expressing CD11b exhibit robust levels of 9-O-acetyl sialic acid, but this carbohydrate modification was completely lost in splenic CD11b + myeloid cells from Casd1-deficient mice ( Figure 1B ).", [["hematopoietic lineages", "ANATOMY", 109, 131], ["spleen", "ANATOMY", 162, 168], ["bone marrow", "ANATOMY", 170, 181], ["lymph nodes", "ANATOMY", 186, 197], ["ResultsWild-type myeloid cells", "ANATOMY", 198, 228], ["splenic CD11b + myeloid cells", "ANATOMY", 353, 382], ["sialic acid 9-O", "CHEMICAL", 74, 89], ["9-O-acetyl sialic acid", "CHEMICAL", 271, 293], ["sialic acid", "CHEMICAL", 74, 85], ["O", "CHEMICAL", 88, 89], ["9-O-acetyl sialic acid", "CHEMICAL", 271, 293], ["carbohydrate", "CHEMICAL", 304, 316], ["Casd1", "GENE_OR_GENE_PRODUCT", 54, 59], ["sialic acid", "SIMPLE_CHEMICAL", 74, 85], ["hematopoietic lineages", "CELL", 109, 131], ["spleen", "ORGAN", 162, 168], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 170, 181], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 186, 197], ["ResultsWild-type myeloid cells", "CELL", 198, 228], ["CD11b", "GENE_OR_GENE_PRODUCT", 240, 245], ["9-O-acetyl sialic acid", "SIMPLE_CHEMICAL", 271, 293], ["CD11", "GENE_OR_GENE_PRODUCT", 361, 365], ["myeloid cells", "CELL", 369, 382], ["Casd1", "GENE_OR_GENE_PRODUCT", 388, 393], ["mice", "ORGANISM", 404, 408], ["Casd1", "PROTEIN", 54, 59], ["hematopoietic lineages", "CELL_TYPE", 109, 131], ["ResultsWild-type myeloid cells", "CELL_LINE", 198, 228], ["CD11b", "PROTEIN", 240, 245], ["splenic CD11b", "CELL_LINE", 353, 366], ["myeloid cells", "CELL_TYPE", 369, 382], ["Casd1", "PROTEIN", 388, 393], ["mice", "SPECIES", 404, 408], ["mice", "SPECIES", 404, 408], ["the CHE-FcD reagent", "TREATMENT", 6, 25], ["Casd1 deficiency", "PROBLEM", 54, 70], ["sialic acid", "TEST", 74, 85], ["acetylation", "TREATMENT", 90, 101], ["all hematopoietic lineages", "PROBLEM", 105, 131], ["our analysis", "TEST", 142, 154], ["lymph nodes", "PROBLEM", 186, 197], ["type myeloid cells", "PROBLEM", 210, 228], ["CD11b", "TEST", 240, 245], ["robust levels", "TEST", 254, 267], ["acetyl sialic acid", "TREATMENT", 275, 293], ["this carbohydrate modification", "TREATMENT", 299, 329], ["myeloid cells", "PROBLEM", 369, 382], ["Casd1", "TEST", 388, 393], ["hematopoietic lineages", "OBSERVATION", 109, 131], ["spleen", "ANATOMY", 162, 168], ["bone marrow", "ANATOMY", 170, 181], ["lymph nodes", "OBSERVATION", 186, 197], ["myeloid cells", "OBSERVATION", 215, 228], ["splenic", "ANATOMY", 353, 360], ["myeloid cells", "OBSERVATION", 369, 382]]], ["CD11b + cells in the bone marrow also express high levels of the mucin-like glycoprotein CD43, suggesting that much of the 9-O-acetylated sialic acid found on the surface of murine myeloid cells may decorate this glycoprotein.", [["CD11b + cells", "ANATOMY", 0, 13], ["bone marrow", "ANATOMY", 21, 32], ["surface", "ANATOMY", 163, 170], ["myeloid cells", "ANATOMY", 181, 194], ["sialic acid", "CHEMICAL", 138, 149], ["9-O-acetylated sialic acid", "CHEMICAL", 123, 149], ["CD11", "GENE_OR_GENE_PRODUCT", 0, 4], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 21, 32], ["mucin", "GENE_OR_GENE_PRODUCT", 65, 70], ["CD43", "GENE_OR_GENE_PRODUCT", 89, 93], ["9-O-acetylated sialic acid", "SIMPLE_CHEMICAL", 123, 149], ["surface", "CELLULAR_COMPONENT", 163, 170], ["murine", "ORGANISM", 174, 180], ["myeloid cells", "CELL", 181, 194], ["CD11b + cells", "CELL_LINE", 0, 13], ["mucin", "PROTEIN", 65, 70], ["glycoprotein CD43", "PROTEIN", 76, 93], ["murine myeloid cells", "CELL_TYPE", 174, 194], ["glycoprotein", "PROTEIN", 213, 225], ["murine", "SPECIES", 174, 180], ["CD11b + cells", "TEST", 0, 13], ["the bone marrow", "TEST", 17, 32], ["the mucin", "TEST", 61, 70], ["acetylated sialic acid", "TREATMENT", 127, 149], ["murine myeloid cells", "TREATMENT", 174, 194], ["+ cells", "OBSERVATION", 6, 13], ["bone marrow", "ANATOMY", 21, 32], ["high levels", "OBSERVATION_MODIFIER", 46, 57], ["murine myeloid cells", "OBSERVATION", 174, 194]]], ["Indeed, mucin-like glycoproteins such as CD43 and CD45RB have been shown to bear 9-Oacetylated sialic acids on mononuclear cells in the spleen (Krishna and Varki 1997) .", [["mononuclear cells", "ANATOMY", 111, 128], ["spleen", "ANATOMY", 136, 142], ["9-Oacetylated sialic acids", "CHEMICAL", 81, 107], ["9-Oacetylated sialic acids", "CHEMICAL", 81, 107], ["mucin-like glycoproteins", "GENE_OR_GENE_PRODUCT", 8, 32], ["CD43", "GENE_OR_GENE_PRODUCT", 41, 45], ["CD45RB", "GENE_OR_GENE_PRODUCT", 50, 56], ["9-Oacetylated sialic acids", "SIMPLE_CHEMICAL", 81, 107], ["mononuclear cells", "CELL", 111, 128], ["spleen", "ORGAN", 136, 142], ["mucin-like glycoproteins", "PROTEIN", 8, 32], ["CD43", "PROTEIN", 41, 45], ["CD45RB", "PROTEIN", 50, 56], ["mononuclear cells", "CELL_TYPE", 111, 128], ["mucin-like glycoproteins", "PROBLEM", 8, 32], ["CD43", "TEST", 41, 45], ["CD45RB", "TREATMENT", 50, 56], ["mononuclear cells", "OBSERVATION", 111, 128], ["spleen", "ANATOMY", 136, 142]]], ["No detectable 9-O-acetyl sialic acid was found on the CD11b + CD43 + population in the bone marrows of Casd1-deficient mice ( Figure 1C) .", [["CD11b + CD43 + population", "ANATOMY", 54, 79], ["bone marrows", "ANATOMY", 87, 99], ["9-O-acetyl sialic acid", "CHEMICAL", 14, 36], ["9-O-acetyl sialic acid", "CHEMICAL", 14, 36], ["9-O-acetyl sialic acid", "SIMPLE_CHEMICAL", 14, 36], ["CD11b", "GENE_OR_GENE_PRODUCT", 54, 59], ["CD43", "GENE_OR_GENE_PRODUCT", 62, 66], ["bone marrows", "MULTI-TISSUE_STRUCTURE", 87, 99], ["Casd1", "GENE_OR_GENE_PRODUCT", 103, 108], ["mice", "ORGANISM", 119, 123], ["CD11b", "PROTEIN", 54, 59], ["CD43", "PROTEIN", 62, 66], ["Casd1", "PROTEIN", 103, 108], ["mice", "SPECIES", 119, 123], ["mice", "SPECIES", 119, 123], ["acetyl sialic acid", "TEST", 18, 36], ["CD43", "TEST", 62, 66], ["the bone marrows", "TEST", 83, 99], ["Casd1", "TEST", 103, 108], ["bone", "ANATOMY", 87, 91], ["marrows", "OBSERVATION", 92, 99]]], ["A large proportion of CD43 + CD11b \u2212 non-myeloid cells, largely hematopoietic progenitors in the bone marrow, also express surface 9-O-acetyl sialic acid in wild type mice, but this was completely lost in Casd1-deficient mice ( Figure 1C ).ResultsWe found no detectable levels of 9-O-acetyl sialic acid on B220 + CD93 + transitional B cells, B220 + CD19 + CD21 lo IgM + follicular B cells and CD21 hi IgM hi marginal zone B cells in the spleen of wild-type (C57BL/6J) or Casd1-deficient ( Figure 1D ).", [["CD43 + CD11b \u2212 non-myeloid cells", "ANATOMY", 22, 54], ["hematopoietic progenitors", "ANATOMY", 64, 89], ["bone marrow", "ANATOMY", 97, 108], ["surface", "ANATOMY", 123, 130], ["B220 + CD93 + transitional B cells", "ANATOMY", 306, 340], ["B220 + CD19 + CD21 lo IgM + follicular B cells", "ANATOMY", 342, 388], ["marginal zone B cells", "ANATOMY", 408, 429], ["spleen", "ANATOMY", 437, 443], ["9-O-acetyl sialic acid", "CHEMICAL", 131, 153], ["9-O-acetyl sialic acid", "CHEMICAL", 280, 302], ["9-O-acetyl sialic acid", "CHEMICAL", 131, 153], ["9-O-acetyl sialic acid", "CHEMICAL", 280, 302], ["CD43", "GENE_OR_GENE_PRODUCT", 22, 26], ["hematopoietic progenitors", "CELL", 64, 89], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 97, 108], ["9-O-acetyl sialic acid", "SIMPLE_CHEMICAL", 131, 153], ["mice", "ORGANISM", 167, 171], ["Casd1", "GENE_OR_GENE_PRODUCT", 205, 210], ["mice", "ORGANISM", 221, 225], ["9-O-acetyl sialic acid", "SIMPLE_CHEMICAL", 280, 302], ["B220", "GENE_OR_GENE_PRODUCT", 306, 310], ["B220", "GENE_OR_GENE_PRODUCT", 342, 346], ["CD19", "GENE_OR_GENE_PRODUCT", 349, 353], ["CD21", "GENE_OR_GENE_PRODUCT", 356, 360], ["CD21", "GENE_OR_GENE_PRODUCT", 393, 397], ["spleen", "ORGAN", 437, 443], ["C57BL/6J)", "ORGANISM", 458, 467], ["Casd1", "GENE_OR_GENE_PRODUCT", 471, 476], ["CD43", "PROTEIN", 22, 26], ["CD11b \u2212 non-myeloid cells", "CELL_TYPE", 29, 54], ["hematopoietic progenitors", "CELL_TYPE", 64, 89], ["Casd1", "PROTEIN", 205, 210], ["B220", "PROTEIN", 306, 310], ["CD93", "PROTEIN", 313, 317], ["transitional B cells", "CELL_TYPE", 320, 340], ["B220", "PROTEIN", 342, 346], ["CD19", "PROTEIN", 349, 353], ["CD21", "PROTEIN", 356, 360], ["IgM", "PROTEIN", 364, 367], ["follicular B cells", "CELL_TYPE", 370, 388], ["CD21 hi IgM hi marginal zone B cells", "CELL_TYPE", 393, 429], ["mice", "SPECIES", 167, 171], ["mice", "SPECIES", 221, 225], ["mice", "SPECIES", 167, 171], ["CD43", "TEST", 22, 26], ["CD11", "TEST", 29, 33], ["non-myeloid cells", "PROBLEM", 37, 54], ["largely hematopoietic progenitors in the bone marrow", "PROBLEM", 56, 108], ["surface", "TEST", 123, 130], ["acetyl sialic acid", "TREATMENT", 135, 153], ["detectable levels", "PROBLEM", 259, 276], ["acetyl sialic acid", "TEST", 284, 302], ["B220", "TEST", 306, 310], ["CD93", "TEST", 313, 317], ["transitional B cells", "PROBLEM", 320, 340], ["B220", "TEST", 342, 346], ["CD19", "TEST", 349, 353], ["CD21", "TEST", 356, 360], ["IgM", "TEST", 364, 367], ["follicular B cells", "TEST", 370, 388], ["CD21", "TEST", 393, 397], ["hi IgM", "TEST", 398, 404], ["Casd1", "PROBLEM", 471, 476], ["large", "OBSERVATION_MODIFIER", 2, 7], ["CD43 +", "OBSERVATION", 22, 28], ["non-myeloid cells", "OBSERVATION", 37, 54], ["largely", "OBSERVATION_MODIFIER", 56, 63], ["hematopoietic progenitors", "OBSERVATION", 64, 89], ["bone marrow", "ANATOMY", 97, 108], ["no", "UNCERTAINTY", 256, 258], ["transitional B cells", "OBSERVATION", 320, 340], ["follicular B cells", "OBSERVATION", 370, 388], ["marginal", "OBSERVATION_MODIFIER", 408, 416], ["zone B cells", "OBSERVATION", 417, 429], ["spleen", "ANATOMY", 437, 443]]], ["We also analyzed B220 + B cells in the bone marrow and lymph nodes, and found no detectable levels of 9-O-acetyl sialic acid on these cells in wild-type or Casd1-deficient mice (Supplementary Figures 1A and B) .ResultsThe CHE-FcD probe revealed no appreciable levels of 9-O-acetyl sialic acids on CD8 + T cells or NK cells (Figure 2A and B) in the spleens of wild-type or Casd1-deficient mice.", [["B220 + B cells", "ANATOMY", 17, 31], ["bone marrow", "ANATOMY", 39, 50], ["lymph nodes", "ANATOMY", 55, 66], ["cells", "ANATOMY", 134, 139], ["CD8 + T cells", "ANATOMY", 297, 310], ["NK cells", "ANATOMY", 314, 322], ["spleens", "ANATOMY", 348, 355], ["9-O-acetyl sialic acid", "CHEMICAL", 102, 124], ["9-O-acetyl sialic acids", "CHEMICAL", 270, 293], ["9-O-acetyl sialic acid", "CHEMICAL", 102, 124], ["9-O-acetyl sialic acids", "CHEMICAL", 270, 293], ["B220", "GENE_OR_GENE_PRODUCT", 17, 21], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 39, 50], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 55, 66], ["9-O-acetyl sialic acid", "SIMPLE_CHEMICAL", 102, 124], ["cells", "CELL", 134, 139], ["Casd1", "GENE_OR_GENE_PRODUCT", 156, 161], ["mice", "ORGANISM", 172, 176], ["9-O-acetyl sialic acids", "SIMPLE_CHEMICAL", 270, 293], ["CD8", "GENE_OR_GENE_PRODUCT", 297, 300], ["NK cells", "CELL", 314, 322], ["Figure 2A", "GENE_OR_GENE_PRODUCT", 324, 333], ["B", "GENE_OR_GENE_PRODUCT", 338, 339], ["spleens", "ORGAN", 348, 355], ["Casd1", "GENE_OR_GENE_PRODUCT", 372, 377], ["mice", "ORGANISM", 388, 392], ["B220", "PROTEIN", 17, 21], ["B cells", "CELL_TYPE", 24, 31], ["Casd1", "PROTEIN", 156, 161], ["CHE-FcD probe", "DNA", 222, 235], ["CD8 + T cells", "CELL_TYPE", 297, 310], ["NK cells", "CELL_TYPE", 314, 322], ["Figure 2A and B", "PROTEIN", 324, 339], ["Casd1", "PROTEIN", 372, 377], ["mice", "SPECIES", 172, 176], ["mice", "SPECIES", 388, 392], ["mice", "SPECIES", 172, 176], ["mice", "SPECIES", 388, 392], ["the bone marrow", "TEST", 35, 50], ["lymph nodes", "TEST", 55, 66], ["detectable levels", "PROBLEM", 81, 98], ["acetyl sialic acid", "TEST", 106, 124], ["these cells", "TEST", 128, 139], ["Casd1", "TEST", 156, 161], ["The CHE", "TEST", 218, 225], ["FcD probe", "TEST", 226, 235], ["appreciable levels", "PROBLEM", 248, 266], ["acetyl sialic acids", "TEST", 274, 293], ["CD8", "TEST", 297, 300], ["NK cells", "PROBLEM", 314, 322], ["Figure", "TEST", 324, 330], ["B cells", "OBSERVATION", 24, 31], ["bone marrow", "ANATOMY", 39, 50], ["lymph nodes", "OBSERVATION", 55, 66], ["no", "UNCERTAINTY", 78, 80], ["no", "UNCERTAINTY", 245, 247], ["NK cells", "OBSERVATION", 314, 322], ["spleens", "ANATOMY", 348, 355]]], ["Similar results were observed in the lymph nodes ( Supplementary Figures 2A and 2B ).", [["lymph nodes", "ANATOMY", 37, 48], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 37, 48], ["lymph nodes", "OBSERVATION", 37, 48]]], ["CD4 + T cells express high levels of 9-O-acetylated sialic acids (Figure 2A ), which is partly on mucin-type glycoproteins and partly on gangliosides (Krishna and Varki 1997) .", [["CD4 + T cells", "ANATOMY", 0, 13], ["9-O-acetylated sialic acids", "CHEMICAL", 37, 64], ["9-O-acetylated sialic acids", "CHEMICAL", 37, 64], ["CD4", "GENE_OR_GENE_PRODUCT", 0, 3], ["9-O-acetylated sialic acids", "SIMPLE_CHEMICAL", 37, 64], ["mucin-type glycoproteins", "GENE_OR_GENE_PRODUCT", 98, 122], ["gangliosides", "GENE_OR_GENE_PRODUCT", 137, 149], ["CD4", "PROTEIN", 0, 3], ["T cells", "CELL_TYPE", 6, 13], ["mucin-type glycoproteins", "PROTEIN", 98, 122], ["CD4", "TEST", 0, 3], ["T cells", "TEST", 6, 13], ["high levels", "PROBLEM", 22, 33], ["acetylated sialic acids", "TEST", 41, 64], ["mucin-type glycoproteins", "PROBLEM", 98, 122], ["gangliosides", "TEST", 137, 149], ["Krishna", "TEST", 151, 158]]], ["We found that naive CD62L hi CD4 + T cells had higher levels of 9-O-acetyl sialic acid than CD62L lo effector memory CD4 + T cells ( Figure 2C ).", [["CD62L hi CD4 + T cells", "ANATOMY", 20, 42], ["CD62L lo effector memory CD4 + T cells", "ANATOMY", 92, 130], ["9-O-acetyl sialic acid", "CHEMICAL", 64, 86], ["9-O-acetyl sialic acid", "CHEMICAL", 64, 86], ["CD62L", "GENE_OR_GENE_PRODUCT", 20, 25], ["CD4", "GENE_OR_GENE_PRODUCT", 29, 32], ["9-O-acetyl sialic acid", "SIMPLE_CHEMICAL", 64, 86], ["CD62L", "GENE_OR_GENE_PRODUCT", 92, 97], ["naive CD62L hi CD4 + T cells", "CELL_TYPE", 14, 42], ["CD62L", "PROTEIN", 92, 97], ["effector memory CD4 + T cells", "CELL_TYPE", 101, 130], ["naive CD62L", "TEST", 14, 25], ["CD4", "TEST", 29, 32], ["T cells", "TEST", 35, 42], ["acetyl sialic acid", "TEST", 68, 86], ["CD62L", "TEST", 92, 97]]], ["The 9-Oacetylation of sialic acid normally observed on both naive and memory wild-type CD4 + T cells in the spleen was completely lost in Casd1-deficient mice (Figure 2A and C).", [["memory wild-type CD4 + T cells", "ANATOMY", 70, 100], ["spleen", "ANATOMY", 108, 114], ["sialic acid", "CHEMICAL", 22, 33], ["sialic acid", "CHEMICAL", 22, 33], ["sialic acid", "SIMPLE_CHEMICAL", 22, 33], ["CD4", "GENE_OR_GENE_PRODUCT", 87, 90], ["spleen", "ORGAN", 108, 114], ["Casd1", "GENE_OR_GENE_PRODUCT", 138, 143], ["mice", "ORGANISM", 154, 158], ["naive and memory wild-type CD4 + T cells", "CELL_TYPE", 60, 100], ["Casd1", "PROTEIN", 138, 143], ["mice", "SPECIES", 154, 158], ["mice", "SPECIES", 154, 158], ["sialic acid", "PROBLEM", 22, 33], ["T cells in the spleen", "PROBLEM", 93, 114], ["Casd1", "TEST", 138, 143], ["spleen", "ANATOMY", 108, 114]]], ["The 9-O-acetyl sialic acid on wild-type CD4 + T cells was also eliminated by influenza C hemagglutinin esterase (CHE-Fc) treatment ( Figure 2D ).ResultsThe TER-119 monoclonal antibody fails to bind to Casd1-deficient murine erythrocytes and erythrocyte progenitors Erythrocytes from Casd1-deficient mice also lost reactivity to CHE-FcD ( Figure 3A ).", [["wild-type CD4 + T cells", "ANATOMY", 30, 53], ["erythrocytes", "ANATOMY", 224, 236], ["erythrocyte progenitors", "ANATOMY", 241, 264], ["Erythrocytes", "ANATOMY", 265, 277], ["9-O-acetyl sialic acid", "CHEMICAL", 4, 26], ["CHE-Fc", "CHEMICAL", 113, 119], ["CHE-FcD", "CHEMICAL", 328, 335], ["9-O-acetyl sialic acid", "CHEMICAL", 4, 26], ["9-O-acetyl sialic acid", "SIMPLE_CHEMICAL", 4, 26], ["CD4", "GENE_OR_GENE_PRODUCT", 40, 43], ["CHE-Fc", "GENE_OR_GENE_PRODUCT", 113, 119], ["TER-119", "GENE_OR_GENE_PRODUCT", 156, 163], ["Casd1", "GENE_OR_GENE_PRODUCT", 201, 206], ["murine", "ORGANISM", 217, 223], ["erythrocytes", "CELL", 224, 236], ["erythrocyte progenitors", "CELL", 241, 264], ["Erythrocytes", "CELL", 265, 277], ["Casd1", "GENE_OR_GENE_PRODUCT", 283, 288], ["mice", "ORGANISM", 299, 303], ["CHE-FcD", "SIMPLE_CHEMICAL", 328, 335], ["wild-type CD4 + T cells", "CELL_TYPE", 30, 53], ["influenza C hemagglutinin esterase", "PROTEIN", 77, 111], ["CHE", "PROTEIN", 113, 116], ["Fc", "PROTEIN", 117, 119], ["TER-119 monoclonal antibody", "PROTEIN", 156, 183], ["Casd1", "PROTEIN", 201, 206], ["murine erythrocytes", "CELL_TYPE", 217, 236], ["erythrocyte progenitors", "CELL_TYPE", 241, 264], ["Erythrocytes", "CELL_TYPE", 265, 277], ["Casd1", "PROTEIN", 283, 288], ["murine", "SPECIES", 217, 223], ["mice", "SPECIES", 299, 303], ["mice", "SPECIES", 299, 303], ["acetyl sialic acid", "TEST", 8, 26], ["T cells", "PROBLEM", 46, 53], ["influenza C hemagglutinin esterase", "PROBLEM", 77, 111], ["CHE-Fc) treatment", "TREATMENT", 113, 130], ["The TER", "TEST", 152, 159], ["monoclonal antibody", "TEST", 164, 183], ["Casd1", "TEST", 201, 206], ["murine erythrocytes", "TEST", 217, 236], ["erythrocyte progenitors", "TEST", 241, 264], ["Erythrocytes", "TEST", 265, 277], ["Casd1", "TEST", 283, 288], ["deficient mice", "PROBLEM", 289, 303], ["CHE", "TEST", 328, 331], ["erythrocyte progenitors Erythrocytes", "OBSERVATION", 241, 277]]], ["Despite the loss of 9-O-acetylation on erythrocytes, there was no evidence of anemia or other obvious change in RBC physiology.", [["erythrocytes", "ANATOMY", 39, 51], ["RBC", "ANATOMY", 112, 115], ["9-O", "CHEMICAL", 20, 23], ["anemia", "DISEASE", 78, 84], ["9-O", "CHEMICAL", 20, 23], ["9-O", "SIMPLE_CHEMICAL", 20, 23], ["erythrocytes", "CELL", 39, 51], ["RBC", "CELL", 112, 115], ["erythrocytes", "CELL_TYPE", 39, 51], ["RBC", "CELL_TYPE", 112, 115], ["acetylation on erythrocytes", "PROBLEM", 24, 51], ["anemia", "PROBLEM", 78, 84], ["other obvious change", "PROBLEM", 88, 108], ["RBC physiology", "PROBLEM", 112, 126], ["loss", "OBSERVATION_MODIFIER", 12, 16], ["no evidence of", "UNCERTAINTY", 63, 77], ["anemia", "OBSERVATION", 78, 84], ["obvious", "OBSERVATION_MODIFIER", 94, 101], ["change", "OBSERVATION", 102, 108], ["RBC physiology", "OBSERVATION", 112, 126]]], ["Surprisingly, Casd1-deficient erythrocytes, which lack 9-O-acetyl sialic acid based on the lack of binding to CHE-FcD, also lost reactivity to TER-119, suggesting that this antibody may recognize a 9-O-acetyl sialic acid glyco-epitope ( Figure 3A) .", [["erythrocytes", "ANATOMY", 30, 42], ["9-O-acetyl sialic acid", "CHEMICAL", 55, 77], ["TER-119", "CHEMICAL", 143, 150], ["9-O-acetyl sialic acid", "CHEMICAL", 198, 220], ["9-O-acetyl sialic acid", "CHEMICAL", 55, 77], ["TER-119", "CHEMICAL", 143, 150], ["9-O-acetyl sialic acid", "CHEMICAL", 198, 220], ["Casd1", "GENE_OR_GENE_PRODUCT", 14, 19], ["erythrocytes", "CELL", 30, 42], ["9-O-acetyl sialic acid", "SIMPLE_CHEMICAL", 55, 77], ["CHE-FcD", "GENE_OR_GENE_PRODUCT", 110, 117], ["TER-119", "GENE_OR_GENE_PRODUCT", 143, 150], ["9-O-acetyl sialic acid", "SIMPLE_CHEMICAL", 198, 220], ["Casd1", "PROTEIN", 14, 19], ["deficient erythrocytes", "CELL_TYPE", 20, 42], ["CHE", "PROTEIN", 110, 113], ["FcD", "PROTEIN", 114, 117], ["Casd1", "TEST", 14, 19], ["deficient erythrocytes", "PROBLEM", 20, 42], ["acetyl sialic acid", "TREATMENT", 59, 77], ["CHE", "TEST", 110, 113], ["TER", "TEST", 143, 146], ["this antibody", "TEST", 168, 181], ["acetyl sialic acid glyco-epitope", "TREATMENT", 202, 234], ["deficient erythrocytes", "OBSERVATION", 20, 42]]], ["A previous study on the identification of the target of TER-119 suggested that this antibody can immunoprecipitate proteins of 110 kDa, 60 kDa, 52 kDa and 32 kDa from the erythrocyte membrane (Kina et al. 2000) .", [["erythrocyte membrane", "ANATOMY", 171, 191], ["TER-119", "GENE_OR_GENE_PRODUCT", 56, 63], ["erythrocyte membrane", "CELLULAR_COMPONENT", 171, 191], ["TER", "PROTEIN", 56, 59], ["110 kDa", "PROTEIN", 127, 134], ["52 kDa", "PROTEIN", 144, 150], ["32 kDa", "PROTEIN", 155, 161], ["A previous study", "TEST", 0, 16], ["this antibody", "TEST", 79, 92], ["kDa", "TEST", 147, 150], ["kDa", "TEST", 158, 161], ["the erythrocyte membrane", "TEST", 167, 191], ["erythrocyte membrane", "ANATOMY", 171, 191]]], ["Of these, only the 52 kDa protein was detectable in a western blot using TER-119.", [["TER-119", "CHEMICAL", 73, 80], ["52 kDa protein", "PROTEIN", 19, 33], ["the 52 kDa protein", "TEST", 15, 33], ["TER", "TEST", 73, 76]]], ["However, the identity of this protein was not deciphered, and it was suspected to be a glycophorin A associated molecule.ResultsErythrocyte precursors in the bone marrow can be identified based on CD71 and TER-119 staining and are divided into the Ery-A (TER-119 + CD71 + FSC hi ), Ery-B (TER-119 + CD71 + FSC lo ) and Ery-C (TER-119 + CD71 \u2212 FSC lo ) flow cytometric fractions based on CD71, TER-119 and forward scatter (FSC) ( Figure 3B ) (Chen et al. 2009; Koulnis et al. 2011) .", [["Erythrocyte precursors", "ANATOMY", 128, 150], ["bone marrow", "ANATOMY", 158, 169], ["TER-119 + CD71 + FSC lo", "ANATOMY", 289, 312], ["TER-119 + CD71 \u2212 FSC lo", "ANATOMY", 326, 349], ["glycophorin A", "GENE_OR_GENE_PRODUCT", 87, 100], ["Erythrocyte precursors", "CELL", 128, 150], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 158, 169], ["CD71", "GENE_OR_GENE_PRODUCT", 197, 201], ["TER-119", "GENE_OR_GENE_PRODUCT", 206, 213], ["CD71", "GENE_OR_GENE_PRODUCT", 265, 269], ["Ery-B", "GENE_OR_GENE_PRODUCT", 282, 287], ["CD71", "GENE_OR_GENE_PRODUCT", 299, 303], ["Ery-C", "GENE_OR_GENE_PRODUCT", 319, 324], ["CD71", "GENE_OR_GENE_PRODUCT", 336, 340], ["CD71", "GENE_OR_GENE_PRODUCT", 387, 391], ["glycophorin A associated molecule", "PROTEIN", 87, 120], ["Erythrocyte precursors", "CELL_TYPE", 128, 150], ["CD71", "PROTEIN", 197, 201], ["TER", "PROTEIN", 206, 209], ["Ery-A", "PROTEIN", 248, 253], ["TER", "PROTEIN", 255, 258], ["CD71", "PROTEIN", 265, 269], ["Ery-B (TER-119", "CELL_LINE", 282, 296], ["CD71", "PROTEIN", 299, 303], ["Ery-C (TER-119", "CELL_LINE", 319, 333], ["CD71", "PROTEIN", 336, 340], ["CD71", "PROTEIN", 387, 391], ["TER", "PROTEIN", 393, 396], ["this protein", "TEST", 25, 37], ["a glycophorin A associated molecule", "PROBLEM", 85, 120], ["Erythrocyte precursors", "TEST", 128, 150], ["CD71", "TEST", 197, 201], ["TER", "TEST", 206, 209], ["TER", "TEST", 255, 258], ["CD71", "TEST", 265, 269], ["FSC hi", "TEST", 272, 278], ["Ery-B", "TEST", 282, 287], ["TER", "TEST", 289, 292], ["CD71", "TEST", 299, 303], ["FSC lo", "TEST", 306, 312], ["Ery-C", "TEST", 319, 324], ["TER", "TEST", 326, 329], ["CD71", "TEST", 336, 340], ["FSC lo", "TEST", 343, 349], ["flow cytometric fractions", "TEST", 352, 377], ["CD71", "TEST", 387, 391], ["TER", "TEST", 393, 396], ["forward scatter", "TEST", 405, 420], ["FSC", "TEST", 422, 425], ["bone", "ANATOMY", 158, 162]]], ["We found that surface 9-O-acetyl sialic acid identified using CHE-FcD staining appears only at the most mature Ery-C stage in the erythroid lineage.", [["surface", "ANATOMY", 14, 21], ["erythroid lineage", "ANATOMY", 130, 147], ["9-O-acetyl sialic acid", "CHEMICAL", 22, 44], ["CHE", "CHEMICAL", 62, 65], ["9-O-acetyl sialic acid", "CHEMICAL", 22, 44], ["9-O-acetyl sialic acid", "SIMPLE_CHEMICAL", 22, 44], ["CHE-FcD", "GENE_OR_GENE_PRODUCT", 62, 69], ["erythroid lineage", "CELL", 130, 147], ["FcD", "PROTEIN", 66, 69], ["erythroid lineage", "CELL_TYPE", 130, 147], ["surface", "TEST", 14, 21], ["acetyl sialic acid", "TEST", 26, 44], ["CHE-FcD staining", "TEST", 62, 78], ["C stage in the erythroid lineage", "PROBLEM", 115, 147], ["C stage", "OBSERVATION_MODIFIER", 115, 122], ["erythroid lineage", "OBSERVATION", 130, 147]]], ["We did not observe any CD71 positive cells that lacked TER-119 in the wild-type mouse bone marrow, suggesting that CD71 and FSC alone could be used to identify the Ery-A and Ery-B erythroblast fractions in the bone marrow of Casd1-deficient mice (that lack the TER-119 epitope) ( Figure 3B ).", [["CD71 positive cells", "ANATOMY", 23, 42], ["bone marrow", "ANATOMY", 86, 97], ["Ery-B erythroblast fractions", "ANATOMY", 174, 202], ["bone marrow", "ANATOMY", 210, 221], ["TER-119", "CHEMICAL", 55, 62], ["CD71", "GENE_OR_GENE_PRODUCT", 23, 27], ["cells", "CELL", 37, 42], ["TER-119", "GENE_OR_GENE_PRODUCT", 55, 62], ["mouse", "ORGANISM", 80, 85], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 86, 97], ["CD71", "GENE_OR_GENE_PRODUCT", 115, 119], ["FSC", "GENE_OR_GENE_PRODUCT", 124, 127], ["Ery-A", "GENE_OR_GENE_PRODUCT", 164, 169], ["Ery-B erythroblast", "CELL", 174, 192], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 210, 221], ["Casd1", "GENE_OR_GENE_PRODUCT", 225, 230], ["mice", "ORGANISM", 241, 245], ["CD71 positive cells", "CELL_TYPE", 23, 42], ["TER", "PROTEIN", 55, 58], ["CD71", "PROTEIN", 115, 119], ["FSC", "CELL_TYPE", 124, 127], ["Casd1", "PROTEIN", 225, 230], ["TER", "PROTEIN", 261, 264], ["mouse", "SPECIES", 80, 85], ["mice", "SPECIES", 241, 245], ["mouse", "SPECIES", 80, 85], ["mice", "SPECIES", 241, 245], ["CD71 positive cells", "PROBLEM", 23, 42], ["TER", "TEST", 55, 58], ["CD71", "TEST", 115, 119], ["FSC", "TEST", 124, 127], ["the Ery", "TEST", 160, 167], ["Ery", "TEST", 174, 177], ["Casd1", "TEST", 225, 230], ["deficient mice", "PROBLEM", 231, 245], ["the TER", "TEST", 257, 264], ["bone marrow", "ANATOMY", 86, 97], ["erythroblast fractions", "OBSERVATION", 180, 202], ["bone marrow", "ANATOMY", 210, 221]]], ["As in wild-type mice, in the bone marrow of Casd1-deficient mice, there was also no detectable surface 9-O-acetylation on CD71 + Ery-A and Ery-B erythroid progenitors based upon staining with CHE-FcD ( Figure 3B ).", [["bone marrow", "ANATOMY", 29, 40], ["surface", "ANATOMY", 95, 102], ["Ery-B erythroid progenitors", "ANATOMY", 139, 166], ["mice", "ORGANISM", 16, 20], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 29, 40], ["Casd1", "GENE_OR_GENE_PRODUCT", 44, 49], ["mice", "ORGANISM", 60, 64], ["CD71", "GENE_OR_GENE_PRODUCT", 122, 126], ["Ery-A", "GENE_OR_GENE_PRODUCT", 129, 134], ["Ery-B", "GENE_OR_GENE_PRODUCT", 139, 144], ["CHE-FcD", "SIMPLE_CHEMICAL", 192, 199], ["Casd1", "PROTEIN", 44, 49], ["CD71", "PROTEIN", 122, 126], ["Ery-A and Ery-B erythroid progenitors", "CELL_LINE", 129, 166], ["CHE", "PROTEIN", 192, 195], ["mice", "SPECIES", 16, 20], ["mice", "SPECIES", 60, 64], ["mice", "SPECIES", 16, 20], ["mice", "SPECIES", 60, 64], ["CD71", "TEST", 122, 126], ["Ery", "TEST", 129, 132], ["Ery", "TEST", 139, 142], ["erythroid progenitors", "PROBLEM", 145, 166], ["CHE", "TEST", 192, 195], ["bone marrow", "ANATOMY", 29, 40], ["no", "UNCERTAINTY", 81, 83], ["erythroid progenitors", "OBSERVATION", 145, 166]]], ["Our flow cytometry analysis suggests that Casd1-deficient mice exhibit a pan-hematopoietic loss of 9-Oacetyl sialic acids in the myeloid, lymphoid and erythroid lineages.ResultsThe TER-119 epitope is sensitive to the hemagglutinin esterase from bovine coronavirus but not influenza C Given that the Casd1-deficient mice exhibited a complete loss of TER-119 staining in the erythroid lineage, we considered the possibility that the TER-119 monoclonal antibody recognized a 9-O-acetyl sialic acid dependent epitope.", [["myeloid", "ANATOMY", 129, 136], ["lymphoid", "ANATOMY", 138, 146], ["erythroid lineages", "ANATOMY", 151, 169], ["erythroid lineage", "ANATOMY", 373, 390], ["9-Oacetyl sialic acids", "CHEMICAL", 99, 121], ["9-O-acetyl sialic acid", "CHEMICAL", 472, 494], ["9-Oacetyl sialic acids", "CHEMICAL", 99, 121], ["9-O-acetyl sialic acid", "CHEMICAL", 472, 494], ["Casd1", "GENE_OR_GENE_PRODUCT", 42, 47], ["mice", "ORGANISM", 58, 62], ["9-Oacetyl sialic acids", "SIMPLE_CHEMICAL", 99, 121], ["myeloid", "CELL", 129, 136], ["lymphoid", "CELL", 138, 146], ["erythroid lineages", "CELL", 151, 169], ["TER-119", "GENE_OR_GENE_PRODUCT", 181, 188], ["hemagglutinin esterase", "GENE_OR_GENE_PRODUCT", 217, 239], ["bovine coronavirus", "ORGANISM", 245, 263], ["influenza C", "ORGANISM", 272, 283], ["Casd1", "GENE_OR_GENE_PRODUCT", 299, 304], ["mice", "ORGANISM", 315, 319], ["TER-119", "GENE_OR_GENE_PRODUCT", 349, 356], ["erythroid lineage", "CELL", 373, 390], ["TER", "GENE_OR_GENE_PRODUCT", 431, 434], ["9-O-acetyl sialic acid", "SIMPLE_CHEMICAL", 472, 494], ["Casd1", "PROTEIN", 42, 47], ["myeloid, lymphoid and erythroid lineages", "CELL_TYPE", 129, 169], ["TER-119 epitope", "PROTEIN", 181, 196], ["hemagglutinin esterase", "PROTEIN", 217, 239], ["Casd1", "PROTEIN", 299, 304], ["TER", "PROTEIN", 349, 352], ["erythroid lineage", "CELL_TYPE", 373, 390], ["TER-119 monoclonal antibody", "PROTEIN", 431, 458], ["acetyl sialic acid dependent epitope", "PROTEIN", 476, 512], ["mice", "SPECIES", 58, 62], ["bovine", "SPECIES", 245, 251], ["coronavirus", "SPECIES", 252, 263], ["mice", "SPECIES", 315, 319], ["mice", "SPECIES", 58, 62], ["bovine coronavirus", "SPECIES", 245, 263], ["mice", "SPECIES", 315, 319], ["Our flow cytometry analysis", "TEST", 0, 27], ["Casd1", "TEST", 42, 47], ["deficient mice", "PROBLEM", 48, 62], ["a pan-hematopoietic loss", "PROBLEM", 71, 95], ["Oacetyl sialic acids", "TREATMENT", 101, 121], ["The TER", "TEST", 177, 184], ["the hemagglutinin esterase", "PROBLEM", 213, 239], ["bovine coronavirus", "PROBLEM", 245, 263], ["influenza", "PROBLEM", 272, 281], ["the Casd1", "TEST", 295, 304], ["a complete loss of TER", "PROBLEM", 330, 352], ["the TER", "TEST", 427, 434], ["monoclonal antibody", "TEST", 439, 458], ["acetyl sialic acid dependent epitope", "TREATMENT", 476, 512], ["pan-hematopoietic loss", "OBSERVATION", 73, 95], ["myeloid", "ANATOMY", 129, 136], ["lymphoid", "ANATOMY", 138, 146], ["erythroid lineages", "OBSERVATION", 151, 169], ["erythroid lineage", "OBSERVATION", 373, 390]]], ["However, the Ery-A and Ery-B erythroid precursors that normally express the TER-119 epitope in wild-type mice do not express any 9-O-acetyl sialic acid that is detectable by CHE-FcD staining.", [["Ery-B erythroid precursors", "ANATOMY", 23, 49], ["9-O-acetyl sialic acid", "CHEMICAL", 129, 151], ["9-O-acetyl sialic acid", "CHEMICAL", 129, 151], ["Ery-A", "GENE_OR_GENE_PRODUCT", 13, 18], ["Ery-B", "GENE_OR_GENE_PRODUCT", 23, 28], ["TER", "GENE_OR_GENE_PRODUCT", 76, 79], ["mice", "ORGANISM", 105, 109], ["9-O-acetyl sialic acid", "SIMPLE_CHEMICAL", 129, 151], ["CHE-FcD", "GENE_OR_GENE_PRODUCT", 174, 181], ["Ery-A and Ery-B erythroid precursors", "CELL_LINE", 13, 49], ["TER-119 epitope", "PROTEIN", 76, 91], ["mice", "SPECIES", 105, 109], ["mice", "SPECIES", 105, 109], ["acetyl sialic acid", "TEST", 133, 151], ["FcD staining", "PROBLEM", 178, 190], ["erythroid precursors", "OBSERVATION", 29, 49]]], ["Therefore, we decided to examine the relationship between 9-O-acetyl sialic acid and the TER-119 epitope in greater detail.", [["9-O-acetyl sialic acid", "CHEMICAL", 58, 80], ["9-O-acetyl sialic acid", "CHEMICAL", 58, 80], ["9-O-acetyl sialic acid", "SIMPLE_CHEMICAL", 58, 80], ["TER-119 epitope", "PROTEIN", 89, 104], ["acetyl sialic acid", "TREATMENT", 62, 80], ["the TER", "TEST", 85, 92]]], ["The hemagglutinin-esterase from bovine coronavirus Mebus strain (BHE) also recognizes 9-O-acetyl sialic acid, but in a manner that is structurally distinct from CHE (Zeng et al. 2008 ).", [["BHE", "CHEMICAL", 65, 68], ["9-O-acetyl sialic acid", "CHEMICAL", 86, 108], ["9-O-acetyl sialic acid", "CHEMICAL", 86, 108], ["hemagglutinin-esterase", "GENE_OR_GENE_PRODUCT", 4, 26], ["bovine coronavirus Mebus strain", "ORGANISM", 32, 63], ["BHE", "CELL", 65, 68], ["9-O-acetyl sialic acid", "SIMPLE_CHEMICAL", 86, 108], ["hemagglutinin-esterase", "PROTEIN", 4, 26], ["bovine", "SPECIES", 32, 38], ["coronavirus Mebus", "SPECIES", 39, 56], ["bovine coronavirus", "SPECIES", 32, 50], ["The hemagglutinin-esterase", "TEST", 0, 26], ["bovine coronavirus Mebus strain", "PROBLEM", 32, 63], ["acetyl sialic acid", "TREATMENT", 90, 108], ["coronavirus Mebus", "OBSERVATION", 39, 56]]], ["Furthermore, unlike CHE, the BHE lectin recognizes 7,9-di-O-acetyl sialic acid in addition to 9-O-acetyl sialic acid Bakkers et al. 2016) .", [["CHE", "CHEMICAL", 20, 23], ["7,9-di-O-acetyl sialic acid", "CHEMICAL", 51, 78], ["9-O-acetyl sialic acid", "CHEMICAL", 94, 116], ["7,9-di-O-acetyl sialic acid", "CHEMICAL", 51, 78], ["9-O-acetyl sialic acid", "CHEMICAL", 94, 116], ["CHE", "SIMPLE_CHEMICAL", 20, 23], ["BHE lectin", "GENE_OR_GENE_PRODUCT", 29, 39], ["7,9-di-O-acetyl sialic acid", "SIMPLE_CHEMICAL", 51, 78], ["9-O-acetyl sialic acid", "SIMPLE_CHEMICAL", 94, 116], ["CHE", "PROTEIN", 20, 23], ["BHE lectin", "PROTEIN", 29, 39], ["the BHE lectin", "TEST", 25, 39], ["acetyl sialic acid", "TREATMENT", 60, 78], ["acetyl sialic acid", "TREATMENT", 98, 116]]], ["Therefore, we expressed BHE as an Fc-fusion protein (BHE-Fc) analogous to the approach used to generate CHE-Fc.", [["BHE", "GENE_OR_GENE_PRODUCT", 24, 27], ["Fc-", "GENE_OR_GENE_PRODUCT", 34, 37], ["BHE-Fc", "GENE_OR_GENE_PRODUCT", 53, 59], ["BHE", "PROTEIN", 24, 27], ["Fc-fusion protein", "PROTEIN", 34, 51], ["BHE", "PROTEIN", 53, 56], ["Fc", "PROTEIN", 57, 59], ["an Fc-fusion protein", "TEST", 31, 51], ["CHE", "TEST", 104, 107]]], ["In addition, we also generated a catalytically inactive form of BHE-Fc bearing the S40A substitution (BHE-Fc-S40A) whose ability to bind 9-O-acetyl sialic acids is unhindered as previously described (Zeng et al. 2008) .", [["BHE", "CHEMICAL", 64, 67], ["9-O-acetyl sialic acids", "CHEMICAL", 137, 160], ["9-O-acetyl sialic acids", "CHEMICAL", 137, 160], ["BHE-Fc", "GENE_OR_GENE_PRODUCT", 64, 70], ["S40A", "GENE_OR_GENE_PRODUCT", 83, 87], ["BHE-Fc-S40A", "GENE_OR_GENE_PRODUCT", 102, 113], ["9-O-acetyl sialic acids", "SIMPLE_CHEMICAL", 137, 160], ["catalytically inactive form", "PROTEIN", 33, 60], ["BHE", "PROTEIN", 64, 67], ["Fc", "PROTEIN", 68, 70], ["S40A", "PROTEIN", 83, 87], ["BHE", "PROTEIN", 102, 105], ["Fc", "PROTEIN", 106, 108], ["S40A", "PROTEIN", 109, 113], ["BHE", "TEST", 64, 67], ["BHE", "TEST", 102, 105], ["acetyl sialic acids", "TREATMENT", 141, 160]]], ["We found that the TER-119 + CD71 + Ery-A and Ery-B precursors from wild-type mice exhibited strong staining with BHE-Fc-S40A but not with CHE-FcD ( Figures 3B and 4A ).", [["TER-119 + CD71 + Ery-A", "ANATOMY", 18, 40], ["Ery-B precursors", "ANATOMY", 45, 61], ["TER-119", "GENE_OR_GENE_PRODUCT", 18, 25], ["CD71", "GENE_OR_GENE_PRODUCT", 28, 32], ["Ery-A", "GENE_OR_GENE_PRODUCT", 35, 40], ["Ery-B", "GENE_OR_GENE_PRODUCT", 45, 50], ["mice", "ORGANISM", 77, 81], ["BHE-Fc", "GENE_OR_GENE_PRODUCT", 113, 119], ["CHE-FcD", "GENE_OR_GENE_PRODUCT", 138, 145], ["TER", "PROTEIN", 18, 21], ["CD71", "PROTEIN", 28, 32], ["Ery-A and Ery-B precursors", "CELL_LINE", 35, 61], ["BHE", "PROTEIN", 113, 116], ["Fc", "PROTEIN", 117, 119], ["S40A", "PROTEIN", 120, 124], ["CHE", "PROTEIN", 138, 141], ["FcD", "PROTEIN", 142, 145], ["mice", "SPECIES", 77, 81], ["mice", "SPECIES", 77, 81], ["the TER", "TEST", 14, 21], ["CD71", "TEST", 28, 32], ["Ery", "TEST", 35, 38], ["Ery", "TEST", 45, 48], ["BHE", "TEST", 113, 116], ["Fc", "TEST", 117, 119], ["CHE", "TEST", 138, 141]]], ["This suggested to us that the TER-119 epitope may be recognized by the BHE virolectin but not by CHE.", [["CHE", "CHEMICAL", 97, 100], ["TER-119", "GENE_OR_GENE_PRODUCT", 30, 37], ["virolectin", "GENE_OR_GENE_PRODUCT", 75, 85], ["TER-119 epitope", "PROTEIN", 30, 45], ["BHE virolectin", "PROTEIN", 71, 85], ["CHE", "PROTEIN", 97, 100], ["the TER", "TEST", 26, 33]]], ["We next used murine RBCs to examine the interactions of the TER-119 epitope with CHE and BHE.ResultsInfluenza C hemagglutinin esterase (CHE-Fc) pre-treatment eliminated 9-O-acetyl sialic acid-dependent CHE-FcD binding on murine erythrocytes, rendering them indistinguishable from Casd1deficient erythrocytes based on CHE-FcD staining ( Figure 4B ).", [["RBCs", "ANATOMY", 20, 24], ["erythrocytes", "ANATOMY", 228, 240], ["erythrocytes", "ANATOMY", 295, 307], ["CHE", "CHEMICAL", 81, 84], ["CHE-Fc", "CHEMICAL", 136, 142], ["9-O-acetyl", "CHEMICAL", 169, 179], ["CHE", "CHEMICAL", 202, 205], ["9-O-acetyl", "CHEMICAL", 169, 179], ["murine", "ORGANISM", 13, 19], ["RBCs", "CELL", 20, 24], ["TER", "GENE_OR_GENE_PRODUCT", 60, 63], ["CHE", "SIMPLE_CHEMICAL", 81, 84], ["BHE", "SIMPLE_CHEMICAL", 89, 92], ["C hemagglutinin esterase", "GENE_OR_GENE_PRODUCT", 110, 134], ["CHE-Fc", "GENE_OR_GENE_PRODUCT", 136, 142], ["9-O-acetyl sialic acid-dependent CHE-FcD", "SIMPLE_CHEMICAL", 169, 209], ["murine", "ORGANISM", 221, 227], ["erythrocytes", "CELL", 228, 240], ["Casd1deficient erythrocytes", "CELL", 280, 307], ["CHE-FcD", "GENE_OR_GENE_PRODUCT", 317, 324], ["murine RBCs", "CELL_TYPE", 13, 24], ["TER-119 epitope", "PROTEIN", 60, 75], ["Influenza C hemagglutinin esterase", "PROTEIN", 100, 134], ["CHE", "PROTEIN", 136, 139], ["Fc", "PROTEIN", 140, 142], ["FcD", "PROTEIN", 206, 209], ["murine erythrocytes", "CELL_TYPE", 221, 240], ["Casd1deficient erythrocytes", "CELL_LINE", 280, 307], ["murine", "SPECIES", 13, 19], ["murine", "SPECIES", 221, 227], ["murine RBCs", "TREATMENT", 13, 24], ["Influenza", "TEST", 100, 109], ["hemagglutinin esterase", "TEST", 112, 134], ["CHE-Fc", "TEST", 136, 142], ["pre-treatment", "TEST", 144, 157], ["FcD binding", "PROBLEM", 206, 217], ["murine erythrocytes", "TEST", 221, 240], ["Casd1deficient erythrocytes", "PROBLEM", 280, 307], ["CHE", "TEST", 317, 320], ["FcD staining", "TEST", 321, 333]]], ["Yet, the TER-119 epitope on murine erythrocytes was surprisingly resistant to treatment with CHE ( Figure 4B ).", [["erythrocytes", "ANATOMY", 35, 47], ["CHE", "CHEMICAL", 93, 96], ["TER-119", "GENE_OR_GENE_PRODUCT", 9, 16], ["murine", "ORGANISM", 28, 34], ["erythrocytes", "CELL", 35, 47], ["TER-119 epitope", "PROTEIN", 9, 24], ["murine erythrocytes", "CELL_TYPE", 28, 47], ["murine", "SPECIES", 28, 34], ["the TER", "TEST", 5, 12], ["murine erythrocytes", "PROBLEM", 28, 47], ["treatment", "TREATMENT", 78, 87], ["CHE ( Figure 4B", "TREATMENT", 93, 108]]], ["As a control, and as previously shown by Varki et al., we also showed that CHE-Fc pre-treatment completely eliminated CHE-FcD binding on CD4 + T lymphocytes ( Figure 2D) .", [["CD4 + T lymphocytes", "ANATOMY", 137, 156], ["CHE", "CHEMICAL", 75, 78], ["CHE", "CHEMICAL", 118, 121], ["CHE-Fc", "GENE_OR_GENE_PRODUCT", 75, 81], ["CHE-FcD", "SIMPLE_CHEMICAL", 118, 125], ["CD4", "GENE_OR_GENE_PRODUCT", 137, 140], ["FcD", "PROTEIN", 122, 125], ["CD4", "PROTEIN", 137, 140], ["T lymphocytes", "CELL_TYPE", 143, 156], ["CHE", "TEST", 75, 78], ["CHE", "TEST", 118, 121], ["FcD binding", "PROBLEM", 122, 133], ["CD4", "TEST", 137, 140], ["lymphocytes", "TEST", 145, 156]]], ["Interestingly, the TER-119 epitope on murine RBCs was sensitive to BHE-Fc but not CHE-Fc esterase treatment ( Figure 4B ).", [["RBCs", "ANATOMY", 45, 49], ["BHE", "CHEMICAL", 67, 70], ["TER-119", "GENE_OR_GENE_PRODUCT", 19, 26], ["murine", "ORGANISM", 38, 44], ["RBCs", "CELL", 45, 49], ["BHE-Fc", "GENE_OR_GENE_PRODUCT", 67, 73], ["CHE-Fc esterase", "GENE_OR_GENE_PRODUCT", 82, 97], ["TER-119 epitope", "PROTEIN", 19, 34], ["murine RBCs", "CELL_TYPE", 38, 49], ["BHE", "PROTEIN", 67, 70], ["Fc", "PROTEIN", 71, 73], ["CHE", "PROTEIN", 82, 85], ["Fc esterase", "PROTEIN", 86, 97], ["murine", "SPECIES", 38, 44], ["the TER", "TEST", 15, 22], ["murine RBCs", "TEST", 38, 49], ["BHE", "TEST", 67, 70], ["CHE", "TEST", 82, 85], ["Fc esterase treatment", "TREATMENT", 86, 107]]], ["In contrast, pre-treatment with an enzymatically inactive version of BHE-Fc bearing the S40A catalytic site mutation (BHE-S40A-Fc) had a negligible effect on TER-119 staining (data not shown).ResultsHowever, in the setting of a competitive binding assay, the lectin domain of BHE modestly hampered TER-119 binding to its epitope in a dose-dependent manner ( Figure 4C ).", [["BHE", "CHEMICAL", 69, 72], ["BHE", "CHEMICAL", 276, 279], ["TER-119", "CHEMICAL", 298, 305], ["TER-119", "CHEMICAL", 298, 305], ["BHE-Fc", "GENE_OR_GENE_PRODUCT", 69, 75], ["S40A", "GENE_OR_GENE_PRODUCT", 88, 92], ["BHE-S40A-Fc", "GENE_OR_GENE_PRODUCT", 118, 129], ["TER-119", "GENE_OR_GENE_PRODUCT", 158, 165], ["BHE", "SIMPLE_CHEMICAL", 276, 279], ["TER-119", "GENE_OR_GENE_PRODUCT", 298, 305], ["BHE", "PROTEIN", 69, 72], ["Fc", "PROTEIN", 73, 75], ["S40A", "PROTEIN", 88, 92], ["BHE-S40A-Fc", "DNA", 118, 129], ["lectin domain", "PROTEIN", 259, 272], ["BHE", "PROTEIN", 276, 279], ["TER", "PROTEIN", 298, 301], ["BHE", "TEST", 69, 72], ["BHE", "TEST", 118, 121], ["TER", "TEST", 158, 161], ["a competitive binding assay", "PROBLEM", 226, 253], ["inactive", "OBSERVATION", 49, 57]]], ["Given that both CHE and BHE have evolved as receptor-destroying enzymes that recognize 9-O-acetyl sialic acids, it was not surprising that both CHE-Fc and BHE-Fc pre-treatment of mouse RBCs was able to eliminate the corresponding virolectin receptor binding ( Figure 4D ).", [["RBCs", "ANATOMY", 185, 189], ["CHE", "CHEMICAL", 16, 19], ["BHE", "CHEMICAL", 24, 27], ["9-O-acetyl sialic acids", "CHEMICAL", 87, 110], ["CHE", "CHEMICAL", 144, 147], ["BHE", "CHEMICAL", 155, 158], ["9-O-acetyl sialic acids", "CHEMICAL", 87, 110], ["CHE", "SIMPLE_CHEMICAL", 16, 19], ["BHE", "SIMPLE_CHEMICAL", 24, 27], ["9-O-acetyl sialic acids", "SIMPLE_CHEMICAL", 87, 110], ["CHE-Fc", "GENE_OR_GENE_PRODUCT", 144, 150], ["BHE-Fc", "SIMPLE_CHEMICAL", 155, 161], ["mouse", "ORGANISM", 179, 184], ["RBCs", "CELL", 185, 189], ["virolectin receptor", "GENE_OR_GENE_PRODUCT", 230, 249], ["Fc", "PROTEIN", 148, 150], ["Fc", "PROTEIN", 159, 161], ["mouse RBCs", "CELL_TYPE", 179, 189], ["virolectin receptor", "PROTEIN", 230, 249], ["mouse", "SPECIES", 179, 184], ["mouse", "SPECIES", 179, 184], ["acetyl sialic acids", "TREATMENT", 91, 110], ["CHE", "TEST", 144, 147], ["BHE", "TEST", 155, 158], ["mouse RBCs", "PROBLEM", 179, 189]]], ["Although treatment with BHE-Fc completely eliminated CHE-FcD binding, CHE only partially eliminated BHE-S40A-Fc binding ( Figure 4D ).", [["BHE", "CHEMICAL", 24, 27], ["CHE", "CHEMICAL", 53, 56], ["CHE", "CHEMICAL", 70, 73], ["BHE", "CHEMICAL", 100, 103], ["CHE-FcD", "CHEMICAL", 53, 60], ["CHE", "CHEMICAL", 70, 73], ["BHE-Fc", "SIMPLE_CHEMICAL", 24, 30], ["CHE-FcD", "SIMPLE_CHEMICAL", 53, 60], ["CHE", "SIMPLE_CHEMICAL", 70, 73], ["BHE", "SIMPLE_CHEMICAL", 100, 103], ["BHE", "PROTEIN", 24, 27], ["Fc", "PROTEIN", 28, 30], ["FcD", "PROTEIN", 57, 60], ["BHE", "PROTEIN", 100, 103], ["S40A", "PROTEIN", 104, 108], ["Fc", "PROTEIN", 109, 111], ["FcD binding", "PROBLEM", 57, 68], ["CHE", "TEST", 70, 73], ["BHE", "TEST", 100, 103]]], ["These data are consistent with the notion that the BHE virolectin and enzyme has the ability to recognize modified 9-O-acetyl sialic acid ligands that are not recognized by CHE.", [["virolectin", "CHEMICAL", 55, 65], ["9-O-acetyl sialic acid", "CHEMICAL", 115, 137], ["9-O-acetyl sialic acid", "CHEMICAL", 115, 137], ["BHE virolectin", "GENE_OR_GENE_PRODUCT", 51, 65], ["9-O-acetyl sialic acid", "SIMPLE_CHEMICAL", 115, 137], ["CHE", "SIMPLE_CHEMICAL", 173, 176], ["BHE virolectin", "PROTEIN", 51, 65], ["the BHE virolectin", "TEST", 47, 65], ["acetyl sialic acid ligands", "TREATMENT", 119, 145], ["consistent with", "UNCERTAINTY", 15, 30], ["acid ligands", "OBSERVATION", 133, 145]]], ["Since BHE has been shown to bind to 7,9-di-O-acetyl sialic acid while CHE cannot Bakkers et al. 2016) , our results are compatible with the notion that 7,9 di-O-acetyl sialic acid is a component of the TER-119 epitope and is expressed in the erythroid lineage from the Ery-A stage onwards.", [["erythroid lineage", "ANATOMY", 242, 259], ["BHE", "CHEMICAL", 6, 9], ["7,9-di-O-acetyl sialic acid", "CHEMICAL", 36, 63], ["CHE", "CHEMICAL", 70, 73], ["7,9 di-O-acetyl sialic acid", "CHEMICAL", 152, 179], ["7,9-di-O-acetyl sialic acid", "CHEMICAL", 36, 63], ["7,9 di-O-acetyl sialic acid", "CHEMICAL", 152, 179], ["BHE", "GENE_OR_GENE_PRODUCT", 6, 9], ["7,9-di-O-acetyl sialic acid", "SIMPLE_CHEMICAL", 36, 63], ["7,9 di-O-acetyl sialic acid", "SIMPLE_CHEMICAL", 152, 179], ["TER", "GENE_OR_GENE_PRODUCT", 202, 205], ["erythroid lineage", "CELL", 242, 259], ["BHE", "PROTEIN", 6, 9], ["TER-119 epitope", "PROTEIN", 202, 217], ["erythroid lineage", "CELL_TYPE", 242, 259], ["acetyl sialic acid", "TREATMENT", 45, 63], ["acetyl sialic acid", "TREATMENT", 161, 179], ["the TER", "TEST", 198, 205], ["erythroid lineage", "OBSERVATION", 242, 259]]], ["However, definitive identification of this moiety will require further structural analyses.DiscussionPrior studies of Baumann et al. (2015) have shown that CASD1 catalyzes the transfer of acetyl moieties from acetyl-CoA to CMP-sialic acid through the formation of a covalent acetyl-enzyme intermediate.", [["CASD1", "CHEMICAL", 156, 161], ["acetyl", "CHEMICAL", 188, 194], ["acetyl-CoA", "CHEMICAL", 209, 219], ["CMP-sialic acid", "CHEMICAL", 223, 238], ["acetyl", "CHEMICAL", 275, 281], ["acetyl", "CHEMICAL", 188, 194], ["acetyl-CoA", "CHEMICAL", 209, 219], ["CMP-sialic acid", "CHEMICAL", 223, 238], ["acetyl", "CHEMICAL", 275, 281], ["CASD1", "GENE_OR_GENE_PRODUCT", 156, 161], ["acetyl moieties", "SIMPLE_CHEMICAL", 188, 203], ["acetyl-CoA", "SIMPLE_CHEMICAL", 209, 219], ["CMP-sialic acid", "SIMPLE_CHEMICAL", 223, 238], ["CASD1", "PROTEIN", 156, 161], ["this moiety", "PROBLEM", 38, 49], ["further structural analyses", "TEST", 63, 90], ["acetyl moieties", "TREATMENT", 188, 203], ["acetyl", "TREATMENT", 209, 215], ["CMP", "TEST", 223, 226], ["sialic acid", "TREATMENT", 227, 238], ["a covalent acetyl", "TREATMENT", 264, 281]]], ["Of note, CASD1 is unable to use the unactivated form of sialic acid or other sialic acid that is already incorporated into sialoconjugates (e.g., fetuin (N-linked), bovine submandibular mucin (O-linked), 2,3/ 2,6-sialolactose, or GD3) as substrates.", [["submandibular", "ANATOMY", 172, 185], ["sialic acid", "CHEMICAL", 56, 67], ["sialic acid", "CHEMICAL", 77, 88], ["2,3/ 2,6-sialolactose", "CHEMICAL", 204, 225], ["sialic acid", "CHEMICAL", 56, 67], ["sialic acid", "CHEMICAL", 77, 88], ["CASD1", "GENE_OR_GENE_PRODUCT", 9, 14], ["sialic acid", "SIMPLE_CHEMICAL", 56, 67], ["sialic acid", "SIMPLE_CHEMICAL", 77, 88], ["sialoconjugates", "SIMPLE_CHEMICAL", 123, 138], ["fetuin", "GENE_OR_GENE_PRODUCT", 146, 152], ["bovine", "ORGANISM", 165, 171], ["submandibular", "ORGAN", 172, 185], ["mucin", "GENE_OR_GENE_PRODUCT", 186, 191], ["O-linked)", "SIMPLE_CHEMICAL", 193, 202], ["2,3/ 2,6-sialolactose", "SIMPLE_CHEMICAL", 204, 225], ["GD3", "SIMPLE_CHEMICAL", 230, 233], ["CASD1", "PROTEIN", 9, 14], ["fetuin", "PROTEIN", 146, 152], ["bovine", "SPECIES", 165, 171], ["sialic acid", "PROBLEM", 56, 67], ["other sialic acid", "PROBLEM", 71, 88], ["fetuin", "TEST", 146, 152], ["bovine submandibular mucin", "TEST", 165, 191], ["submandibular", "ANATOMY", 172, 185]]], ["The authors proposed that the 9-O-acetylated CMP-sialic acid is subsequently incorporated into sialoglycans.", [["9-O", "CHEMICAL", 30, 33], ["CMP-sialic acid", "CHEMICAL", 45, 60], ["9-O-acetylated CMP-sialic acid", "CHEMICAL", 30, 60], ["9-O-acetylated CMP-sialic acid", "SIMPLE_CHEMICAL", 30, 60], ["sialoglycans", "GENE_OR_GENE_PRODUCT", 95, 107], ["sialoglycans", "PROTEIN", 95, 107], ["sialic acid", "PROBLEM", 49, 60]]], ["CASD1 is widely expressed in most tissues (based on the Protein and RNA Expression Atlas); this may indicate that most 9-Oacetyl sialoglycans are generated in a CASD1-dependent manner (Uhl\u00e9n et al. 2015) .", [["tissues", "ANATOMY", 34, 41], ["9-Oacetyl", "CHEMICAL", 119, 128], ["CASD1", "GENE_OR_GENE_PRODUCT", 0, 5], ["tissues", "TISSUE", 34, 41], ["9-Oacetyl sialoglycans", "SIMPLE_CHEMICAL", 119, 141], ["CASD1", "GENE_OR_GENE_PRODUCT", 161, 166], ["CASD1", "PROTEIN", 0, 5], ["Oacetyl sialoglycans", "PROTEIN", 121, 141], ["CASD1", "PROTEIN", 161, 166], ["the Protein", "TEST", 52, 63], ["Oacetyl sialoglycans", "TREATMENT", 121, 141], ["widely", "OBSERVATION_MODIFIER", 9, 15], ["most tissues", "OBSERVATION_MODIFIER", 29, 41]]], ["Salvage of sialic acids from dietary sialogycans may serve as an additional source of sialic acid, but it remains unclear if the 9-O-acetyl moiety is preserved during this process.", [["sialic acids", "CHEMICAL", 11, 23], ["sialogycans", "CHEMICAL", 37, 48], ["sialic acid", "CHEMICAL", 86, 97], ["9-O-acetyl", "CHEMICAL", 129, 139], ["sialic acids", "CHEMICAL", 11, 23], ["sialic acid", "CHEMICAL", 86, 97], ["9-O-acetyl", "CHEMICAL", 129, 139], ["sialic acids", "SIMPLE_CHEMICAL", 11, 23], ["sialogycans", "SIMPLE_CHEMICAL", 37, 48], ["sialic acid", "SIMPLE_CHEMICAL", 86, 97], ["9-O-acetyl moiety", "SIMPLE_CHEMICAL", 129, 146], ["Salvage of sialic acids", "TREATMENT", 0, 23], ["dietary sialogycans", "TREATMENT", 29, 48], ["sialic acid", "PROBLEM", 86, 97], ["O-acetyl moiety", "TREATMENT", 131, 146], ["sialic acids", "OBSERVATION", 11, 23], ["preserved", "OBSERVATION", 150, 159]]], ["Our results suggest that CASD1 is necessary for the synthesis of 9-O-acetyl sialic acid at least in all hematopoietic cells.DiscussionIn mammals, O-acetylation of sialic acid has been observed at the 4, 7 and 9 positions.", [["hematopoietic cells", "ANATOMY", 104, 123], ["9-O-acetyl sialic acid", "CHEMICAL", 65, 87], ["sialic acid", "CHEMICAL", 163, 174], ["9-O-acetyl sialic acid", "CHEMICAL", 65, 87], ["sialic acid", "CHEMICAL", 163, 174], ["CASD1", "GENE_OR_GENE_PRODUCT", 25, 30], ["9-O-acetyl sialic acid", "SIMPLE_CHEMICAL", 65, 87], ["hematopoietic cells", "CELL", 104, 123], ["sialic acid", "SIMPLE_CHEMICAL", 163, 174], ["CASD1", "PROTEIN", 25, 30], ["hematopoietic cells", "CELL_TYPE", 104, 123], ["CASD1", "TEST", 25, 30], ["the synthesis", "TEST", 48, 61], ["acetyl sialic acid", "TEST", 69, 87], ["O-acetylation of sialic acid", "TREATMENT", 146, 174], ["hematopoietic cells", "OBSERVATION", 104, 123]]], ["In addition, enzymatic activity corresponding to transferases and esterases capable of adding or removing these substitutions have been successfully enriched from subcellular fractions of tissues rich in O-acetylated sialic acids.", [["subcellular fractions", "ANATOMY", 163, 184], ["tissues", "ANATOMY", 188, 195], ["sialic acids", "CHEMICAL", 217, 229], ["O-acetylated sialic acids", "CHEMICAL", 204, 229], ["tissues", "TISSUE", 188, 195], ["O-acetylated sialic acids", "SIMPLE_CHEMICAL", 204, 229], ["transferases", "PROTEIN", 49, 61], ["esterases", "PROTEIN", 66, 75], ["enzymatic activity", "PROBLEM", 13, 31], ["these substitutions", "PROBLEM", 106, 125], ["acetylated sialic acids", "TREATMENT", 206, 229], ["enzymatic activity", "OBSERVATION", 13, 31], ["subcellular fractions", "OBSERVATION", 163, 184], ["sialic acids", "OBSERVATION", 217, 229]]], ["Among these, CASD1 is the only mammalian enzyme that has been cloned and biochemically characterized; we have described the generation of a Casd1 knockout mouse in this study.", [["CASD1", "GENE_OR_GENE_PRODUCT", 13, 18], ["Casd1", "GENE_OR_GENE_PRODUCT", 140, 145], ["mouse", "ORGANISM", 155, 160], ["CASD1", "PROTEIN", 13, 18], ["mammalian enzyme", "PROTEIN", 31, 47], ["Casd1", "PROTEIN", 140, 145], ["mouse", "SPECIES", 155, 160], ["mouse", "SPECIES", 155, 160], ["mammalian enzyme", "TEST", 31, 47], ["this study", "TEST", 164, 174]]], ["However, our knowledge of the mammalian enzymes O-acetylating sialic acids remains incomplete and there has been a debate about the number of enzymes involved in generating the pool of 9-O-acetyl sialic acids in vivo.", [["sialic acids", "CHEMICAL", 62, 74], ["9-O-acetyl sialic acids", "CHEMICAL", 185, 208], ["sialic acids", "CHEMICAL", 62, 74], ["9-O-acetyl sialic acids", "CHEMICAL", 185, 208], ["sialic acids", "AMINO_ACID", 62, 74], ["9-O-acetyl sialic acids", "SIMPLE_CHEMICAL", 185, 208], ["mammalian enzymes", "PROTEIN", 30, 47], ["enzymes", "PROTEIN", 142, 149], ["the mammalian enzymes", "TEST", 26, 47], ["sialic acids", "TEST", 62, 74], ["acetyl sialic acids", "TREATMENT", 189, 208]]], ["It remains to be established whether incorporation of 9-O-acetylated form of CMP-NANA into glycans is the only mechanism of generating 9-O-acetylated sialogycans.", [["9-O", "CHEMICAL", 54, 57], ["CMP-NANA", "CHEMICAL", 77, 85], ["9-O", "CHEMICAL", 135, 138], ["9-O", "CHEMICAL", 54, 57], ["9-O-acetylated sialogycans", "CHEMICAL", 135, 161], ["9-O-acetylated", "SIMPLE_CHEMICAL", 54, 68], ["CMP-NANA", "SIMPLE_CHEMICAL", 77, 85], ["9-O-acetylated sialogycans", "SIMPLE_CHEMICAL", 135, 161], ["NANA", "PROTEIN", 81, 85], ["CMP", "PROBLEM", 77, 80], ["NANA into glycans", "PROBLEM", 81, 98]]], ["The complete loss of 9-O-acetyl sialic acids on the surface of erythroid, myeloid and CD4 T lineages suggests that at least in unmanipulated Casd1-deficient mice, CASD1 may be the only enzyme capable of acetylating sialic acids in the 9-OH position on these cell types.", [["surface", "ANATOMY", 52, 59], ["erythroid", "ANATOMY", 63, 72], ["myeloid", "ANATOMY", 74, 81], ["CD4 T lineages", "ANATOMY", 86, 100], ["cell", "ANATOMY", 258, 262], ["9-O-acetyl sialic acids", "CHEMICAL", 21, 44], ["sialic acids", "CHEMICAL", 215, 227], ["9-OH", "CHEMICAL", 235, 239], ["9-O-acetyl sialic acids", "CHEMICAL", 21, 44], ["sialic acids", "CHEMICAL", 215, 227], ["9-OH", "CHEMICAL", 235, 239], ["9-O-acetyl sialic acids", "SIMPLE_CHEMICAL", 21, 44], ["surface", "CELLULAR_COMPONENT", 52, 59], ["erythroid", "CELL", 63, 72], ["myeloid", "CELL", 74, 81], ["CD4 T", "GENE_OR_GENE_PRODUCT", 86, 91], ["Casd1", "GENE_OR_GENE_PRODUCT", 141, 146], ["mice", "ORGANISM", 157, 161], ["CASD1", "GENE_OR_GENE_PRODUCT", 163, 168], ["sialic acids", "SIMPLE_CHEMICAL", 215, 227], ["9-OH", "SIMPLE_CHEMICAL", 235, 239], ["cell", "CELL", 258, 262], ["erythroid, myeloid and CD4 T lineages", "CELL_TYPE", 63, 100], ["Casd1", "PROTEIN", 141, 146], ["CASD1", "PROTEIN", 163, 168], ["mice", "SPECIES", 157, 161], ["mice", "SPECIES", 157, 161], ["acetyl sialic acids", "TREATMENT", 25, 44], ["myeloid and CD4 T lineages", "PROBLEM", 74, 100], ["acetylating sialic acids", "PROBLEM", 203, 227], ["loss", "OBSERVATION_MODIFIER", 13, 17], ["erythroid", "ANATOMY", 63, 72], ["myeloid", "ANATOMY", 74, 81], ["sialic acids", "OBSERVATION", 215, 227], ["cell types", "OBSERVATION", 258, 268]]], ["Our results also suggest that CASD1 is required A B Fig. 3 .", [["CASD1", "GENE_OR_GENE_PRODUCT", 30, 35], ["CASD1", "PROTEIN", 30, 35]]], ["TER-119 monoclonal antibody fails to bind Casd1-deficient murine erythrocytes.", [["erythrocytes", "ANATOMY", 65, 77], ["TER-119", "CHEMICAL", 0, 7], ["TER-119", "GENE_OR_GENE_PRODUCT", 0, 7], ["Casd1", "GENE_OR_GENE_PRODUCT", 42, 47], ["murine", "ORGANISM", 58, 64], ["erythrocytes", "CELL", 65, 77], ["TER-119 monoclonal antibody", "PROTEIN", 0, 27], ["Casd1", "PROTEIN", 42, 47], ["murine erythrocytes", "CELL_TYPE", 58, 77], ["murine", "SPECIES", 58, 64], ["TER", "TEST", 0, 3], ["monoclonal antibody", "TEST", 8, 27], ["Casd1", "TEST", 42, 47], ["deficient murine erythrocytes", "PROBLEM", 48, 77], ["murine erythrocytes", "OBSERVATION", 58, 77]]], ["(A) TER-119 and CHE-FcD staining on circulating red blood cells from Casd1-deficient and wild-type (C57BL/6 J) mice.", [["red blood cells", "ANATOMY", 48, 63], ["TER-119", "CHEMICAL", 4, 11], ["CHE-FcD", "CHEMICAL", 16, 23], ["TER-119", "GENE_OR_GENE_PRODUCT", 4, 11], ["CHE-FcD", "GENE_OR_GENE_PRODUCT", 16, 23], ["red blood cells", "CELL", 48, 63], ["Casd1", "GENE_OR_GENE_PRODUCT", 69, 74], ["wild-type (C57BL/6 J) mice", "ORGANISM", 89, 115], ["circulating red blood cells", "CELL_TYPE", 36, 63], ["Casd1", "PROTEIN", 69, 74], ["mice", "SPECIES", 111, 115], ["mice", "SPECIES", 111, 115], ["A) TER", "TEST", 1, 7], ["CHE-FcD staining", "TEST", 16, 32], ["circulating red blood cells", "TEST", 36, 63], ["Casd1", "TEST", 69, 74], ["type (C57BL/6 J) mice", "TREATMENT", 94, 115]]], ["(B) Flow cytometric analysis of CHE-FcD levels on erythroid precursors in the bone marrow of wild-type (C57BL/ 6 J) and Casd1-deficient mice.", [["erythroid precursors", "ANATOMY", 50, 70], ["bone marrow", "ANATOMY", 78, 89], ["CHE-FcD", "GENE_OR_GENE_PRODUCT", 32, 39], ["erythroid precursors", "CELL", 50, 70], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 78, 89], ["C57BL/ 6 J)", "ORGANISM", 104, 115], ["Casd1", "GENE_OR_GENE_PRODUCT", 120, 125], ["mice", "ORGANISM", 136, 140], ["CHE", "PROTEIN", 32, 35], ["FcD", "PROTEIN", 36, 39], ["erythroid precursors", "CELL_TYPE", 50, 70], ["mice", "SPECIES", 136, 140], ["mice", "SPECIES", 136, 140], ["Flow cytometric analysis", "TEST", 4, 28], ["CHE", "TEST", 32, 35], ["FcD levels", "TEST", 36, 46], ["erythroid precursors", "TEST", 50, 70], ["the bone marrow", "TEST", 74, 89], ["erythroid precursors", "OBSERVATION", 50, 70], ["bone marrow", "ANATOMY", 78, 89]]], ["Please note that due to the loss of TER-119 in the erythroid lineage in Casd1-deficient mice, only the Ery-A and Ery-B precursors but not the Ery-C precursors can be definitively identified in Casd1-deficient mice using CD71 expression and FSC.Discussionfor the generation of the TER-119 epitope in the murine erythroid lineage.DiscussionBased on our analysis of the differential binding or inactivation of the TER-119 epitope by BHE and CHE virolectins and receptordestroying esterases, the TER-119 antibody appears to recognize an epitope bearing 7,9-di-O-acetyl sialic acid.", [["erythroid lineage", "ANATOMY", 51, 68], ["Ery-B precursors", "ANATOMY", 113, 129], ["Ery-C precursors", "ANATOMY", 142, 158], ["erythroid lineage", "ANATOMY", 310, 327], ["BHE", "CHEMICAL", 430, 433], ["CHE", "CHEMICAL", 438, 441], ["7,9-di-O-acetyl sialic acid", "CHEMICAL", 549, 576], ["7,9-di-O-acetyl sialic acid", "CHEMICAL", 549, 576], ["TER-119", "GENE_OR_GENE_PRODUCT", 36, 43], ["erythroid lineage", "CELL", 51, 68], ["Casd1", "GENE_OR_GENE_PRODUCT", 72, 77], ["mice", "ORGANISM", 88, 92], ["Ery-A", "GENE_OR_GENE_PRODUCT", 103, 108], ["Ery-B", "GENE_OR_GENE_PRODUCT", 113, 118], ["Ery-C", "GENE_OR_GENE_PRODUCT", 142, 147], ["Casd1", "GENE_OR_GENE_PRODUCT", 193, 198], ["mice", "ORGANISM", 209, 213], ["CD71", "GENE_OR_GENE_PRODUCT", 220, 224], ["murine", "ORGANISM", 303, 309], ["erythroid lineage", "CELL", 310, 327], ["BHE", "SIMPLE_CHEMICAL", 430, 433], ["CHE virolectins", "SIMPLE_CHEMICAL", 438, 453], ["TER-119 antibody", "GENE_OR_GENE_PRODUCT", 492, 508], ["7,9-di-O-acetyl sialic acid", "SIMPLE_CHEMICAL", 549, 576], ["TER-119", "DNA", 36, 43], ["erythroid lineage", "CELL_TYPE", 51, 68], ["Casd1", "PROTEIN", 72, 77], ["Ery-A and Ery-B precursors", "CELL_LINE", 103, 129], ["Ery-C precursors", "CELL_LINE", 142, 158], ["Casd1", "PROTEIN", 193, 198], ["CD71", "PROTEIN", 220, 224], ["FSC", "CELL_TYPE", 240, 243], ["TER-119 epitope", "PROTEIN", 280, 295], ["murine erythroid lineage", "CELL_TYPE", 303, 327], ["TER-119 epitope", "PROTEIN", 411, 426], ["BHE", "PROTEIN", 430, 433], ["CHE virolectins", "PROTEIN", 438, 453], ["TER-119 antibody", "PROTEIN", 492, 508], ["mice", "SPECIES", 88, 92], ["mice", "SPECIES", 209, 213], ["murine", "SPECIES", 303, 309], ["mice", "SPECIES", 88, 92], ["mice", "SPECIES", 209, 213], ["the loss of TER", "PROBLEM", 24, 39], ["the Ery", "TEST", 99, 106], ["the Ery-C precursors", "PROBLEM", 138, 158], ["CD71 expression", "TEST", 220, 235], ["FSC", "TEST", 240, 243], ["the TER", "TREATMENT", 276, 283], ["our analysis", "TEST", 347, 359], ["the differential binding", "PROBLEM", 363, 387], ["the TER", "TEST", 407, 414], ["BHE", "TEST", 430, 433], ["CHE virolectins", "TEST", 438, 453], ["receptordestroying esterases", "TEST", 458, 486], ["the TER", "TEST", 488, 495], ["an epitope bearing", "TEST", 530, 548], ["acetyl sialic acid", "TREATMENT", 558, 576], ["erythroid lineage", "OBSERVATION", 51, 68], ["erythroid lineage", "OBSERVATION", 310, 327]]], ["However, further structural analysis will be required to establish this.", [["further structural analysis", "TEST", 9, 36]]], ["The analysis of the ligand-bound structures of BHE and CHE shows that although there is some structural homology between the two hemagglutinins, they bind the 9-O-acetyl sialic acid ligand in opposite orientations (Zeng et al. 2008) .", [["BHE", "CHEMICAL", 47, 50], ["CHE", "CHEMICAL", 55, 58], ["9-O-acetyl sialic acid", "CHEMICAL", 159, 181], ["9-O-acetyl sialic acid", "CHEMICAL", 159, 181], ["BHE", "SIMPLE_CHEMICAL", 47, 50], ["CHE", "SIMPLE_CHEMICAL", 55, 58], ["9-O-acetyl sialic acid", "SIMPLE_CHEMICAL", 159, 181], ["BHE", "PROTEIN", 47, 50], ["CHE", "PROTEIN", 55, 58], ["The analysis", "TEST", 0, 12], ["CHE", "TEST", 55, 58], ["some structural homology between the two hemagglutinins", "PROBLEM", 88, 143], ["acetyl sialic acid ligand", "TREATMENT", 163, 188]]], ["Thus, it is theoretically possible that the conformation of the specific 9-O-acetyl sialic acid glycoform recognized by TER-119 is sterically constrained in the context of a particular glycan that favors binding and recognition by BHE over CHE.", [["9-O-acetyl sialic acid", "CHEMICAL", 73, 95], ["TER-119", "CHEMICAL", 120, 127], ["BHE", "CHEMICAL", 231, 234], ["CHE", "CHEMICAL", 240, 243], ["9-O-acetyl sialic acid", "CHEMICAL", 73, 95], ["TER-119", "CHEMICAL", 120, 127], ["9-O-acetyl sialic acid", "SIMPLE_CHEMICAL", 73, 95], ["TER-119", "SIMPLE_CHEMICAL", 120, 127], ["BHE", "SIMPLE_CHEMICAL", 231, 234], ["CHE", "SIMPLE_CHEMICAL", 240, 243], ["acetyl sialic acid glycoform", "TREATMENT", 77, 105]]], ["Although both BHE and CHE are lectins fused to receptor-destroying enzymes, it is particularly interesting that the esterase and hemagglutinin activities appear to have evolutionarily converged at the level of the specific glyco-conformations of 9-O-acetyl sialic acids.", [["BHE", "CHEMICAL", 14, 17], ["CHE", "CHEMICAL", 22, 25], ["9-O-acetyl sialic acids", "CHEMICAL", 246, 269], ["9-O-acetyl sialic acids", "CHEMICAL", 246, 269], ["BHE", "SIMPLE_CHEMICAL", 14, 17], ["CHE", "SIMPLE_CHEMICAL", 22, 25], ["esterase", "GENE_OR_GENE_PRODUCT", 116, 124], ["9-O-acetyl sialic acids", "SIMPLE_CHEMICAL", 246, 269], ["receptor-destroying enzymes", "PROTEIN", 47, 74], ["esterase", "PROTEIN", 116, 124], ["destroying enzymes", "TEST", 56, 74], ["the esterase and hemagglutinin activities", "PROBLEM", 112, 153], ["acetyl sialic acids", "TREATMENT", 250, 269]]], ["Thus study reveals an additional layer of complexity and diversity among the O-acetylated sialic acids and establishes the developmental regulation of the sequential acquisition of two different forms of 9-O-acetyl sialic acid during murine erythroid differentiation.Generation of Casd1 knockout miceMouse embryonic stem cells (C57BL/6N background) carrying a knockout-first targeted allele of Casd1 (Casd1 tm1a(EUCOMM)Hmgu ) were obtained from the EUCOMM consortium.", [["erythroid", "ANATOMY", 241, 250], ["embryonic stem cells", "ANATOMY", 306, 326], ["C57BL/6N", "ANATOMY", 328, 336], ["sialic acids", "CHEMICAL", 90, 102], ["9-O-acetyl sialic acid", "CHEMICAL", 204, 226], ["O-acetylated sialic acids", "CHEMICAL", 77, 102], ["9-O-acetyl sialic acid", "CHEMICAL", 204, 226], ["sialic acids", "AMINO_ACID", 90, 102], ["9-O-acetyl sialic acid", "SIMPLE_CHEMICAL", 204, 226], ["murine", "ORGANISM", 234, 240], ["erythroid", "CELL", 241, 250], ["Casd1", "GENE_OR_GENE_PRODUCT", 281, 286], ["embryonic stem cells", "CELL", 306, 326], ["C57BL/6N background", "ORGANISM", 328, 347], ["Casd1", "GENE_OR_GENE_PRODUCT", 394, 399], ["Casd1 tm1a(EUCOMM)Hmgu", "GENE_OR_GENE_PRODUCT", 401, 423], ["Casd1 knockout miceMouse embryonic stem cells", "CELL_LINE", 281, 326], ["C57BL/6N background", "CELL_LINE", 328, 347], ["knockout-first targeted allele", "DNA", 360, 390], ["Casd1", "DNA", 394, 399], ["Casd1 tm1a", "DNA", 401, 411], ["EUCOMM", "DNA", 412, 418], ["Hmgu", "DNA", 419, 423], ["murine", "SPECIES", 234, 240], ["Thus study", "TEST", 0, 10], ["the O-acetylated sialic acids", "TREATMENT", 73, 102], ["acetyl sialic acid", "TREATMENT", 208, 226], ["Casd1", "TEST", 281, 286], ["embryonic stem cells", "PROBLEM", 306, 326], ["additional", "OBSERVATION_MODIFIER", 22, 32], ["layer", "OBSERVATION_MODIFIER", 33, 38], ["complexity", "OBSERVATION_MODIFIER", 42, 52], ["diversity", "OBSERVATION_MODIFIER", 57, 66], ["erythroid differentiation", "OBSERVATION", 241, 266], ["embryonic stem cells", "OBSERVATION", 306, 326]]], ["Casd1 knock-in mice were generated at the BWH Transgenic Core facility.", [["Casd1", "GENE_OR_GENE_PRODUCT", 0, 5], ["mice", "ORGANISM", 15, 19], ["mice", "SPECIES", 15, 19], ["mice", "SPECIES", 15, 19], ["Casd1 knock", "TEST", 0, 11]]], ["The resulting chimeric mice were crossed into C57BL/6NTac (Taconic) and interbred to homozygosity.", [["mice", "ORGANISM", 23, 27], ["C57BL/6NTac", "ORGANISM", 46, 57], ["mice", "SPECIES", 23, 27], ["mice", "SPECIES", 23, 27]]], ["They were then crossed into (B6.C-Tg(CMVcre)1Cgn/J mice, (stock # 006054, Jackson Laboratory) to obtain the Casd1 tm1b null allele, which lacks exon 2 of Casd1.", [["Casd1 tm1b", "GENE_OR_GENE_PRODUCT", 108, 118], ["Casd1", "GENE_OR_GENE_PRODUCT", 154, 159], ["Casd1 tm1b null allele", "DNA", 108, 130], ["exon 2", "DNA", 144, 150], ["Casd1", "DNA", 154, 159], ["mice", "SPECIES", 51, 55], ["the Casd1", "TEST", 104, 113], ["null allele", "PROBLEM", 119, 130]]], ["Excision of the neomycin expression cassette ( Figure 1A) was confirmed by PCR.", [["neomycin", "CHEMICAL", 16, 24], ["neomycin", "CHEMICAL", 16, 24], ["neomycin", "GENE_OR_GENE_PRODUCT", 16, 24], ["neomycin expression cassette", "DNA", 16, 44], ["Excision", "TREATMENT", 0, 8], ["the neomycin expression cassette", "TREATMENT", 12, 44], ["PCR", "TEST", 75, 78]]], ["The following primers were used for genotyping.", [["The following primers", "TREATMENT", 0, 21], ["genotyping", "TEST", 36, 46]]], ["The wild-type allele was specifically amplified using TCCTCCCTCACTGTTCCTTC and AGGTGGGGAGGAAAGACAGT (291 bp) and the Casd1 tm1b allele could be selectively amplified using TCCTCCCTCACTGTTCCTTC and GACAGCCAGTCACACAGCTT (5540 bp).", [["Casd1 tm1b", "GENE_OR_GENE_PRODUCT", 117, 127], ["wild-type allele", "DNA", 4, 20], ["Casd1 tm1b allele", "DNA", 117, 134], ["TCCTCCCTCACTGTTCCTTC", "TREATMENT", 54, 74], ["AGGTGGGGAGGAAAGACAGT", "TEST", 79, 99], ["bp", "TEST", 105, 107], ["the Casd1 tm1b allele", "TREATMENT", 113, 134], ["TCCTCCCTCACTGTTCCTTC and GACAGCCAGTCACACAGCTT", "TREATMENT", 172, 217]]], ["This allele was interbred to homozygosity to yield Casd1 tm1b/tm1b mice (referred to as Casd1-KO mice in the accompanying figures).", [["tm1b", "GENE_OR_GENE_PRODUCT", 62, 66], ["Casd1", "GENE_OR_GENE_PRODUCT", 88, 93], ["allele", "DNA", 5, 11], ["Casd1 tm1b", "PROTEIN", 51, 61], ["Casd1", "PROTEIN", 88, 93], ["mice", "SPECIES", 67, 71], ["mice", "SPECIES", 97, 101], ["mice", "SPECIES", 67, 71]]], ["The Casd1-deficient mice were viable and fertile.", [["Casd1", "GENE_OR_GENE_PRODUCT", 4, 9], ["mice", "ORGANISM", 20, 24], ["Casd1", "PROTEIN", 4, 9], ["mice", "SPECIES", 20, 24], ["mice", "SPECIES", 20, 24], ["The Casd1-deficient mice", "TREATMENT", 0, 24]]], ["The Casd1 knockout colony was maintained by homozygous mating.", [["colony", "ANATOMY", 19, 25], ["Casd1", "GENE_OR_GENE_PRODUCT", 4, 9], ["Casd1", "PROTEIN", 4, 9], ["The Casd1 knockout colony", "TREATMENT", 0, 25], ["knockout colony", "OBSERVATION", 10, 25]]], ["Each experiment was performed at least twice on three mice each.Flow cytometrySingle cell suspensions were obtained from the blood, spleen, lymph nodes, thymus or bone marrow and flow cytometry analysis was performed using the following monoclonal antibodies: B220 (RA3-6B2), CD4 (GK1.5), CD8 (53-6.7), CD44 (IM7) Monoclonal antibody clones are indicated in parentheses.", [["cell", "ANATOMY", 85, 89], ["blood", "ANATOMY", 125, 130], ["spleen", "ANATOMY", 132, 138], ["lymph nodes", "ANATOMY", 140, 151], ["thymus", "ANATOMY", 153, 159], ["bone marrow", "ANATOMY", 163, 174], ["mice", "ORGANISM", 54, 58], ["cell suspensions", "CELL", 85, 101], ["blood", "ORGANISM_SUBSTANCE", 125, 130], ["spleen", "ORGAN", 132, 138], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 140, 151], ["thymus", "ORGAN", 153, 159], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 163, 174], ["B220", "GENE_OR_GENE_PRODUCT", 260, 264], ["RA3-6B2", "GENE_OR_GENE_PRODUCT", 266, 273], ["CD4", "GENE_OR_GENE_PRODUCT", 276, 279], ["GK1.5", "GENE_OR_GENE_PRODUCT", 281, 286], ["CD8", "GENE_OR_GENE_PRODUCT", 289, 292], ["CD44", "GENE_OR_GENE_PRODUCT", 303, 307], ["monoclonal antibodies", "PROTEIN", 237, 258], ["B220", "PROTEIN", 260, 264], ["RA3", "PROTEIN", 266, 269], ["6B2", "PROTEIN", 270, 273], ["CD4", "PROTEIN", 276, 279], ["GK1.5", "PROTEIN", 281, 286], ["CD8 (53-6.7), CD44 (IM7) Monoclonal antibody clones", "CELL_LINE", 289, 340], ["mice", "SPECIES", 54, 58], ["mice", "SPECIES", 54, 58], ["Flow cytometry", "TEST", 64, 78], ["Single cell suspensions", "TEST", 78, 101], ["the blood", "TEST", 121, 130], ["flow cytometry analysis", "TEST", 179, 202], ["monoclonal antibodies", "TEST", 237, 258], ["RA3", "TEST", 266, 269], ["CD4", "TEST", 276, 279], ["CD8", "TEST", 289, 292], ["CD44", "TEST", 303, 307], ["Monoclonal antibody clones", "PROBLEM", 314, 340], ["cell suspensions", "OBSERVATION", 85, 101], ["blood", "ANATOMY", 125, 130], ["spleen", "ANATOMY", 132, 138], ["lymph nodes", "OBSERVATION", 140, 151], ["thymus", "ANATOMY", 153, 159], ["bone marrow", "ANATOMY", 163, 174], ["flow cytometry", "OBSERVATION", 179, 193]]], ["All antibodies were obtained from Biolegend Inc. unless otherwise indicated.", [["antibodies", "PROTEIN", 4, 14], ["Biolegend", "PROTEIN", 34, 43], ["All antibodies", "TEST", 0, 14]]], ["One representative flow cytometry plot is shown for each condition.Studies with coronavirus and influenza C virolectinsInfluenza C hemagglutinin esterase (CHE) was recombinantly expressed as an Fc-fusion protein and the esterase activity of CHE was inactivated with di-isofluoropropyl phosphate to generate the CHE-FcD reagent as previously described (Muchmore and Varki 1987) .", [["CHE", "CHEMICAL", 155, 158], ["CHE", "CHEMICAL", 241, 244], ["di-isofluoropropyl phosphate", "CHEMICAL", 266, 294], ["CHE", "CHEMICAL", 311, 314], ["di-isofluoropropyl phosphate", "CHEMICAL", 266, 294], ["CHE-FcD", "CHEMICAL", 311, 318], ["coronavirus", "ORGANISM", 80, 91], ["influenza C virolectins", "ORGANISM", 96, 119], ["Influenza C hemagglutinin esterase", "GENE_OR_GENE_PRODUCT", 119, 153], ["CHE", "GENE_OR_GENE_PRODUCT", 155, 158], ["Fc", "GENE_OR_GENE_PRODUCT", 194, 196], ["CHE", "SIMPLE_CHEMICAL", 241, 244], ["di-isofluoropropyl phosphate", "SIMPLE_CHEMICAL", 266, 294], ["CHE", "SIMPLE_CHEMICAL", 311, 314], ["coronavirus and influenza C virolectins", "PROTEIN", 80, 119], ["Influenza C hemagglutinin esterase", "PROTEIN", 119, 153], ["CHE", "PROTEIN", 155, 158], ["Fc", "PROTEIN", 194, 196], ["fusion protein", "PROTEIN", 197, 211], ["esterase", "PROTEIN", 220, 228], ["coronavirus", "SPECIES", 80, 91], ["influenza C virolectins", "SPECIES", 96, 119], ["Influenza C hemagglutinin", "SPECIES", 119, 144], ["One representative flow cytometry plot", "TEST", 0, 38], ["Studies", "TEST", 67, 74], ["coronavirus", "PROBLEM", 80, 91], ["influenza C virolectinsInfluenza C hemagglutinin esterase", "PROBLEM", 96, 153], ["an Fc-fusion protein", "TEST", 191, 211], ["the esterase activity", "TEST", 216, 237], ["CHE", "TEST", 241, 244], ["di-isofluoropropyl phosphate", "TREATMENT", 266, 294], ["the CHE-FcD reagent", "TREATMENT", 307, 326], ["flow cytometry", "OBSERVATION", 19, 33], ["coronavirus", "OBSERVATION", 80, 91]]], ["Bovine coronavirus hemagglutinin esterase (Mebus strain, Uniprot accession number, P15776.1) was cloned into the pFUSE-mFc2a vector (Invivogen) into the EcoRI and BglII sites.", [["Bovine coronavirus", "ORGANISM", 0, 18], ["hemagglutinin esterase", "GENE_OR_GENE_PRODUCT", 19, 41], ["Mebus strain", "ORGANISM", 43, 55], ["pFUSE", "GENE_OR_GENE_PRODUCT", 113, 118], ["mFc2a", "GENE_OR_GENE_PRODUCT", 119, 124], ["EcoRI", "GENE_OR_GENE_PRODUCT", 153, 158], ["BglII", "GENE_OR_GENE_PRODUCT", 163, 168], ["Bovine coronavirus hemagglutinin esterase", "PROTEIN", 0, 41], ["pFUSE-mFc2a vector", "DNA", 113, 131], ["Invivogen", "DNA", 133, 142], ["EcoRI and BglII sites", "DNA", 153, 174], ["Bovine coronavirus hemagglutinin", "SPECIES", 0, 32], ["Bovine coronavirus", "SPECIES", 0, 18], ["Bovine coronavirus hemagglutinin esterase (Mebus strain", "TREATMENT", 0, 55], ["the pFUSE-mFc2a vector", "TREATMENT", 109, 131], ["the EcoRI and BglII sites", "TREATMENT", 149, 174], ["coronavirus", "OBSERVATION_MODIFIER", 7, 18], ["hemagglutinin esterase", "OBSERVATION", 19, 41]]], ["A catalytically dead variant of BHE-Fc (BHE-S40A-Fc) was generated by site-directed mutagenesis.", [["BHE-Fc", "GENE_OR_GENE_PRODUCT", 32, 38], ["BHE-S40A-Fc", "GENE_OR_GENE_PRODUCT", 40, 51], ["BHE", "PROTEIN", 32, 35], ["Fc", "PROTEIN", 36, 38], ["BHE", "PROTEIN", 40, 43], ["S40A", "PROTEIN", 44, 48], ["Fc", "PROTEIN", 49, 51], ["A catalytically dead variant", "PROBLEM", 0, 28], ["BHE", "TEST", 32, 35], ["BHE", "TEST", 40, 43], ["catalytically", "OBSERVATION_MODIFIER", 2, 15], ["dead variant", "OBSERVATION", 16, 28]]], ["The Fc-fusion proteins were expressed in 293 T cells and affinity purified using protein G. The CHE-FcD probe recognizes 9-Oacetyl sialic acids, and the BHE-S40A-Fc virolectin can bind both 9-Oacetyl and 7,9-di-O-acetyl sialic acids Bakkers et al. 2016) .", [["293 T cells", "ANATOMY", 41, 52], ["9-Oacetyl sialic acids", "CHEMICAL", 121, 143], ["9-Oacetyl and 7,9-di-O-acetyl sialic acids", "CHEMICAL", 190, 232], ["9-Oacetyl sialic acids", "CHEMICAL", 121, 143], ["9-Oacetyl", "CHEMICAL", 190, 199], ["7,9-di-O-acetyl sialic acids", "CHEMICAL", 204, 232], ["293 T cells", "CELL", 41, 52], ["9-Oacetyl sialic acids", "SIMPLE_CHEMICAL", 121, 143], ["BHE", "SIMPLE_CHEMICAL", 153, 156], ["9-Oacetyl", "SIMPLE_CHEMICAL", 190, 199], ["7,9-di-O-acetyl sialic acids", "SIMPLE_CHEMICAL", 204, 232], ["Fc-fusion proteins", "PROTEIN", 4, 22], ["293 T cells", "CELL_LINE", 41, 52], ["CHE-FcD probe", "DNA", 96, 109], ["BHE", "PROTEIN", 153, 156], ["S40A", "PROTEIN", 157, 161], ["Fc virolectin", "PROTEIN", 162, 175], ["The Fc-fusion proteins", "TEST", 0, 22], ["protein G.", "TEST", 81, 91], ["The CHE", "TEST", 92, 99], ["FcD probe", "TEST", 100, 109], ["Oacetyl sialic acids", "TREATMENT", 123, 143], ["the BHE", "TEST", 149, 156], ["di-O-acetyl sialic acids", "TREATMENT", 208, 232]]], ["Briefly, a two-step staining procedure with CHE-FcD as the primary and anti-human IgG1-PE (clone HP6017) as the secondary or with BHE-S40A-Fc as the primary and anti-mouse IgG2a-FITC (clone RMG2a-62) as the secondary antibody were used.Studies with coronavirus and influenza C virolectinsTo assess the effect of CHE or BHE on 9-O-acetyl sialic acids on murine erythrocytes, a 1:100 dilution of whole blood in PBS, was treated with 10 \u03bcg/mL of CHE-Fc or BHE-Fc at 37\u00b0C for 1 hour.", [["primary", "ANATOMY", 149, 156], ["erythrocytes", "ANATOMY", 360, 372], ["whole blood", "ANATOMY", 394, 405], ["CHE-FcD", "CHEMICAL", 44, 51], ["CHE", "CHEMICAL", 312, 315], ["BHE", "CHEMICAL", 319, 322], ["9-O-acetyl sialic acids", "CHEMICAL", 326, 349], ["CHE", "CHEMICAL", 443, 446], ["BHE", "CHEMICAL", 453, 456], ["FITC", "CHEMICAL", 178, 182], ["CHE", "CHEMICAL", 312, 315], ["BHE", "CHEMICAL", 319, 322], ["9-O-acetyl sialic acids", "CHEMICAL", 326, 349], ["CHE-FcD", "SIMPLE_CHEMICAL", 44, 51], ["IgG1", "GENE_OR_GENE_PRODUCT", 82, 86], ["clone", "ORGANISM", 91, 96], ["BHE-S40A-Fc", "GENE_OR_GENE_PRODUCT", 130, 141], ["IgG2a-FITC", "GENE_OR_GENE_PRODUCT", 172, 182], ["coronavirus", "ORGANISM", 249, 260], ["influenza C virolectins", "ORGANISM", 265, 288], ["CHE", "SIMPLE_CHEMICAL", 312, 315], ["BHE", "SIMPLE_CHEMICAL", 319, 322], ["9-O-acetyl sialic acids", "SIMPLE_CHEMICAL", 326, 349], ["murine", "ORGANISM", 353, 359], ["erythrocytes", "CELL", 360, 372], ["blood", "ORGANISM_SUBSTANCE", 400, 405], ["CHE-Fc", "SIMPLE_CHEMICAL", 443, 449], ["BHE-Fc", "SIMPLE_CHEMICAL", 453, 459], ["37\u00b0C", "SIMPLE_CHEMICAL", 463, 467], ["CHE", "PROTEIN", 44, 47], ["FcD", "PROTEIN", 48, 51], ["IgG1", "PROTEIN", 82, 86], ["PE", "PROTEIN", 87, 89], ["clone HP6017", "PROTEIN", 91, 103], ["BHE", "PROTEIN", 130, 133], ["S40A", "PROTEIN", 134, 138], ["Fc", "PROTEIN", 139, 141], ["IgG2a", "PROTEIN", 172, 177], ["FITC", "PROTEIN", 178, 182], ["clone RMG2a-62", "PROTEIN", 184, 198], ["secondary antibody", "PROTEIN", 207, 225], ["murine erythrocytes", "CELL_TYPE", 353, 372], ["Fc", "PROTEIN", 447, 449], ["Fc", "PROTEIN", 457, 459], ["anti-mouse", "SPECIES", 161, 171], ["coronavirus", "SPECIES", 249, 260], ["murine", "SPECIES", 353, 359], ["a two-step staining procedure", "TREATMENT", 9, 38], ["CHE-FcD", "TREATMENT", 44, 51], ["anti-human IgG1", "TEST", 71, 86], ["PE", "PROBLEM", 87, 89], ["BHE", "TEST", 130, 133], ["anti-mouse IgG2a", "TEST", 161, 177], ["clone RMG2a", "TEST", 184, 195], ["the secondary antibody", "TREATMENT", 203, 225], ["Studies", "TEST", 236, 243], ["coronavirus", "PROBLEM", 249, 260], ["influenza C virolectins", "PROBLEM", 265, 288], ["CHE", "PROBLEM", 312, 315], ["BHE", "TEST", 319, 322], ["acetyl sialic acids", "TREATMENT", 330, 349], ["murine erythrocytes", "TREATMENT", 353, 372], ["whole blood in PBS", "TREATMENT", 394, 412], ["PE", "OBSERVATION", 87, 89]]], ["The cells were washed twice with PBS at room temperature and stained with CHE-FcD as described above.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["CHE-FcD", "SIMPLE_CHEMICAL", 74, 81], ["PBS", "TREATMENT", 33, 36], ["CHE-FcD", "TREATMENT", 74, 81], ["FcD", "OBSERVATION", 78, 81]]], ["Analysis of competitive binding between TER-119 and BHE-S40A-Fc was performed as follows.", [["TER-119", "CHEMICAL", 40, 47], ["TER-119", "CHEMICAL", 40, 47], ["TER-119", "SIMPLE_CHEMICAL", 40, 47], ["BHE-S40A-Fc", "GENE_OR_GENE_PRODUCT", 52, 63], ["TER-119 and BHE-S40A-Fc", "DNA", 40, 63], ["competitive binding", "PROBLEM", 12, 31], ["TER", "TEST", 40, 43], ["BHE", "TEST", 52, 55]]], ["A 1:100 dilution of whole blood in PBS was incubated with varying concentrations of BHE-S40A-Fc at 37\u00b0C for 1 hour followed by the addition of 2 \u03bcg/mL of labeled TER-119 antibody for 10 min in the continued presence of the virolectin.", [["whole blood", "ANATOMY", 20, 31], ["BHE-S40A-Fc", "CHEMICAL", 84, 95], ["TER-119", "CHEMICAL", 162, 169], ["virolectin", "CHEMICAL", 223, 233], ["virolectin", "CHEMICAL", 223, 233], ["blood", "ORGANISM_SUBSTANCE", 26, 31], ["BHE-S40A-Fc", "SIMPLE_CHEMICAL", 84, 95], ["37\u00b0C", "SIMPLE_CHEMICAL", 99, 103], ["TER-119 antibody", "GENE_OR_GENE_PRODUCT", 162, 178], ["virolectin", "GENE_OR_GENE_PRODUCT", 223, 233], ["Fc", "PROTEIN", 93, 95], ["virolectin", "PROTEIN", 223, 233], ["whole blood in PBS", "TREATMENT", 20, 38], ["BHE", "TEST", 84, 87], ["labeled TER", "TEST", 154, 165]]], ["The cells were washed twice with ice cold PBS and analyzed by flow cytometry.Supplementary dataSupplementary data is available at Glycobiology online.FundingThis work was supported by research grants from the National Institutes of Health to SP (AI064930 and AI110495) and VM (AI113163).", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["ice cold PBS", "TREATMENT", 33, 45], ["flow cytometry", "TEST", 62, 76], ["VM", "PROBLEM", 273, 275], ["VM", "ANATOMY", 273, 275]]]], "f607a200032e94638be8949dc81e3ecfd03f85d3": [["INTRODUCTIONBrucellosis is an acute or chronic infectious disease of man and animals.", [["man", "ORGANISM", 69, 72], ["man", "SPECIES", 69, 72], ["an acute or chronic infectious disease", "PROBLEM", 27, 65], ["acute", "OBSERVATION_MODIFIER", 30, 35], ["chronic", "OBSERVATION_MODIFIER", 39, 46], ["infectious", "OBSERVATION", 47, 57]]], ["The incidence of human brucellosis in many developed countries is low: 12 and 114 cases were diagnosed in Canada and the U. S., respectively, in 1987 (Canada Diseases Weekly Report, 1988 Morbidity and Mortality Weekly Report, 1988) .", [["brucellosis", "DISEASE", 23, 34], ["human", "ORGANISM", 17, 22], ["human", "SPECIES", 17, 22], ["human", "SPECIES", 17, 22], ["human brucellosis", "PROBLEM", 17, 34], ["human", "OBSERVATION_MODIFIER", 17, 22], ["brucellosis", "OBSERVATION", 23, 34]]], ["While infection with BruceUa in animals has been eradicated in some countries, it is endemic in others, thereby creating serious human health problems and causing considerable economic loss.INTRODUCTIONDetection of antibody has been a useful tool in the bovine brucellosis eradication programs established by many countries.", [["infection", "DISEASE", 6, 15], ["BruceUa", "CHEMICAL", 21, 28], ["brucellosis", "DISEASE", 261, 272], ["human", "ORGANISM", 129, 134], ["bovine", "ORGANISM", 254, 260], ["human", "SPECIES", 129, 134], ["bovine", "SPECIES", 254, 260], ["human", "SPECIES", 129, 134], ["bovine", "SPECIES", 254, 260], ["infection", "PROBLEM", 6, 15], ["BruceUa in animals", "PROBLEM", 21, 39], ["considerable economic loss", "PROBLEM", 163, 189], ["the bovine brucellosis eradication programs", "TREATMENT", 250, 293], ["infection", "OBSERVATION", 6, 15], ["endemic", "OBSERVATION_MODIFIER", 85, 92], ["considerable", "OBSERVATION_MODIFIER", 163, 175], ["economic loss", "OBSERVATION", 176, 189]]], ["Because of the cost of these programs, most research into methods of antibody detection has taken place in this species.", [["these programs", "TREATMENT", 23, 37], ["antibody detection", "TEST", 69, 87]]], ["Research efforts have led to the development of primary binding assays such as the enzyme immunoassay (ELISA) for both antibody and antigen detection in serum and milk.", [["serum", "ANATOMY", 153, 158], ["milk", "ANATOMY", 163, 167], ["serum", "ORGANISM_SUBSTANCE", 153, 158], ["milk", "ORGANISM_SUBSTANCE", 163, 167], ["primary binding assays", "PROBLEM", 48, 70], ["the enzyme immunoassay", "TEST", 79, 101], ["ELISA", "TEST", 103, 108], ["both antibody", "TEST", 114, 127], ["antigen detection", "TEST", 132, 149], ["serum", "TEST", 153, 158]]], ["Such work has generally been undertaken to overcome the limitations of conventional serological tests not detecting one or more of the relevant antibody isotopes (Table 1 ) .", [["conventional serological tests", "TEST", 71, 101]]], ["These limitations require the use of two or more tests to ensure effective (sensitive and specific) serological diagnosis.", [["more tests", "TEST", 44, 54]]], ["For example, the complement fixation test (CFT) and the tube agglutination test (SAT), both used as confirmatory tests, fail to detect IgG2 and IgG1, respectively (Table 1) .", [["tube", "TISSUE", 56, 60], ["IgG2", "GENE_OR_GENE_PRODUCT", 135, 139], ["IgG1", "GENE_OR_GENE_PRODUCT", 144, 148], ["IgG2", "PROTEIN", 135, 139], ["IgG1", "PROTEIN", 144, 148], ["the complement fixation test", "TEST", 13, 41], ["CFT", "TEST", 43, 46], ["the tube agglutination test", "TEST", 52, 79], ["SAT", "TEST", 81, 84], ["confirmatory tests", "TEST", 100, 118], ["IgG2", "TEST", 135, 139]]], ["These shortcomings can be eliminated by using an indirect ELISA, given careful selection of antigen, anti-immunoglobulin and enzyme-based detection system.", [["anti-immunoglobulin", "SIMPLE_CHEMICAL", 101, 120], ["anti-immunoglobulin", "PROTEIN", 101, 120], ["enzyme", "PROTEIN", 125, 131], ["an indirect ELISA", "TEST", 46, 63], ["anti-immunoglobulin", "TREATMENT", 101, 120], ["enzyme", "TEST", 125, 131]]], ["In some laboratories the ELISA hasbeen implemented and studies are underway in many other laboratories to determine if these technical improvements can be turned to practical advantage in terms of the cost and effectiveness of diagnostic testing for disease control or eradication programs.", [["the ELISA hasbeen", "TEST", 21, 38], ["studies", "TEST", 55, 62], ["diagnostic testing", "TEST", 227, 245], ["disease control", "TREATMENT", 250, 265], ["eradication programs", "TREATMENT", 269, 289]]], ["In this review, antigens ofB. abortus, literature pertaining to various ELISA test methods, antiglobulin reagent selection and application of computer technology to ELISA are described.BRUCELLA ANTIGENSA comprehensive review of the antigens of BruceUa abortus is beyond the scope of this paper (for reviews see Olitsky, 1970; Jones and Berman, 1976; Berman, 1981; Raybould, 1982 and Corbel, 1985) .BRUCELLA ANTIGENSAs indicated in Table 2 , a variety of antigen preparations ranging from whole cells to purified components have been used in ELISA for antibody.", [["whole cells", "ANATOMY", 488, 499], ["ofB", "GENE_OR_GENE_PRODUCT", 25, 28], ["abortus", "ORGANISM", 30, 37], ["BruceUa abortus", "ORGANISM", 244, 259], ["cells", "CELL", 494, 499], ["antigens", "PROTEIN", 16, 24], ["ofB", "PROTEIN", 25, 28], ["whole cells", "CELL_TYPE", 488, 499], ["abortus", "SPECIES", 30, 37], ["BruceUa abortus", "SPECIES", 244, 259], ["abortus", "SPECIES", 30, 37], ["BruceUa abortus", "SPECIES", 244, 259], ["abortus", "PROBLEM", 30, 37], ["various ELISA test methods", "TEST", 64, 90], ["antiglobulin reagent selection", "TREATMENT", 92, 122], ["BruceUa abortus", "PROBLEM", 244, 259], ["a variety of antigen preparations", "TREATMENT", 441, 474], ["whole cells to purified components", "TREATMENT", 488, 522]]], ["In most assay procedures, antigen mixtures such as BruceUa abortus soluble antigen (BASA) have been used, although smooth-lipopolysaccharide (sLPS) was probably the major antigenic component both in terms of antigenicity (im- Ruppanner et al., 1980a cell G Cargill et al., 1985 Sonicated --Ruppanner et al., 1980b glob.", [["lipopolysaccharide", "CHEMICAL", 122, 140], ["sLPS", "CHEMICAL", 142, 146], ["BruceUa abortus soluble antigen", "GENE_OR_GENE_PRODUCT", 51, 82], ["BASA", "GENE_OR_GENE_PRODUCT", 84, 88], ["smooth-lipopolysaccharide", "GENE_OR_GENE_PRODUCT", 115, 140], ["sLPS", "SIMPLE_CHEMICAL", 142, 146], ["BruceUa abortus soluble antigen", "PROTEIN", 51, 82], ["BASA", "PROTEIN", 84, 88], ["BruceUa abortus", "SPECIES", 51, 66], ["BruceUa abortus", "SPECIES", 51, 66], ["antigen mixtures", "TREATMENT", 26, 42], ["BruceUa abortus soluble antigen", "TREATMENT", 51, 82], ["the major antigenic component", "PROBLEM", 161, 190], ["smooth", "OBSERVATION_MODIFIER", 115, 121]]], ["Saunders et al., 1977 Heck et al., 1979 G Byrd et al., 1979 Heck et al., 1980a ,b G,G2,M Berman et al., 1980 G,G2,M,A Butler, 1981 Protein G Tabatabai and Deyoe, 1984 LPS ~, glob.", [["G2", "TEST", 111, 113], ["Protein", "TEST", 131, 138], ["Tabatabai", "TEST", 141, 150], ["Deyoe", "TEST", 155, 160], ["LPS", "TEST", 167, 170], ["glob", "PROBLEM", 174, 178]]], ["Thoen et al., 1979a , 1980 G Heck et al., 1980b Filtered G Boraker et al., 1981 Poly B G,G2,A Bruner et al., 1983 Antigen detection munodominance) and in its ability to adsorb to polystyrene.", [["polystyrene", "CHEMICAL", 179, 190], ["Poly B G", "CHEMICAL", 80, 88], ["polystyrene", "CHEMICAL", 179, 190], ["polystyrene", "SIMPLE_CHEMICAL", 179, 190], ["polystyrene", "TREATMENT", 179, 190]]], ["Another possibility for an antigen is the so-called poly B, a polysaccharide shown to distinguish strain 19 vaccinated animals from B. abortus field infected animals by gel diffusion.", [["poly B", "CHEMICAL", 52, 58], ["poly B", "CHEMICAL", 52, 58], ["poly B", "SIMPLE_CHEMICAL", 52, 58], ["B. abortus", "ORGANISM", 132, 142], ["poly B", "PROTEIN", 52, 58], ["B. abortus", "SPECIES", 132, 142], ["B. abortus", "SPECIES", 132, 142], ["an antigen", "PROBLEM", 24, 34], ["a polysaccharide", "TEST", 60, 76], ["strain 19 vaccinated animals", "PROBLEM", 98, 126], ["possibility for", "UNCERTAINTY", 8, 23]]], ["The chemistry and uses of sLPS and poly B will be discussed below.BRUCELLA ANTIGENSSmooth-lipopolysaccharides (sLPS) are long chain molecules consisting of a region of several polysaccharide repeating units (the O-chain), a small chain of a few carbohydrates (the core) and lipids (Lipid A) which bind the complex to the cell wall (Luderitz et al., 1971) .", [["cell wall", "ANATOMY", 321, 330], ["poly B", "CHEMICAL", 35, 41], ["sLPS", "CHEMICAL", 26, 30], ["poly B", "CHEMICAL", 35, 41], ["carbohydrates", "CHEMICAL", 245, 258], ["sLPS", "SIMPLE_CHEMICAL", 26, 30], ["poly B", "SIMPLE_CHEMICAL", 35, 41], ["ANTIGENSSmooth-lipopolysaccharides", "GENE_OR_GENE_PRODUCT", 75, 109], ["sLPS", "SIMPLE_CHEMICAL", 111, 115], ["carbohydrates", "SIMPLE_CHEMICAL", 245, 258], ["lipids", "SIMPLE_CHEMICAL", 274, 280], ["Lipid A", "SIMPLE_CHEMICAL", 282, 289], ["cell wall", "TISSUE", 321, 330], ["sLPS", "PROTEIN", 26, 30], ["poly B", "PROTEIN", 35, 41], ["sLPS", "PROTEIN", 111, 115], ["polysaccharide repeating units", "PROTEIN", 176, 206], ["O-chain", "PROTEIN", 212, 219], ["The chemistry", "TEST", 0, 13], ["sLPS and poly B", "TREATMENT", 26, 41], ["lipopolysaccharides", "PROBLEM", 90, 109], ["long chain molecules", "PROBLEM", 121, 141], ["lipids (Lipid A)", "TREATMENT", 274, 290], ["lipopolysaccharides", "OBSERVATION_MODIFIER", 90, 109], ["small", "OBSERVATION_MODIFIER", 224, 229], ["cell wall", "ANATOMY", 321, 330]]], ["For BruceUa, it is the sLPS-complex which is involved in almost all serological tests (Diaz et al., 1968 ).", [["sLPS", "GENE_OR_GENE_PRODUCT", 23, 27], ["sLPS", "PROTEIN", 23, 27], ["BruceUa", "PROBLEM", 4, 11]]], ["Some controversy exists as to whether the sLPS of BruceUa is complexed to proteins (Perera et al., 1984) or can be isolated (Caroff et al., 1984a) .", [["BruceUa", "CHEMICAL", 50, 57], ["BruceUa", "SIMPLE_CHEMICAL", 50, 57], ["sLPS", "PROTEIN", 42, 46], ["the sLPS of BruceUa", "PROBLEM", 38, 57]]], ["Possibly both groups are correct or, depending on the preparation, the sLPS may be a population of molecules varying in the amount of covalently bound proteins.", [["covalently bound proteins", "PROTEIN", 134, 159], ["a population of molecules", "PROBLEM", 83, 108], ["covalently bound proteins", "PROBLEM", 134, 159]]], ["In either case, sLPS can be purified with only minor amounts of protein (Moreno et al., 1979 ) to yield a standardized antigen.", [["sLPS", "SIMPLE_CHEMICAL", 16, 20], ["sLPS", "PROTEIN", 16, 20], ["a standardized antigen", "TEST", 104, 126]]], ["The sLPS readily adsorbs to plastics (Nielsen et al., 1983b) and has been used in ELISA studies (Lamb et al., 1979; Stemshorn et al., 1980; Schurig et al., 1984; Bundle et al., 1984) .BRUCELLA ANTIGENSThere are two limitations in the use of sLPS as antigen for the enzyme immunoassay and other serological tests.", [["sLPS", "CHEMICAL", 4, 8], ["sLPS", "SIMPLE_CHEMICAL", 4, 8], ["sLPS", "SIMPLE_CHEMICAL", 241, 245], ["sLPS", "PROTEIN", 241, 245], ["the enzyme immunoassay", "TEST", 261, 283], ["other serological tests", "TEST", 288, 311]]], ["The first is that cattle vaccinated with attenuated B. abortus strain 19 have residual antibody specific for sLPS which cannot be distinguished from that resulting from field strain infection (World Health Organization, 1971 ).", [["infection", "DISEASE", 182, 191], ["cattle", "ORGANISM", 18, 24], ["B. abortus strain 19", "ORGANISM", 52, 72], ["sLPS", "GENE_OR_GENE_PRODUCT", 109, 113], ["sLPS", "PROTEIN", 109, 113], ["cattle", "SPECIES", 18, 24], ["B. abortus", "SPECIES", 52, 62], ["cattle", "SPECIES", 18, 24], ["B. abortus strain 19", "SPECIES", 52, 72], ["attenuated B. abortus strain", "PROBLEM", 41, 69], ["residual antibody", "PROBLEM", 78, 95], ["sLPS", "PROBLEM", 109, 113], ["field strain infection", "PROBLEM", 169, 191]]], ["The second is that the sLPS of bacteria such as Yersinia enterocolitica 0:9 (Ahvonen et al., 1969; Granfors et al., 1981; Lindberg et al., 1982) , Vibrio cholerae (Sandulache and Marx, 1978) , Escherichia coli and Salmonella Kauffmann-White Group N (Corbel, 1975) cross-react with B. abortus.", [["Yersinia enterocolitica", "DISEASE", 48, 71], ["Yersinia enterocolitica 0:9", "ORGANISM", 48, 75], ["Vibrio cholerae", "ORGANISM", 147, 162], ["Escherichia coli", "ORGANISM", 193, 209], ["Salmonella Kauffmann-White Group N", "ORGANISM", 214, 248], ["B. abortus", "ORGANISM", 281, 291], ["Yersinia enterocolitica", "SPECIES", 48, 71], ["Vibrio cholerae", "SPECIES", 147, 162], ["Escherichia coli", "SPECIES", 193, 209], ["Salmonella Kauffmann", "SPECIES", 214, 234], ["B. abortus", "SPECIES", 281, 291], ["Yersinia enterocolitica", "SPECIES", 48, 71], ["Vibrio cholerae", "SPECIES", 147, 162], ["Escherichia coli", "SPECIES", 193, 209], ["Salmonella Kauffmann-White Group N (Corbel, 1975)", "SPECIES", 214, 263], ["B. abortus", "SPECIES", 281, 291], ["bacteria", "PROBLEM", 31, 39], ["Yersinia enterocolitica", "PROBLEM", 48, 71], ["Escherichia coli", "PROBLEM", 193, 209], ["Salmonella Kauffmann", "TREATMENT", 214, 234], ["bacteria", "OBSERVATION", 31, 39], ["Escherichia coli", "OBSERVATION", 193, 209]]], ["For the latter, it has recently been determined that the O-chains of both B. abortus and Y. enterocolitica 0:9 are identical, consisting of a polymer of 4-formamido-4,6-dideoxy-D-mannopyranosyl units (Caroff et al., 1984a,b) .", [["4-formamido-4,6-dideoxy-D-mannopyranosyl", "CHEMICAL", 153, 193], ["O", "CHEMICAL", 57, 58], ["4-formamido-4,6-dideoxy-D-mannopyranosyl", "CHEMICAL", 153, 193], ["B. abortus", "ORGANISM", 74, 84], ["Y. enterocolitica", "ORGANISM", 89, 106], ["0:9", "ORGANISM", 107, 110], ["4-formamido-4,6-dideoxy-D-mannopyranosyl", "SIMPLE_CHEMICAL", 153, 193], ["O-chains", "PROTEIN", 57, 65], ["B. abortus", "SPECIES", 74, 84], ["Y. enterocolitica", "SPECIES", 89, 106], ["B. abortus", "SPECIES", 74, 84], ["Y. enterocolitica", "SPECIES", 89, 106], ["a polymer", "TEST", 140, 149], ["formamido", "TEST", 155, 164], ["dideoxy", "TREATMENT", 169, 176], ["D-mannopyranosyl units", "TREATMENT", 177, 199]]], ["V. cholerae has an N-acylated derivative of this sugar (Caroff et al., 1984b) , E. coli 0157:H7 has a tetramer, with one of the carbohydrates being an N-acylated derivative of the above (Perry et al., 1986a) , and the O-chain of Salmonella landau (Bundle et al., 1986) , S. urbana and S. godesberg (Perry et al., 1986b) have the same derivative but as a pentamer of repeating sugars.", [["N-acylated", "CHEMICAL", 19, 29], ["sugar", "CHEMICAL", 49, 54], ["carbohydrates", "CHEMICAL", 128, 141], ["N-acylated", "CHEMICAL", 151, 161], ["sugars", "CHEMICAL", 376, 382], ["V. cholerae", "ORGANISM", 0, 11], ["sugar", "SIMPLE_CHEMICAL", 49, 54], ["E. coli 0157:H7", "ORGANISM", 80, 95], ["Salmonella landau", "ORGANISM", 229, 246], ["S. urbana", "ORGANISM", 271, 280], ["S. godesberg", "ORGANISM", 285, 297], ["sugars", "SIMPLE_CHEMICAL", 376, 382], ["V. cholerae", "SPECIES", 0, 11], ["E. coli", "SPECIES", 80, 87], ["Salmonella landau", "SPECIES", 229, 246], ["S. urbana", "SPECIES", 271, 280], ["S. godesberg", "SPECIES", 285, 297], ["V. cholerae", "SPECIES", 0, 11], ["E. coli", "SPECIES", 80, 87], ["Salmonella landau", "SPECIES", 229, 246], ["S. urbana", "SPECIES", 271, 280], ["S. godesberg", "SPECIES", 285, 297], ["E. coli", "PROBLEM", 80, 87], ["the carbohydrates", "TREATMENT", 124, 141], ["an N-acylated derivative", "TREATMENT", 148, 172], ["repeating sugars", "TEST", 366, 382]]], ["It is likely, therefore, that the cross-reaction is due to the common N-acylated 4-amino-4,6-dideoxy-D-mannose in the O-chains of sLPS of the various species of bacteria.", [["N-acylated 4-amino-4,6-dideoxy-D-mannose", "CHEMICAL", 70, 110], ["N-acylated 4-amino-4,6-dideoxy-D-mannose", "CHEMICAL", 70, 110], ["O", "CHEMICAL", 118, 119], ["N-acylated 4-amino-4,6-dideoxy-D-mannose", "SIMPLE_CHEMICAL", 70, 110], ["O-chains", "SIMPLE_CHEMICAL", 118, 126], ["sLPS", "SIMPLE_CHEMICAL", 130, 134], ["O-chains", "PROTEIN", 118, 126], ["sLPS", "PROTEIN", 130, 134], ["amino", "TEST", 83, 88], ["dideoxy", "TREATMENT", 93, 100], ["D-mannose", "TREATMENT", 101, 110], ["the various species of bacteria", "PROBLEM", 138, 169], ["is likely", "UNCERTAINTY", 3, 12], ["bacteria", "OBSERVATION", 161, 169]]], ["Using the cross-reaction between B. abortus and Y. enterocolitica 0:9 as an example, it may be possible to differentiate serological reactions by the use of specific antigens (Corbel and Cullen, 1970; Mittal and Tizard, 1979; Mittal et al., 1980) .", [["Y. enterocolitica", "DISEASE", 48, 65], ["B. abortus", "ORGANISM", 33, 43], ["Y. enterocolitica 0:9", "ORGANISM", 48, 69], ["specific antigens", "PROTEIN", 157, 174], ["B. abortus", "SPECIES", 33, 43], ["Y. enterocolitica", "SPECIES", 48, 65], ["B. abortus", "SPECIES", 33, 43], ["Y. enterocolitica", "SPECIES", 48, 65], ["serological reactions", "PROBLEM", 121, 142], ["may be possible", "UNCERTAINTY", 88, 103]]], ["Because of its relative ease of preparation, its ability to passively attach to plastics and its immunodominance in the immune response of cattle, LPS is a widely used antigen in the ELISA for B. abortus antibody.BRUCELLA ANTIGENSAnother component of Brucella which has a potential use in ELISA is poly B (also called Component 1, second component or PB ) a low molecular weight carbohydrate released from the rough strain B. melitensis Bl15 as well as other BruceUa strains with trichloroacetic acid (Diaz et al., 1968 (Diaz et al., , 1981 .BRUCELLA ANTIGENSPoly B has received considerable interest because B. abortus infected animals produce antibodies which precipitate this carbohydrate while vaccinated animals do not (Diaz et al., 1979; Jones et al., 1980) .", [["LPS", "CHEMICAL", 147, 150], ["poly B", "CHEMICAL", 298, 304], ["trichloroacetic acid", "CHEMICAL", 480, 500], ["poly B", "CHEMICAL", 298, 304], ["carbohydrate", "CHEMICAL", 379, 391], ["trichloroacetic acid", "CHEMICAL", 480, 500], ["carbohydrate", "CHEMICAL", 679, 691], ["cattle", "ORGANISM", 139, 145], ["LPS", "SIMPLE_CHEMICAL", 147, 150], ["B. abortus antibody", "ORGANISM", 193, 212], ["Brucella", "ORGANISM", 251, 259], ["poly B", "SIMPLE_CHEMICAL", 298, 304], ["B. melitensis", "ORGANISM", 423, 436], ["Bl15", "ORGANISM", 437, 441], ["trichloroacetic acid", "SIMPLE_CHEMICAL", 480, 500], ["B. abortus", "ORGANISM", 609, 619], ["animals", "ORGANISM", 629, 636], ["B. abortus antibody", "PROTEIN", 193, 212], ["antibodies", "PROTEIN", 645, 655], ["cattle", "SPECIES", 139, 145], ["B. abortus", "SPECIES", 193, 203], ["B. melitensis", "SPECIES", 423, 436], ["B. abortus", "SPECIES", 609, 619], ["cattle", "SPECIES", 139, 145], ["B. abortus", "SPECIES", 193, 203], ["B. melitensis", "SPECIES", 423, 436], ["B. abortus", "SPECIES", 609, 619], ["plastics", "TREATMENT", 80, 88], ["the ELISA", "TEST", 179, 188], ["B. abortus antibody", "TEST", 193, 212], ["Brucella", "PROBLEM", 251, 259], ["a low molecular weight carbohydrate", "PROBLEM", 356, 391], ["the rough strain B. melitensis Bl15", "PROBLEM", 406, 441], ["other BruceUa strains", "PROBLEM", 453, 474], ["trichloroacetic acid", "TEST", 480, 500], ["B. abortus infected animals produce antibodies", "PROBLEM", 609, 655], ["Brucella", "OBSERVATION", 251, 259], ["melitensis", "OBSERVATION", 426, 436]]], ["Its composition is unclear; it is chemically different from native hapten (NH) or acid hapten (AH) (Moreno et al., 1981; Perera et al., 1984) ; it is purified from rough rather than smooth strains , it is made within the cell of rough strains and it is immunologically distinct as determined by its inability to absorb out all antibodies to NH (Moreno et al., 1981 ) .", [["smooth strains", "ANATOMY", 182, 196], ["cell", "ANATOMY", 221, 225], ["strains", "ANATOMY", 235, 242], ["NH", "CHEMICAL", 75, 77], ["NH", "CHEMICAL", 75, 77], ["hapten", "SIMPLE_CHEMICAL", 67, 73], ["NH", "SIMPLE_CHEMICAL", 75, 77], ["acid hapten", "SIMPLE_CHEMICAL", 82, 93], ["cell", "CELL", 221, 225], ["antibodies", "PROTEIN", 327, 337], ["acid hapten", "PROBLEM", 82, 93], ["smooth strains", "PROBLEM", 182, 196], ["rough strains", "PROBLEM", 229, 242]]], ["Although it does not bind antibodies when adsorbed to polystyrene tubes for an ELISA (Moreno et al., 1981 ) another interpretation might be that this carbohydrate does not adsorb to polystyrene (Diaz et al., 1984 ) .", [["polystyrene", "CHEMICAL", 182, 193], ["polystyrene", "CHEMICAL", 54, 65], ["carbohydrate", "CHEMICAL", 150, 162], ["polystyrene", "CHEMICAL", 182, 193], ["polystyrene", "SIMPLE_CHEMICAL", 182, 193], ["antibodies", "PROTEIN", 26, 36], ["polystyrene tubes", "TREATMENT", 54, 71], ["an ELISA", "TEST", 76, 84]]], ["Clearly more studies are warranted for poly B and its use as a discriminating antigen between vaccinated and infected cattle.BRUCELLA ANTIGENSWhile the ideal of antigen (s) for ELISA diagnosis of BruceUa infection is far from obvious at the present time, two features should be recalled at the time of decision.", [["poly B", "CHEMICAL", 39, 45], ["BruceUa infection", "DISEASE", 196, 213], ["poly B", "CHEMICAL", 39, 45], ["poly B", "SIMPLE_CHEMICAL", 39, 45], ["cattle", "ORGANISM", 118, 124], ["antigen", "GENE_OR_GENE_PRODUCT", 161, 168], ["BruceUa", "CANCER", 196, 203], ["cattle", "SPECIES", 118, 124], ["cattle", "SPECIES", 118, 124], ["poly B", "PROBLEM", 39, 45], ["ELISA diagnosis", "TEST", 177, 192], ["BruceUa infection", "PROBLEM", 196, 213], ["infection", "OBSERVATION", 204, 213]]], ["Firstly, it is very tedious to prepare a pure antigen totally free of sLPS contamination, and secondly, in addition to all the characteristics described above, the antigen must be one to which all field infected cattle produce a measureable immune response.ASSAY TECHNIQUESA compendium of ELISA techniques for the detection of bovine antibody to, and antigens of, B. abortus is presented in Table 2 .", [["sLPS", "SIMPLE_CHEMICAL", 70, 74], ["cattle", "ORGANISM", 212, 218], ["bovine", "ORGANISM", 327, 333], ["B. abortus", "ORGANISM", 364, 374], ["bovine antibody", "PROTEIN", 327, 342], ["antigens", "PROTEIN", 351, 359], ["cattle", "SPECIES", 212, 218], ["bovine", "SPECIES", 327, 333], ["B. abortus", "SPECIES", 364, 374], ["cattle", "SPECIES", 212, 218], ["bovine", "SPECIES", 327, 333], ["B. abortus", "SPECIES", 364, 374], ["a pure antigen", "TEST", 39, 53], ["sLPS contamination", "PROBLEM", 70, 88], ["ELISA techniques", "TEST", 289, 305], ["the detection", "TEST", 310, 323], ["bovine antibody", "PROBLEM", 327, 342]]], ["All antibody assays described are 'heterogeneous' assays requiring immobilization of antigen, usually on a plastic surface (Voller, 1980) .", [["surface", "ANATOMY", 115, 122], ["All antibody assays", "TEST", 0, 19], ["'heterogeneous' assays", "PROBLEM", 34, 56], ["immobilization of antigen", "TREATMENT", 67, 92], ["heterogeneous", "OBSERVATION_MODIFIER", 35, 48]]], ["This method, suitable for most proteins and sLPS antigens, relies on the hydrophobic interaction between the antigen and the plastic for attachment.", [["sLPS antigens", "GENE_OR_GENE_PRODUCT", 44, 57], ["sLPS antigens", "PROTEIN", 44, 57], ["This method", "TEST", 0, 11], ["most proteins and sLPS antigens", "PROBLEM", 26, 57]]], ["The choice of antigens used in the ELISA varies considerably, from whole cells to semi-purified cell components.", [["whole cells", "ANATOMY", 67, 78], ["cell", "ANATOMY", 96, 100], ["cells", "CELL", 73, 78], ["cell", "CELL", 96, 100], ["antigens", "PROTEIN", 14, 22], ["whole cells", "CELL_TYPE", 67, 78], ["the ELISA", "TEST", 31, 40], ["semi-purified cell components", "OBSERVATION", 82, 111]]], ["Nearly all antigens contain sLPS which appears to be of major diagnostic importance in most B. abortus assays.ASSAY TECHNIQUESThis antigen is now well characterized (Caroff et al., 1984a,b) , its preparation relatively simple (Nielsen et al., 1984b) , it adsorbs very well to plastics (Nielsen et al., 1983b) and infected cattle (as well as vaccinated animals) appear to preferentially produce antibody to this antigen (i.e., it is immunodominant).SAMPLE DILUTIONAntibody isotypes produced in response to B. abortus infection in cattle include IgM, IgG1, IgG2 and IgA (Rose and Amerault, 1964; Rice et al., 1966; Rice and Boyes, 1971; Beh, 1973 Beh, ,1974 Beh, ,1975 Levieux, 1974a,b; Jones, 1977; Butler et al., 1981) .", [["B. abortus infection", "DISEASE", 505, 525], ["sLPS", "GENE_OR_GENE_PRODUCT", 28, 32], ["B. abortus", "ORGANISM", 92, 102], ["cattle", "ORGANISM", 322, 328], ["B. abortus", "ORGANISM", 505, 515], ["cattle", "ORGANISM", 529, 535], ["IgM", "GENE_OR_GENE_PRODUCT", 544, 547], ["IgG1", "GENE_OR_GENE_PRODUCT", 549, 553], ["IgG2", "GENE_OR_GENE_PRODUCT", 555, 559], ["IgA", "GENE_OR_GENE_PRODUCT", 564, 567], ["sLPS", "PROTEIN", 28, 32], ["DILUTIONAntibody isotypes", "PROTEIN", 455, 480], ["IgM", "PROTEIN", 544, 547], ["IgG1", "PROTEIN", 549, 553], ["IgG2", "PROTEIN", 555, 559], ["IgA", "PROTEIN", 564, 567], ["B. abortus", "SPECIES", 92, 102], ["cattle", "SPECIES", 322, 328], ["B. abortus", "SPECIES", 505, 515], ["cattle", "SPECIES", 529, 535], ["B. abortus", "SPECIES", 92, 102], ["cattle", "SPECIES", 322, 328], ["B. abortus", "SPECIES", 505, 515], ["cattle", "SPECIES", 529, 535], ["SAMPLE DILUTIONAntibody isotypes", "TREATMENT", 448, 480], ["B. abortus infection", "PROBLEM", 505, 525], ["IgM", "TEST", 544, 547], ["IgG1", "TEST", 549, 553], ["IgG2", "TEST", 555, 559], ["IgA", "TEST", 564, 567], ["Beh", "TEST", 635, 638], ["Levieux", "TEST", 667, 674], ["appears to be of", "UNCERTAINTY", 39, 55]]], ["In some cases in the very early antibody response IgM may be the main antibody class found in serum (Rose and Amerault, 1964; Beh, 1974 ) while in other cases the IgG isotypes prevail (Rice et al., 1966; Beh, 1974) .", [["serum", "ANATOMY", 94, 99], ["IgM", "GENE_OR_GENE_PRODUCT", 50, 53], ["serum", "ORGANISM_SUBSTANCE", 94, 99], ["IgG isotypes", "GENE_OR_GENE_PRODUCT", 163, 175], ["IgM", "PROTEIN", 50, 53], ["IgG isotypes", "PROTEIN", 163, 175], ["serum", "TEST", 94, 99], ["the IgG isotypes", "TEST", 159, 175]]], ["All four isotypes of antibody are present in milk (Beh, 1973; Collin, 1976) although IgG1 and/or IgA predominate.", [["milk", "ANATOMY", 45, 49], ["milk", "ORGANISM_SUBSTANCE", 45, 49], ["IgG1", "GENE_OR_GENE_PRODUCT", 85, 89], ["IgA", "GENE_OR_GENE_PRODUCT", 97, 100], ["IgG1", "PROTEIN", 85, 89], ["IgA", "PROTEIN", 97, 100], ["IgG1", "TEST", 85, 89], ["four", "OBSERVATION_MODIFIER", 4, 8], ["isotypes", "OBSERVATION_MODIFIER", 9, 17]]], ["These factors have a substantial impact on the choice of dilution of serum or milk to be used in the assay.", [["serum", "ANATOMY", 69, 74], ["milk", "ANATOMY", 78, 82], ["serum", "ORGANISM_SUBSTANCE", 69, 74], ["milk", "ORGANISM_SUBSTANCE", 78, 82], ["dilution of serum or milk", "TREATMENT", 57, 82], ["substantial", "OBSERVATION_MODIFIER", 21, 32], ["impact", "OBSERVATION_MODIFIER", 33, 39]]], ["Although IgM accounts for up to 5 mg protein per ml, the percentage of antibody of a given specificity is low.", [["IgM", "GENE_OR_GENE_PRODUCT", 9, 12], ["IgM", "PROTEIN", 9, 12], ["IgM", "TEST", 9, 12], ["antibody", "TEST", 71, 79], ["low", "OBSERVATION_MODIFIER", 106, 109]]], ["Therefore a high dilution may cause IgM antibody to be diluted to extinction.", [["IgM antibody", "GENE_OR_GENE_PRODUCT", 36, 48], ["IgM antibody", "PROTEIN", 36, 48], ["a high dilution", "TREATMENT", 10, 25], ["IgM antibody", "PROBLEM", 36, 48], ["may cause", "UNCERTAINTY", 26, 35], ["IgM antibody", "OBSERVATION", 36, 48]]], ["For example, at 5 mg per ml and containing 2% antibody to B. abortus, a 1:100 dilution would result in the application of 200 ng of IgM antibody in a 200-#1 test sample.", [["B. abortus", "ORGANISM", 58, 68], ["IgM antibody", "PROTEIN", 132, 144], ["B. abortus", "SPECIES", 58, 68], ["B. abortus", "SPECIES", 58, 68], ["2% antibody", "TREATMENT", 43, 54], ["a 1:100 dilution", "TREATMENT", 70, 86], ["IgM antibody", "TEST", 132, 144], ["1 test sample", "TEST", 155, 168]]], ["According to Table 1 ,200 ng is detectable; however a 1:200 dilution would place only 100 ng in the test sample, possibly avoiding detection.", [["sample", "ANATOMY", 105, 111], ["a 1:200 dilution", "TREATMENT", 52, 68], ["the test sample", "TEST", 96, 111]]], ["Conversely, a low serum/milk dilution may result in false positive reactions due to non-specifically reacting IgM and perhaps negative reactions due to increased 'background' activity.ANTIGLOBULIN REAGENTSThe specificity of the antiglobulin to be conjugated with enzyme and used as a detecting reagent in the indirect ELISA is also an important consideration.", [["serum", "ANATOMY", 18, 23], ["milk", "ANATOMY", 24, 28], ["serum", "ORGANISM_SUBSTANCE", 18, 23], ["milk", "ORGANISM_SUBSTANCE", 24, 28], ["IgM", "GENE_OR_GENE_PRODUCT", 110, 113], ["antiglobulin", "GENE_OR_GENE_PRODUCT", 228, 240], ["IgM", "PROTEIN", 110, 113], ["antiglobulin", "PROTEIN", 228, 240], ["enzyme", "PROTEIN", 263, 269], ["a low serum/milk dilution", "PROBLEM", 12, 37], ["false positive reactions", "PROBLEM", 52, 76], ["non-specifically reacting IgM", "PROBLEM", 84, 113], ["negative reactions", "PROBLEM", 126, 144], ["increased 'background' activity", "PROBLEM", 152, 183], ["ANTIGLOBULIN", "TEST", 184, 196], ["the antiglobulin", "TEST", 224, 240], ["enzyme", "TREATMENT", 263, 269], ["a detecting reagent in the indirect ELISA", "PROBLEM", 282, 323], ["false positive reactions", "OBSERVATION", 52, 76], ["important consideration", "UNCERTAINTY", 335, 358]]], ["For a global estimate of antibody activity, a Coomb's reagent with specificity for all heavy (H) and both light (L) chains could be used.", [["light (L) chains", "PROTEIN", 106, 122], ["antibody activity", "PROBLEM", 25, 42], ["a Coomb's reagent", "TEST", 44, 61], ["both light (L) chains", "TREATMENT", 101, 122], ["antibody activity", "OBSERVATION", 25, 42]]], ["However, this type of reagent would introduce a bias in favour of detection of IgM and therefore likely decrease assay specificity due to the non-specific nature of IgM reactivity.", [["IgM", "GENE_OR_GENE_PRODUCT", 79, 82], ["IgM", "GENE_OR_GENE_PRODUCT", 165, 168], ["IgM", "PROTEIN", 79, 82], ["IgM", "PROTEIN", 165, 168], ["IgM", "TEST", 79, 82], ["assay specificity", "TEST", 113, 130], ["IgM reactivity", "PROBLEM", 165, 179], ["non-specific", "OBSERVATION_MODIFIER", 142, 154], ["IgM reactivity", "OBSERVATION", 165, 179]]], ["This bias could be reduced by using an anti-IgG (H and L chain) which would still allow for the detection of IgM based on anti-L chain reactivity.", [["IgM", "GENE_OR_GENE_PRODUCT", 109, 112], ["anti-L chain", "GENE_OR_GENE_PRODUCT", 122, 134], ["anti-IgG (H and L chain", "PROTEIN", 39, 62], ["IgM", "PROTEIN", 109, 112], ["anti-L chain", "PROTEIN", 122, 134], ["an anti-IgG (H and L chain", "TREATMENT", 36, 62], ["the detection", "TEST", 92, 105], ["IgM", "PROBLEM", 109, 112], ["anti-L chain reactivity", "PROBLEM", 122, 145], ["reduced", "OBSERVATION_MODIFIER", 19, 26]]], ["It has been our experience that this type of reagent works well when applied to cattle populations where vaccination with B. abortus strain 19 is not practised.", [["cattle", "ORGANISM", 80, 86], ["B. abortus strain 19", "ORGANISM", 122, 142], ["B. abortus", "SPECIES", 122, 132], ["cattle", "SPECIES", 80, 86], ["B. abortus strain 19", "SPECIES", 122, 142], ["vaccination with B. abortus strain", "TREATMENT", 105, 139]]], ["In the testing of calfhood vaccinates (Fig. 1 ) , we have found this type of reagent to be overly sensitive in the detection of low levels of residual vaccinal antibody, thus lowering or establishing separate diagnostic thresholds for nonvaccinated and vaccinated populations.", [["vaccinal antibody", "PROTEIN", 151, 168], ["low levels of residual vaccinal antibody", "PROBLEM", 128, 168], ["nonvaccinated and vaccinated populations", "PROBLEM", 235, 275], ["low levels", "OBSERVATION_MODIFIER", 128, 138], ["residual", "OBSERVATION_MODIFIER", 142, 150], ["vaccinal antibody", "OBSERVATION", 151, 168]]], ["The types of bias introduced by the use of reagents with H chain specificities could be further reduced by using an anti-L chain reagent (Fig. 1 ) .", [["H", "CHEMICAL", 57, 58], ["H", "CHEMICAL", 57, 58], ["an anti-L chain reagent", "TREATMENT", 113, 136]]], ["We are currently using a monoclonal antibody specific for an epitope present on both lambda and kappa L chains.", [["kappa L chains", "GENE_OR_GENE_PRODUCT", 96, 110], ["monoclonal antibody", "PROTEIN", 25, 44], ["lambda and kappa L chains", "PROTEIN", 85, 110], ["a monoclonal antibody", "TREATMENT", 23, 44], ["an epitope", "PROBLEM", 58, 68], ["both lambda and kappa L chains", "TREATMENT", 80, 110]]], ["This re- agent has not compromised assay sensitivity but has considerably improved assay specificity, especially amongst vaccinated cattle.", [["cattle", "ORGANISM", 132, 138], ["cattle", "SPECIES", 132, 138], ["cattle", "SPECIES", 132, 138], ["compromised assay sensitivity", "PROBLEM", 23, 52]]], ["Monospecific reagents may be used where it is desirable to distinguish isotypic responses.", [["Monospecific reagents", "TREATMENT", 0, 21]]], ["In the case of IgM or to partially discriminate vaccinated from infected animals with an anti-IgG1, it may be preferable to use separate assays; however, this obviously also increases the cost.", [["IgM", "GENE_OR_GENE_PRODUCT", 15, 18], ["anti-IgG1", "SIMPLE_CHEMICAL", 89, 98], ["IgM", "PROTEIN", 15, 18], ["IgM", "PROBLEM", 15, 18], ["separate assays", "TEST", 128, 143], ["infected", "OBSERVATION", 64, 72]]], ["Antibody competition for limited antigenic determinants creates a problem when using monospecific antiglobulins in the indirect ELISA.", [["antiglobulins", "GENE_OR_GENE_PRODUCT", 98, 111], ["monospecific antiglobulins", "PROTEIN", 85, 111], ["Antibody competition", "TEST", 0, 20], ["limited antigenic determinants", "PROBLEM", 25, 55], ["monospecific antiglobulins", "TREATMENT", 85, 111]]], ["It has been reported that IgM antibody could not be assessed because of such competition (Lamb et al., 1979 ) .", [["IgM antibody", "GENE_OR_GENE_PRODUCT", 26, 38], ["IgM antibody", "PROTEIN", 26, 38], ["IgM antibody", "TEST", 26, 38], ["IgM antibody", "OBSERVATION", 26, 38]]], ["This problem can be overcome to a certain extent by increasing the number of available antigenic sites (however, steric hindrance or detachment may result) or by the use of an amplified ELISA (Butler, 1981 ) .", [["available antigenic sites", "PROBLEM", 77, 102], ["steric hindrance", "PROBLEM", 113, 129], ["detachment", "PROBLEM", 133, 143], ["increasing", "OBSERVATION_MODIFIER", 52, 62]]], ["In addition, important consideration should also be given to whether antibody concentration or affinity is being measured (Butler et al., 1978) .", [["antibody concentration", "PROBLEM", 69, 91]]], ["Perhaps a more appropriate technique for isotype detection is a class-capture ELISA in which antiimmunoglobulin is immobilized and used to capture immunoglobulin which is then reacted with antigen (as described in, for example, Vejtorp, 1981; Yolken and Leister, 1981; Payne et al., 1982; Gustafsson, 1984; Nielsen et al., 1985) .ANTIGLOBULIN REAGENTSFor diagnostic purposes, in laboratories receiving hundreds of thousands of samples yearly, a test using a single polyvalent antiglobulin reagent such as anti-IgG (H and L ) may be preferable due to ease of production and versatility.", [["antiimmunoglobulin", "GENE_OR_GENE_PRODUCT", 93, 111], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 147, 161], ["anti-IgG", "SIMPLE_CHEMICAL", 505, 513], ["antiimmunoglobulin", "PROTEIN", 93, 111], ["immunoglobulin", "PROTEIN", 147, 161], ["anti-IgG", "PROTEIN", 505, 513], ["isotype detection", "TEST", 41, 58], ["capture ELISA", "TEST", 70, 83], ["immunoglobulin", "TEST", 147, 161], ["diagnostic purposes", "TEST", 355, 374], ["a test", "TEST", 443, 449], ["a single polyvalent antiglobulin reagent", "TREATMENT", 456, 496], ["anti-IgG", "TEST", 505, 513]]], ["However, standardization of antiglobulin reagents for long-term diagnostic use will always remain a problem with polyclonal antisera prepared by conventional means.", [["antiglobulin", "GENE_OR_GENE_PRODUCT", 28, 40], ["antiglobulin reagents", "TREATMENT", 28, 49], ["polyclonal antisera", "TREATMENT", 113, 132]]], ["Each batch of antiglobulin will vary to some extent and enzyme conjugation, also susceptible to variations, may result in considerable discrepancies arising.", [["antiglobulin", "GENE_OR_GENE_PRODUCT", 14, 26], ["antiglobulin", "PROTEIN", 14, 26], ["antiglobulin", "TREATMENT", 14, 26], ["enzyme conjugation", "TEST", 56, 74], ["considerable discrepancies arising", "PROBLEM", 122, 156], ["considerable", "OBSERVATION_MODIFIER", 122, 134], ["discrepancies", "OBSERVATION", 135, 148]]], ["At present, antiglobulin reagents are not standard among laboratories (see Table 2 ) and direct interlaboratory comparison of ELISA data is more difficult than with conventional serological tests.", [["antiglobulin reagents", "TEST", 12, 33], ["direct interlaboratory comparison", "TEST", 89, 122], ["ELISA data", "TEST", 126, 136], ["conventional serological tests", "TEST", 165, 195]]], ["Definitive criteria for performance of enzyme conjugated antiglobulin reagents with respect to analytical sensitivity and specificity may suffice to reduce batch variation and the lack of a universally available reagent.", [["enzyme conjugated antiglobulin reagents", "TREATMENT", 39, 78], ["analytical sensitivity", "TEST", 95, 117], ["batch variation", "PROBLEM", 156, 171]]], ["In our laboratory a monoclonal antibody is used to eliminate these difficulties, as the definable product of a cloned cell does not vary if handled properly.", [["cell", "ANATOMY", 118, 122], ["cell", "CELL", 118, 122], ["monoclonal antibody", "PROTEIN", 20, 39], ["cloned cell", "CELL_LINE", 111, 122], ["a monoclonal antibody", "TEST", 18, 39], ["these difficulties", "PROBLEM", 61, 79], ["a cloned cell", "PROBLEM", 109, 122]]], ["There are, unfortunately, two problems with monoclonal antibodies.", [["monoclonal antibodies", "PROTEIN", 44, 65], ["monoclonal antibodies", "PROBLEM", 44, 65], ["monoclonal antibodies", "OBSERVATION", 44, 65]]], ["Firstly, they are fairly expensive to produce, and secondly, the product of a single cloned cell line may be too specific to detect all molecules of a single antibody class, given that genetic variation within a species may occur, thereby requiring a blend of monoclonals.", [["cell line", "ANATOMY", 92, 101], ["cell line", "CELL", 92, 101], ["cloned cell line", "CELL_LINE", 85, 101], ["antibody class", "PROTEIN", 158, 172], ["a single cloned cell line", "TREATMENT", 76, 101], ["genetic variation", "PROBLEM", 185, 202], ["a blend of monoclonals", "TREATMENT", 249, 271]]], ["At present we are using a mouse monoclonal antibody to the bovine L-chain conjugated with HRPO as a diagnostic reagent.", [["HRPO", "CHEMICAL", 90, 94], ["HRPO", "CHEMICAL", 90, 94], ["mouse", "ORGANISM", 26, 31], ["bovine", "ORGANISM", 59, 65], ["HRPO", "SIMPLE_CHEMICAL", 90, 94], ["mouse monoclonal antibody", "PROTEIN", 26, 51], ["bovine L-chain", "PROTEIN", 59, 73], ["HRPO", "PROTEIN", 90, 94], ["mouse", "SPECIES", 26, 31], ["bovine", "SPECIES", 59, 65], ["mouse", "SPECIES", 26, 31], ["a mouse monoclonal antibody", "TREATMENT", 24, 51], ["the bovine L-chain", "TREATMENT", 55, 73], ["HRPO", "TREATMENT", 90, 94], ["a diagnostic reagent", "TREATMENT", 98, 118]]], ["This reagent has proved stable as a HRPO conjugate for at least 20 months and no detectable differences were observed in conjugating some 25 batches of antibody.", [["HRPO", "CHEMICAL", 36, 40], ["HRPO", "CHEMICAL", 36, 40], ["HRPO", "SIMPLE_CHEMICAL", 36, 40], ["HRPO conjugate", "PROTEIN", 36, 50], ["a HRPO conjugate", "TREATMENT", 34, 50], ["detectable differences", "PROBLEM", 81, 103], ["stable", "OBSERVATION_MODIFIER", 24, 30]]], ["The cell line producing this antibody has been frozen and several batches have been thawed and used for preparation of ascites fluid without noticeable discrepancies in activity.DATA EXPRESSION AND INTERPRETATION OF ANTIBODY ACTIVITYThe end result of any ELISA is the generation of a quantifiable product.", [["cell line", "ANATOMY", 4, 13], ["ascites fluid", "ANATOMY", 119, 132], ["ascites", "DISEASE", 119, 126], ["cell line", "CELL", 4, 13], ["ascites fluid", "ORGANISM_SUBSTANCE", 119, 132], ["cell line", "CELL_LINE", 4, 13], ["The cell line", "TREATMENT", 0, 13], ["this antibody", "TREATMENT", 24, 37], ["ascites fluid", "PROBLEM", 119, 132], ["noticeable discrepancies in activity", "PROBLEM", 141, 177], ["any ELISA", "PROBLEM", 251, 260], ["cell line", "OBSERVATION", 4, 13], ["ascites", "OBSERVATION", 119, 126], ["activity", "OBSERVATION_MODIFIER", 169, 177]]], ["The raw data generated from the measurement of a chromogenic product are expressed in optical density (OD) units.", [["a chromogenic product", "TREATMENT", 47, 68], ["optical density", "OBSERVATION", 86, 101]]], ["There are several methods by which this can be done and the advantages and disadvantages of these various methods have been compared (De Savigny and Voller, 1980; Cremer et al., 1982; Malvano et al., 1982) .DATA EXPRESSION AND INTERPRETATION OF ANTIBODY ACTIVITYThe indirect ELISA is semi-quantitative as a single dilution assay.", [["The indirect ELISA", "TEST", 262, 280], ["a single dilution assay", "TEST", 305, 328]]], ["The most simplistic form of data expression is the OD unit.", [["OD unit", "DNA", 51, 58]]], ["Diagnostic thresholds have been estalished through application of statistical methods to OD values observed in the testing of antibody negative and positive reference populations (Heck et al., 1980a; Heck et al., 1982; Sutherland, 1984) .", [["Diagnostic thresholds", "TEST", 0, 21], ["OD values", "TEST", 89, 98], ["the testing of antibody", "TEST", 111, 134]]], ["In competitive assays, threshold optical density values have been determined relative to the ability of positive and negative reference populations to compete with a monoclonal antibody standard (Heck et al., 1984) .DATA EXPRESSION AND INTERPRETATION OF ANTIBODY ACTIVITYWe have developed a method of monitoring substrate conversion (Nielsen et al., 1984b; Wright et al., 1985) which permits the direct comparison of optical density values from plate-to-plate and day-to-day.", [["threshold optical density values", "PROBLEM", 23, 55], ["positive and negative reference populations", "PROBLEM", 104, 147], ["a monoclonal antibody", "TEST", 164, 185], ["plate", "TEST", 445, 450]]], ["Using this method, a large normal reference population was tested and OD values were arrayed in a frequency distribution.", [["this method", "TREATMENT", 6, 17], ["OD values", "TEST", 70, 79], ["large", "OBSERVATION_MODIFIER", 21, 26], ["normal", "OBSERVATION", 27, 33]]], ["The mean of the 100th percentile was then used as a base for evaluation of the diagnostic performance of the assay (Dohoo et al., 1986) .", [["evaluation", "TEST", 61, 71], ["the assay", "TEST", 105, 114]]], ["A flexible threshold is important as the ultimate usefulness of an assay will depend on its diagnostic performance given a particular prevalence of disease.DATA EXPRESSION AND INTERPRETATION OF ANTIBODY ACTIVITYIf laboratory results are to be reported in a qualitative manner (i.e., positive, negative or 'questionable'), then the method of laboratory expression and interpretation is technically simple.", [["an assay", "TEST", 64, 72], ["disease", "PROBLEM", 148, 155], ["ANTIBODY ACTIVITYIf laboratory", "TEST", 194, 224], ["disease", "OBSERVATION", 148, 155]]], ["This is one of the principle shortcomings of the indirect ELISA technique.", [["the indirect ELISA technique", "TREATMENT", 45, 73]]], ["No single method of data expression has yet been adopted in brucellosis ELISA serology; however, some laboratories have addressed this problem and we are currently engaged in the development of a quantitative method of data expression.GENERAL DATA ACQUISITION AND MANIPULATIONBecause the reading, recording and manipulation of a large number of sample OD values can be a laborious task, automated reading equipment has been developed and linked to computers to expedite the process.GENERAL DATA ACQUISITION AND MANIPULATIONThe result has been the development of ELISA protocols based on a variety of reaction vessels for which automated and semi-automated handling and reading equipment is available.", [["vessels", "ANATOMY", 609, 616], ["brucellosis", "DISEASE", 60, 71], ["vessels", "MULTI-TISSUE_STRUCTURE", 609, 616], ["brucellosis ELISA serology", "TEST", 60, 86], ["ELISA protocols", "TREATMENT", 562, 577], ["a variety of reaction vessels", "TREATMENT", 587, 616], ["single", "OBSERVATION_MODIFIER", 3, 9], ["method", "OBSERVATION", 10, 16], ["large", "OBSERVATION_MODIFIER", 329, 334]]], ["This includes systems based on 96-well microtiter plates (Saunders et al., 1979; Ritchie et al., 1981; Richardson et al., 1983; Slezak et al., 1983; Stemshorn et al., 1983; Caulfield and Shaffer, 1984; Nielsen et al., 1984b ) , plastic cuvettes (Canellas and Karu, 1981; Barlough et al., 1983 ) and plastic tubes (Saunders et al., 1979; Seawright et al., 1981) .GENERAL DATA ACQUISITION AND MANIPULATIONAccompanying the increased sample handling capacity of these systems is the problem of manipulating large amounts of raw data.", [["sample", "ANATOMY", 430, 436], ["the increased sample handling capacity of these systems", "PROBLEM", 416, 471], ["increased", "OBSERVATION_MODIFIER", 420, 429], ["large", "OBSERVATION_MODIFIER", 503, 508], ["amounts", "OBSERVATION_MODIFIER", 509, 516]]], ["This can be especially time-consuming if such operations as replicate mean determinations, sigmoidal curve fitting, linear regression analysis and quality control calculations are performed.", [["such operations", "TREATMENT", 41, 56], ["mean determinations", "TEST", 70, 89], ["sigmoidal curve fitting", "TREATMENT", 91, 114], ["linear regression analysis", "TEST", 116, 142], ["quality control calculations", "TEST", 147, 175]]], ["In some cases the task of data manipulation has been handled through the use of custom computer programs which have been designed to accept data directly from a plate reader (Ritchie et al., 1981; Richardson et al., 1983; Slezak et al., 1983; Caulfield and Shaffer, 1984) or a cuvette reader (Barlough et al., 1983) or from a magnetic tape storage device on which plate reader output has previously been reported off-line (Saunders et al., 1979; Ritchie et al., 1981; Richardson et al., 1983; Slezak et al., 183; Stemshorn et al., 1983; Nielsen et al., 1984b ) , or from manual keyboard entry (Gaines D as and Tydeman, 1980; Raab et al., 1980; Fey, 1981; Morita et al., 1982) .GENERAL DATA ACQUISITION AND MANIPULATIONThe problem of data manipulation has also been addressed by manufacturers who offer plate readers with limited built-in ROM based data acquisition and handling routines which allow 'blanking' on specified wells, matrix printouts, flagging of OD readings within specified ranges, etc. Most plate readers feature a built-in serial RS-232-C port (some also have IEEE 488) to allow transmission of OD values to a computer either directly or over telephone lines through a modem.", [["a magnetic tape storage device", "TREATMENT", 324, 354], ["handling routines", "TREATMENT", 869, 886], ["OD readings", "TEST", 960, 971], ["C port", "TREATMENT", 1054, 1060]]], ["Some newer plate readers also use the serial port to receive computer commands which control plate movement, reading, 'blanking' and filter selection.", [["the serial port", "TREATMENT", 34, 49], ["computer commands", "TREATMENT", 61, 78], ["'blanking' and filter selection", "TREATMENT", 118, 149]]], ["This commercial software typically accepts and files OD data directly from the plate reader, allows the user to specify the well placement of standards, test samples and replicates, and calculates the concentration of unknowns based on linear regression of a standard curve or as some percentage of the concentration of a known positive.", [["test samples", "TEST", 153, 165], ["a standard curve", "TREATMENT", 257, 273], ["a known positive", "PROBLEM", 320, 336]]], ["Although this software usually offers more data-handling flexibility than the built-in plate reader routines, it is often too general to meet the specific needs of a particular ELISA protocol, especially if that protocol requires the calculation of reaction rates based on multiple time point readings or the calculation of a target time as is required by our ELISA for antibody to Brucella.DATA ACQUISITION AND MANIPULATION FOR THE EIA FOR ANTIBODY TO BRUCELLA ABORTUSA simple computer program in support of the indirect ELISA for detection of antibody to Brucella has been described (Nielsen et al., 1984b) .", [["a particular ELISA protocol", "TREATMENT", 164, 191], ["reaction rates", "TREATMENT", 249, 263], ["our ELISA", "TEST", 356, 365], ["Brucella", "PROBLEM", 382, 390], ["DATA ACQUISITION", "TEST", 391, 407], ["THE EIA", "TEST", 429, 436], ["the indirect ELISA", "TEST", 509, 527], ["antibody to Brucella", "PROBLEM", 545, 565]]], ["This protocol calls for the placement of sample replicates in diagonally opposed quadrants of the microtiter plate with the target reference and quality control sera replicated in all four quadrants.", [["sera", "ANATOMY", 161, 165], ["sera", "ORGANISM_SUBSTANCE", 161, 165], ["This protocol", "TREATMENT", 0, 13], ["the placement of sample replicates in diagonally opposed quadrants of the microtiter plate", "TREATMENT", 24, 114], ["microtiter plate", "OBSERVATION", 98, 114]]], ["It also requires that the mean OD of the target reference replicates be calculated after 4 min of substrate development and that this figure be used to calculate a target time at which the mean OD of the target reference replicates will reach 1.0 units.DATA ACQUISITION AND MANIPULATION FOR THE EIA FOR ANTIBODY TO BRUCELLA ABORTUSThe program is written in BASICA 2.0 and although it is intended to run on an IBM-PC operating under DOS 2.0 or higher, the version presented could easily be modified for use on other brands of micro-or mini-computers which allow access to the internal clock, support serial communication and are not operating under time-sharing.", [["DATA ACQUISITION", "TEST", 253, 269], ["THE EIA", "TEST", 291, 298], ["DOS", "TEST", 432, 435], ["micro-or mini-computers", "TREATMENT", 525, 548]]], ["The required plate reader is a computer-controllable FLOW LABORATORIES Titertek Multiskan MCC which is interfaced through the RS-232-C serial port to transmit data to and receive commands from the computer.", [["serial port", "TREATMENT", 135, 146], ["transmit data", "TEST", 150, 163]]], ["The program controls reader operations such as filter selection, blanking, plate movement and reading.", [["reader operations", "TREATMENT", 21, 38], ["filter selection", "TREATMENT", 47, 63], ["plate movement", "OBSERVATION", 75, 89]]], ["It calculates a target time from a 4-min plate reading and automatically reads the plate again at that target time.", [["target", "OBSERVATION_MODIFIER", 16, 22]]], ["Raw OD measurements for each well are then stored on a disk file and the mean, standard deviation (SD) and percent coefficient of variation (%CV) for each replicate sample pair are printed out along with the status (negative or positive) of each sample.", [["Raw OD measurements", "TEST", 0, 19], ["a disk file", "TEST", 53, 64], ["variation (%CV)", "TREATMENT", 130, 145]]], ["The status is dependent on an OD threshold of 0.300 specified within the program.", [["dependent", "OBSERVATION_MODIFIER", 14, 23]]], ["Although the version of the program described does not store the reduced data (i.e., mean, SD, %CV and status) on a disk, this feature is highly desirable if development of a database or further statistical analysis or quality control is required.", [["mean", "TEST", 85, 89], ["SD, %CV and status) on a disk", "PROBLEM", 91, 120], ["a database", "TEST", 173, 183], ["further statistical analysis", "TEST", 187, 215]]], ["For example, some commercial statistical packages will accept only numeric data which would require omission of the status field.", [["numeric data", "TEST", 67, 79]]], ["The format of choice would be one which takes up the least amount of disk place but can still be accessed by available software for further manipulation.", [["further manipulation", "TREATMENT", 132, 152], ["disk", "OBSERVATION", 69, 73]]], ["DISCUSSION In the preceding brief review, consideration was given to the factors influencing the development a diagnostic ELISA with particular emphasis on assay performance and interpretation of results.", [["a diagnostic ELISA", "TEST", 109, 127], ["assay performance", "TEST", 156, 173]]], ["While for the moment this test is very functional, application of research could probably further improve the performance of the test.", [["this test", "TEST", 21, 30], ["the test", "TEST", 125, 133]]], ["Presently, a lipopolysaccharide antigen is used; however, at least two other options are being actively researched at the moment.", [["lipopolysaccharide", "CHEMICAL", 13, 31], ["lipopolysaccharide antigen", "GENE_OR_GENE_PRODUCT", 13, 39], ["lipopolysaccharide antigen", "PROTEIN", 13, 39], ["a lipopolysaccharide antigen", "TEST", 11, 39]]], ["Firstly, the use of the chemically defined O-chain (1,2 linked 4,6 dideoxy-4formamide-~-D-mannopyranose) which can be synthesized and therefore eliminates any variability encountered with extraction of bacterial antigens.", [["1,2 linked 4,6 dideoxy-4formamide-~-D-mannopyranose", "CHEMICAL", 52, 103], ["O", "CHEMICAL", 43, 44], ["4,6 dideoxy-4formamide-~-D-mannopyranose", "CHEMICAL", 63, 103], ["O-chain", "SIMPLE_CHEMICAL", 43, 50], ["1,2 linked 4,6 dideoxy-4formamide-~-D-mannopyranose", "SIMPLE_CHEMICAL", 52, 103], ["bacterial antigens", "PROTEIN", 202, 220], ["dideoxy", "TEST", 67, 74], ["4formamide", "TREATMENT", 75, 85], ["D-mannopyranose", "TREATMENT", 88, 103], ["extraction", "TREATMENT", 188, 198], ["bacterial antigens", "PROBLEM", 202, 220]]], ["The second alternative, the use of polysaccharide, 'poly-B' as an antigen.", [["poly-B", "CHEMICAL", 52, 58], ["poly-B", "SIMPLE_CHEMICAL", 52, 58], ["polysaccharide", "TREATMENT", 35, 49]]], ["An enticing glimpse of its potential has been described in the use of a gel diffusion test to differentiate sera from vaccinated and infected cattle.", [["sera", "ANATOMY", 108, 112], ["sera", "ORGANISM_SUBSTANCE", 108, 112], ["cattle", "ORGANISM", 142, 148], ["cattle", "SPECIES", 142, 148], ["cattle", "SPECIES", 142, 148], ["a gel diffusion test", "TEST", 70, 90], ["sera", "TEST", 108, 112]]], ["Until very recently, poly-B was relatively uncharacterized and difficult to purify; however, analysis and purification methods have advanced considerably (Perry et al., 1986a) .", [["poly-B", "CHEMICAL", 21, 27], ["poly-B", "CHEMICAL", 21, 27], ["poly-B", "SIMPLE_CHEMICAL", 21, 27], ["poly-B", "PROTEIN", 21, 27], ["analysis", "TEST", 93, 101], ["purification methods", "TEST", 106, 126]]], ["With the advent of highly refined antigens, the ELISA test procedure itself may be revised to a much more manageable 'homogeneous assay' in which an epitope of the antigen is labelled with an enzyme, the function of which may be modulated by the binding of antibody to that epitope; in other words, a single-step assay that may be performed very quickly almost anywhere.", [["antibody", "PROTEIN", 257, 265], ["the ELISA test procedure", "TREATMENT", 44, 68], ["an enzyme", "TEST", 189, 198], ["a single-step assay", "TEST", 299, 318]]], ["Alternately, the application of the above-mentioned antigens to an indirect or competitive type of assay and the use of monoclonal antibody conjugated with enzyme may provide highly specific and sensitive assays which could now truly be standardized.", [["monoclonal antibody", "PROTEIN", 120, 139], ["monoclonal antibody", "TEST", 120, 139], ["enzyme", "TEST", 156, 162]]], ["Finally, further developments in cell culture technology may, in the future, allow production of stable monoclonal bovine cell lines that produce antibody of desired specificities.", [["cell", "ANATOMY", 33, 37], ["cell lines", "ANATOMY", 122, 132], ["cell", "CELL", 33, 37], ["bovine", "ORGANISM", 115, 121], ["cell lines", "CELL", 122, 132], ["monoclonal bovine cell lines", "CELL_LINE", 104, 132], ["bovine", "SPECIES", 115, 121], ["cell culture technology", "TEST", 33, 56], ["stable monoclonal bovine cell lines", "TREATMENT", 97, 132], ["stable", "OBSERVATION_MODIFIER", 97, 103], ["monoclonal bovine cell lines", "OBSERVATION", 104, 132]]], ["Thus a monoclonal bovine anti-Brucella antibody would greatly enhance the ultimate standardization of an indirect ELISA and could be used in a competitive ELISA (labelled with an enzyme) as well.DATA ACQUISITION AND MANIPULATION FOR THE EIA FOR ANTIBODY TO BRUCELLA ABORTUSUtilization of micro-processors and robotics will in the very near future allow semi-or complete automation of ELISA procedures and with appropriate programming, once the test sample has been placed in the system, there would be no other human contact until after final data evaluation, regardless of the species being tested.", [["bovine", "ORGANISM", 18, 24], ["human", "ORGANISM", 511, 516], ["monoclonal bovine anti-Brucella antibody", "PROTEIN", 7, 47], ["bovine", "SPECIES", 18, 24], ["human", "SPECIES", 511, 516], ["bovine", "SPECIES", 18, 24], ["human", "SPECIES", 511, 516], ["a monoclonal bovine anti-Brucella antibody", "TREATMENT", 5, 47], ["an indirect ELISA", "TEST", 102, 119], ["an enzyme", "TEST", 176, 185], ["DATA ACQUISITION", "TEST", 195, 211], ["THE EIA", "TEST", 233, 240], ["micro-processors", "TREATMENT", 288, 304], ["robotics", "TREATMENT", 309, 317], ["ELISA procedures", "TREATMENT", 384, 400], ["the test sample", "TEST", 440, 455], ["final data evaluation", "TEST", 537, 558], ["the species", "PROBLEM", 574, 585]]]], "PMC2891641": [["Hope and Coping with Cancer ::: BackgroundPersonal characteristics may have an important effect on adjustment to HCRC genetic testing.", [["Cancer", "ANATOMY", 21, 27], ["Cancer", "DISEASE", 21, 27], ["Cancer", "CANCER", 21, 27], ["HCRC genetic testing", "TEST", 113, 133]]], ["Michie et al. [5] concluded from a longitudinal prospective study that HCRC genetic testing subjects who were low in optimism and self-esteem were more likely to be clinically anxious in the first year after testing.", [["a longitudinal prospective study", "TEST", 33, 65], ["clinically anxious", "PROBLEM", 165, 183], ["testing", "TEST", 208, 215]]], ["The cognitive theory of hope proposed by Snyder and his colleagues [16,17] in helping people to cope with stressors has recently been the focus of much attention.", [["people", "ORGANISM", 86, 92], ["people", "SPECIES", 86, 92]]], ["A guiding assumption of Snyder's hope model is that human actions are goal-directed [16] and goals themselves are the cognitive anchors of hopeful thinking [19].", [["human", "ORGANISM", 52, 57], ["human", "SPECIES", 52, 57], ["human", "SPECIES", 52, 57]]], ["Goals typically contain some degree of uncertainty, yet they must be attainable [21].", [["some degree", "OBSERVATION_MODIFIER", 24, 35]]], ["Snyder's model proposes that when confronted with negative events such as a positive genetic testing result for HCRC, high-hope individuals will be distressed only temporarily and will bounce back full of energy and ideas on how to achieve their life goals [22].", [["HCRC", "DISEASE", 112, 116], ["HCRC", "CANCER", 112, 116], ["a positive genetic testing", "TEST", 74, 100], ["HCRC", "TEST", 112, 116]]], ["Research shows that hope is a significant predictor of psychological well-being not only among healthy people [23] but also among individuals with chronic illnesses such as spinal cord injuries [24] and cancer [25-28].", [["spinal cord", "ANATOMY", 173, 184], ["cancer", "ANATOMY", 203, 209], ["chronic illnesses", "DISEASE", 147, 164], ["spinal cord injuries", "DISEASE", 173, 193], ["cancer", "DISEASE", 203, 209], ["people", "ORGANISM", 103, 109], ["spinal cord", "ORGAN", 173, 184], ["cancer", "CANCER", 203, 209], ["people", "SPECIES", 103, 109], ["chronic illnesses", "PROBLEM", 147, 164], ["spinal cord injuries", "PROBLEM", 173, 193], ["cancer", "PROBLEM", 203, 209], ["spinal cord", "ANATOMY", 173, 184]]], ["For example, Stanton and colleagues [27] investigated hope and coping strategies as predictors of adjustment among 85 women one year after a diagnosis of breast cancer and reported that high-hope women adopting problem-focused coping strategies adjusted better.Prototypical Psychological Outcome Trajectories after a Stressful Event ::: BackgroundAlthough HCRC genetic testing is a stressful event for most people, there are marked differences in how individuals respond to it [29].", [["breast cancer", "ANATOMY", 154, 167], ["breast cancer", "DISEASE", 154, 167], ["women", "ORGANISM", 118, 123], ["breast cancer", "CANCER", 154, 167], ["women", "ORGANISM", 196, 201], ["people", "ORGANISM", 407, 413], ["women", "SPECIES", 118, 123], ["women", "SPECIES", 196, 201], ["people", "SPECIES", 407, 413], ["breast cancer", "PROBLEM", 154, 167], ["genetic testing", "TEST", 361, 376], ["breast", "ANATOMY", 154, 160], ["cancer", "OBSERVATION", 161, 167], ["marked", "OBSERVATION_MODIFIER", 425, 431], ["differences", "OBSERVATION_MODIFIER", 432, 443]]], ["Bonanno and his colleagues [30-33] identified four prototypical patterns or trajectory outcomes that capture most people's long-term psychological responses after a potentially traumatic event.", [["people", "ORGANISM", 114, 120], ["people", "SPECIES", 114, 120], ["a potentially traumatic event", "PROBLEM", 163, 192]]], ["The four trajectories are resilience, chronic dysfunction, recovery, and delayed reaction [33].Prototypical Psychological Outcome Trajectories after a Stressful Event ::: BackgroundResilience is conceptualized as an individual's ability to maintain a relatively stable and healthy level of psychological and physical functioning after a traumatic event [31-35].", [["chronic dysfunction", "DISEASE", 38, 57], ["chronic dysfunction", "PROBLEM", 38, 57], ["delayed reaction", "PROBLEM", 73, 89], ["a traumatic event", "PROBLEM", 335, 352], ["chronic", "OBSERVATION_MODIFIER", 38, 45], ["dysfunction", "OBSERVATION", 46, 57], ["stable", "OBSERVATION_MODIFIER", 262, 268]]], ["People in the chronic dysfunction category show a consistent and persistent pattern of elevated symptoms and distress.", [["chronic dysfunction", "DISEASE", 14, 33], ["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6], ["the chronic dysfunction category", "PROBLEM", 10, 42], ["elevated symptoms", "PROBLEM", 87, 104], ["distress", "PROBLEM", 109, 117], ["chronic", "OBSERVATION_MODIFIER", 14, 21], ["dysfunction", "OBSERVATION", 22, 33], ["persistent", "OBSERVATION_MODIFIER", 65, 75], ["elevated", "OBSERVATION_MODIFIER", 87, 95], ["symptoms", "OBSERVATION", 96, 104]]], ["Typically, only a small percentage of individuals (from 5% to 10%) exhibit this trajectory pattern, but the percentage may vary according to the severity and type of trauma [30].", [["trauma", "DISEASE", 166, 172], ["a small percentage of individuals", "PROBLEM", 16, 49], ["this trajectory pattern", "PROBLEM", 75, 98], ["trauma", "PROBLEM", 166, 172], ["small", "OBSERVATION_MODIFIER", 18, 23], ["percentage", "OBSERVATION_MODIFIER", 24, 34]]], ["Another prototypical trajectory outcome, termed recovery, represents individuals who initially experience elevations in symptoms and distress, followed by a gradual reduction and return to the population norm.", [["elevations in symptoms", "PROBLEM", 106, 128], ["distress", "PROBLEM", 133, 141], ["a gradual reduction", "TREATMENT", 155, 174], ["reduction", "OBSERVATION_MODIFIER", 165, 174]]], ["Finally, the delayed reaction category includes individuals who initially show moderate (sub-threshold) symptom levels after a potentially traumatic event, followed by a gradual increase to above-threshold elevations over time.", [["the delayed reaction category", "PROBLEM", 9, 38], ["moderate (sub-threshold) symptom levels", "PROBLEM", 79, 118], ["a potentially traumatic event", "PROBLEM", 125, 154], ["moderate", "OBSERVATION_MODIFIER", 79, 87], ["traumatic", "OBSERVATION", 139, 148], ["gradual", "OBSERVATION_MODIFIER", 170, 177], ["increase", "OBSERVATION_MODIFIER", 178, 186]]], ["These four prototypical outcome trajectories and the estimated proportion of people in each category as observed in previous studies are shown in Figure 1.", [["people", "ORGANISM", 77, 83], ["people", "SPECIES", 77, 83], ["previous studies", "TEST", 116, 132]]], ["It should be noted that the percentages of people in each category tends to vary depending on the severity and type of trauma [33,36,37].", [["trauma", "DISEASE", 119, 125], ["people", "ORGANISM", 43, 49], ["people", "SPECIES", 43, 49], ["trauma", "PROBLEM", 119, 125]]], ["For example, Bonanno et al. [30] examined the prototypical outcome trajectories of Hong Kong patients who had recovered from severe acute respiratory syndrome (SARS) and reported a higher percentage of people in the chronic dysfunction category (42%) than in other previous studies.Prototypical Psychological Outcome Trajectories after a Stressful Event ::: BackgroundMost previous studies have used a normative comparison approach that defines health and dysfunction on the basis of established norms for the specified outcome measure to define the outcome trajectories [34,38].", [["acute respiratory syndrome", "DISEASE", 132, 158], ["SARS", "DISEASE", 160, 164], ["chronic dysfunction", "DISEASE", 216, 235], ["patients", "ORGANISM", 93, 101], ["people", "ORGANISM", 202, 208], ["patients", "SPECIES", 93, 101], ["people", "SPECIES", 202, 208], ["severe acute respiratory syndrome", "PROBLEM", 125, 158], ["the chronic dysfunction category", "PROBLEM", 212, 244], ["other previous studies", "TEST", 259, 281], ["dysfunction", "PROBLEM", 456, 467], ["severe", "OBSERVATION_MODIFIER", 125, 131], ["acute", "OBSERVATION_MODIFIER", 132, 137], ["respiratory syndrome", "OBSERVATION", 138, 158], ["higher", "OBSERVATION_MODIFIER", 181, 187], ["percentage", "OBSERVATION_MODIFIER", 188, 198], ["chronic", "OBSERVATION_MODIFIER", 216, 223], ["dysfunction", "OBSERVATION", 224, 235]]], ["Prototypical trajectories defined in this way are represented graphically in Figure 1.", [["Prototypical trajectories", "PROBLEM", 0, 25]]], ["The latent class growth curve model has recently been used to classify people into these outcome trajectories [30] although results similar to those obtained under the normative comparison approach were obtained.The Present Study ::: BackgroundThe prospective longitudinal study reported in this paper was aimed at investigating whether the cognitive style of hope can predict prototypical psychological outcome trajectories after HCRC genetic testing.", [["people", "ORGANISM", 71, 77], ["people", "SPECIES", 71, 77], ["The latent class growth curve model", "PROBLEM", 0, 35], ["The prospective longitudinal study", "TEST", 244, 278], ["HCRC genetic testing", "TEST", 431, 451]]], ["In particular, we hypothesized that high-hope HCRC genetic testing recipients would have a higher tendency to show a resilience outcome trajectory pattern than their low-hope counterparts.", [["recipients", "ORGANISM", 67, 77], ["high", "OBSERVATION_MODIFIER", 36, 40]]], ["First, as the only study to have applied the cognitive style of hope to HCRC genetic testing, the findings could have important implications for the psychosocial care of individuals undergoing HCRC genetic testing.", [["individuals", "ORGANISM", 170, 181], ["HCRC genetic testing", "TEST", 72, 92], ["HCRC genetic testing", "TEST", 193, 213]]], ["Furthermore, to the best of our knowledge, no prior study has yet examined the prevalence of the prototypical outcome trajectories following genetic testing.", [["prior study", "TEST", 46, 57], ["genetic testing", "TEST", 141, 156]]], ["Finally, this is one of the rare studies to have employed the prototypical outcome trajectories to study resilience among an Asian population [27].Participants and Procedures ::: MethodsSeventy-six consecutive individuals offered genetic testing by the Hereditary Gastrointestinal Cancer Registry (the Registry) in Hong Kong between April 2003 and August 2006 participated in this study after giving informed consent.", [["Hereditary Gastrointestinal Cancer", "DISEASE", 253, 287], ["individuals", "ORGANISM", 210, 221], ["Participants", "SPECIES", 147, 159], ["MethodsSeventy", "TREATMENT", 179, 193], ["genetic testing", "TEST", 230, 245], ["Gastrointestinal", "ANATOMY", 264, 280], ["Cancer", "OBSERVATION", 281, 287]]], ["All of the subjects came from families with proven HCRC syndromes, including familial adenomatous polyposis (FAP) and hereditary non-polyposis colorectal cancer (HNPCC).", [["FAP", "ANATOMY", 109, 112], ["hereditary non-polyposis colorectal cancer", "ANATOMY", 118, 160], ["HNPCC", "ANATOMY", 162, 167], ["HCRC syndromes", "DISEASE", 51, 65], ["familial adenomatous polyposis", "DISEASE", 77, 107], ["FAP", "DISEASE", 109, 112], ["hereditary non-polyposis colorectal cancer", "DISEASE", 118, 160], ["HNPCC", "DISEASE", 162, 167], ["HCRC", "CANCER", 51, 55], ["familial adenomatous polyposis", "CANCER", 77, 107], ["FAP", "CANCER", 109, 112], ["hereditary non-polyposis colorectal cancer", "CANCER", 118, 160], ["HNPCC", "CANCER", 162, 167], ["HCRC syndromes", "PROBLEM", 51, 65], ["familial adenomatous polyposis", "PROBLEM", 77, 107], ["FAP)", "PROBLEM", 109, 113], ["hereditary non-polyposis colorectal cancer", "PROBLEM", 118, 160], ["familial", "OBSERVATION_MODIFIER", 77, 85], ["adenomatous polyposis", "OBSERVATION", 86, 107], ["hereditary", "OBSERVATION_MODIFIER", 118, 128], ["non-polyposis", "OBSERVATION_MODIFIER", 129, 142], ["colorectal cancer", "OBSERVATION", 143, 160]]], ["Among the 76 participants, 71 individuals (43 men and 28 women) from nine FAP and 24 HNPCC families completed the study, including 39 mutation carriers (12 FAP and 27 HNPCC).", [["FAP", "DISEASE", 74, 77], ["HNPCC", "DISEASE", 85, 90], ["FAP", "DISEASE", 156, 159], ["HNPCC", "DISEASE", 167, 172], ["individuals", "ORGANISM", 30, 41], ["men", "ORGANISM", 46, 49], ["women", "ORGANISM", 57, 62], ["FAP", "CANCER", 74, 77], ["HNPCC", "CANCER", 85, 90], ["HNPCC", "CANCER", 167, 172], ["participants", "SPECIES", 13, 25], ["men", "SPECIES", 46, 49], ["women", "SPECIES", 57, 62], ["the study", "TEST", 110, 119]]], ["There were 27 (38.0%) subjects (15 men, 12 women) from FAP families and 44 (62.0%) subjects (28 men, 16 women) from HNPCC families.", [["FAP", "DISEASE", 55, 58], ["HNPCC", "DISEASE", 116, 121], ["men", "ORGANISM", 35, 38], ["women", "ORGANISM", 43, 48], ["subjects", "ORGANISM", 83, 91], ["men", "ORGANISM", 96, 99], ["women", "ORGANISM", 104, 109], ["HNPCC", "CANCER", 116, 121], ["men", "SPECIES", 35, 38], ["women", "SPECIES", 43, 48], ["men", "SPECIES", 96, 99], ["women", "SPECIES", 104, 109]]], ["Forty-eight (67.6%) subjects were married , among whom 40 (56.3%) had one or more children.", [["subjects", "ORGANISM", 20, 28], ["children", "ORGANISM", 82, 90], ["children", "SPECIES", 82, 90]]], ["There was no significant difference in personal characteristics between FAP and HNPCC family members.Participants and Procedures ::: MethodsThe participants completed a package of psychological inventories four times during the HCRC genetic testing process: immediately before result disclosure (T1); two weeks after result disclosure (T2); four months after result disclosure (T3); and one year after result disclosure (T4).", [["FAP", "DISEASE", 72, 75], ["HNPCC", "DISEASE", 80, 85], ["FAP", "CANCER", 72, 75], ["Participants", "SPECIES", 101, 113], ["participants", "SPECIES", 144, 156], ["Methods", "TREATMENT", 133, 140], ["psychological inventories", "TREATMENT", 180, 205], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35]]], ["The first assessment (T1) was conducted at the Registry on the day immediately before result disclosure.", [["The first assessment", "TEST", 0, 20]]], ["A research assistant was available to answer participants' questions.", [["participants", "SPECIES", 45, 57]]], ["Later assessments (T2 - T4) were conducted at the subjects' homes.", [["Later assessments", "TEST", 0, 17]]], ["Ethical approval was obtained from the Institutional Review Board of Queen Mary Hospital, Hong Kong.Measures ::: MethodsDispositional Hope - The 12-item Adult Trait Hope Scale was rated on the basis of an 8-point Likert scale (1 = definitely false to 8 = definitely true) used to measure hope according to the model of Snyder et al. [17].", [["Likert scale", "TEST", 213, 225]]], ["A Hope Total score is obtained by aggregating the scores for the 12 items.", [["Total score", "TEST", 7, 18]]], ["The Cronbach's alpha for the total sample at T1 was 0.85.Measures ::: MethodsAnxiety and Depression - The 14-item Chinese version of the Hospital Anxiety and Depression Scale was used to indicate negative emotions [39].", [["Depression", "DISEASE", 89, 99], ["Anxiety and Depression", "DISEASE", 146, 168], ["Cronbach's alpha", "GENE_OR_GENE_PRODUCT", 4, 20], ["The Cronbach's alpha", "TEST", 0, 20], ["the total sample at T1", "TEST", 25, 47], ["MethodsAnxiety", "TREATMENT", 70, 84], ["Depression", "PROBLEM", 89, 99], ["Depression Scale", "TREATMENT", 158, 174]]], ["Two scores - HADS Anxiety and HADS Depression- were derived from the questionnaire.", [["Anxiety", "DISEASE", 18, 25], ["Depression", "DISEASE", 35, 45], ["Two scores", "TEST", 0, 10], ["HADS Anxiety", "PROBLEM", 13, 25], ["HADS Depression", "PROBLEM", 30, 45]]], ["Severity of symptom was rated according to a 4-point Likert scale.", [["Severity of symptom", "PROBLEM", 0, 19]]], ["Higher scores correspond to more symptoms of anxiety and depression, respectively.", [["anxiety", "DISEASE", 45, 52], ["depression", "DISEASE", 57, 67], ["Higher scores", "PROBLEM", 0, 13], ["anxiety", "PROBLEM", 45, 52], ["depression", "PROBLEM", 57, 67]]], ["The 7/8 normative cut-off points for HADS Anxiety and HADS Depression were used to classify participants into low (a score of below or equals to 7) or high (a score of above or equals to 8) anxiety and depression, respectively [39].", [["Anxiety", "DISEASE", 42, 49], ["Depression", "DISEASE", 59, 69], ["anxiety", "DISEASE", 190, 197], ["depression", "DISEASE", 202, 212], ["participants", "SPECIES", 92, 104], ["HADS", "PROBLEM", 37, 41], ["Anxiety", "PROBLEM", 42, 49], ["HADS Depression", "PROBLEM", 54, 69], ["anxiety", "PROBLEM", 190, 197], ["depression", "PROBLEM", 202, 212]]], ["For the present sample, the Cronbach's \u221d values for the HADS Anxiety ranged from 0.82 to 0.89 across the four time points (T1 - T4) and those for the HADS Depression from 0.82 to 0.72.Data Analysis ::: MethodsDescriptive statistics were provided first and potential syndrome-group (FAP versus HNPCC) and gender differences were examined.", [["Anxiety", "DISEASE", 61, 68], ["Depression", "DISEASE", 155, 165], ["FAP", "DISEASE", 282, 285], ["HNPCC", "DISEASE", 293, 298], ["the Cronbach's \u221d values", "TEST", 24, 47], ["the HADS", "TEST", 52, 60], ["Anxiety", "TEST", 61, 68], ["the HADS Depression", "PROBLEM", 146, 165], ["potential syndrome", "PROBLEM", 256, 274], ["group (FAP versus HNPCC", "TREATMENT", 275, 298]]], ["Finally, logistic regression analyses were used to investigate whether dispositional hope at T1 could predict psychological outcome trajectories after controlling for anxiety or depression level at T1.", [["anxiety", "DISEASE", 167, 174], ["depression", "DISEASE", 178, 188], ["logistic regression analyses", "TEST", 9, 37], ["anxiety", "PROBLEM", 167, 174], ["depression level at T1", "PROBLEM", 178, 200]]], ["Given that previous studies show that mutation status (carrier versus non-carrier) is an important factor affecting adjustment [7,8], the interaction of hope and mutation status and the interaction of T1 depression or anxiety and mutation status were also entered into the regression equations.Strategies to Establish the Psychological Outcome Trajectories ::: MethodsWe used the normative comparison approach to create longitudinal outcome trajectories for psychological functioning using the HADS Anxiety or HADS Depression score at two weeks (T2), four months (T3), and 12 months (T4) post-HCRC genetic testing as separate outcome indicators.", [["depression", "DISEASE", 204, 214], ["anxiety", "DISEASE", 218, 225], ["Anxiety", "DISEASE", 499, 506], ["Depression", "DISEASE", 515, 525], ["previous studies", "TEST", 11, 27], ["mutation status", "PROBLEM", 38, 53], ["mutation status", "PROBLEM", 162, 177], ["T1 depression", "PROBLEM", 201, 214], ["anxiety", "PROBLEM", 218, 225], ["mutation status", "PROBLEM", 230, 245], ["the HADS Anxiety", "PROBLEM", 490, 506], ["HADS Depression score", "PROBLEM", 510, 531], ["post-HCRC genetic testing", "TEST", 588, 613]]], ["The following steps were employed to create the outcome trajectories.Strategies to Establish the Psychological Outcome Trajectories ::: Methods1.", [["Methods1", "TREATMENT", 136, 144]]], ["For example, if a subject had a HADS Anxiety score of 9 at T2, then he or she was classified as a HADS Anxiety case at T2.", [["Anxiety", "DISEASE", 37, 44], ["Anxiety", "DISEASE", 103, 110], ["a HADS Anxiety score", "TEST", 30, 50], ["a HADS Anxiety case at T2", "PROBLEM", 96, 121]]], ["If the same subject had a HADS Anxiety score of 3 at T3, then he/she was considered to be a HADS Anxiety non-case at T3.Strategies to Establish the Psychological Outcome Trajectories ::: Methods2.", [["Anxiety", "DISEASE", 31, 38], ["HADS", "DISEASE", 92, 96], ["Anxiety", "DISEASE", 97, 104], ["a HADS Anxiety score", "PROBLEM", 24, 44], ["a HADS Anxiety non-case at T3", "PROBLEM", 90, 119], ["Methods2", "TREATMENT", 187, 195]]], ["We mapped all possible combinations of cases and non-cases across the three post-genetic testing result disclosure time points (i.e. two weeks, four months and 12 months post-result disclosure).Strategies to Establish the Psychological Outcome Trajectories ::: Methods3.", [["Methods3", "TREATMENT", 261, 269]]], ["We categorized participants into one of the four prototypical outcome trajectories [33] using the following operational definitions: Resilience was assigned when the subject was a non-case at all three time points; Chronic Dysfunction was assigned when the subject was a case at all three time points; Recovery was assigned when the subject was a case at T2 but became a non-case at both T3 and T4, or when he or she was a case at both T2 and T3 but became a non-case at T4; Delayed Dysfunction was assigned when the subject was a non-case at T2 but became a case at both T3 and T4 or when he or she was a non-case at both T2 and T3 but became a case at T4.", [["participants", "SPECIES", 15, 27], ["Chronic Dysfunction", "PROBLEM", 215, 234], ["a case at T2", "PROBLEM", 345, 357], ["a non-case at both T3 and T4", "PROBLEM", 369, 397], ["a non-case at T4", "PROBLEM", 457, 473], ["Delayed Dysfunction", "PROBLEM", 475, 494], ["a non-case at T2", "PROBLEM", 529, 545], ["a non-case at both T2 and T3", "PROBLEM", 604, 632], ["Chronic", "OBSERVATION_MODIFIER", 215, 222], ["Dysfunction", "OBSERVATION", 223, 234], ["T4", "ANATOMY", 395, 397]]], ["Table 1 summarizes the criteria used in defining the four prototypical outcome trajectories in this study.Intraclass correlation coefficient (ICC) ::: ResultsICC(1) values of predictors at T1 and psychological indicators at T2 were calculated to examine the independence of the data.", [["this study", "TEST", 95, 105], ["predictors", "TEST", 175, 185]]], ["All ICC(1) values were < 0.25 (range: 0 to 0.24) and met the criteria for independent measurement[40].Psychological characteristics ::: ResultsDue to the unequal group sizes, the powers of the analyses undertaken to detect group differences in syndrome type (FAP versus HNPCC) and mutation status (carrier versus non-carrier) were low to modest, ranging from 0.10 to 0.51.", [["FAP", "DISEASE", 259, 262], ["HNPCC", "DISEASE", 270, 275], ["values", "TEST", 11, 17], ["the analyses", "TEST", 189, 201], ["group differences in syndrome type (FAP versus HNPCC", "PROBLEM", 223, 275], ["mutation status", "PROBLEM", 281, 296], ["sizes", "OBSERVATION_MODIFIER", 168, 173]]], ["HNPCC subjects had a higher level of dispositional hope at T1 than FAP subjects (t(67) = -2.06, p = 0.04).", [["HNPCC", "DISEASE", 0, 5], ["FAP", "DISEASE", 67, 70], ["HNPCC", "CANCER", 0, 5], ["HNPCC subjects", "PROBLEM", 0, 14], ["FAP subjects", "TEST", 67, 79]]], ["No difference in the anxiety or depression level between the FAP and HNPCC subjects was observed at any time point.", [["anxiety", "DISEASE", 21, 28], ["depression", "DISEASE", 32, 42], ["FAP", "DISEASE", 61, 64], ["HNPCC", "DISEASE", 69, 74], ["HNPCC", "CANCER", 69, 74], ["the anxiety", "PROBLEM", 17, 28], ["depression level", "PROBLEM", 32, 48], ["HNPCC subjects", "PROBLEM", 69, 83], ["difference", "OBSERVATION_MODIFIER", 3, 13]]], ["Independent sample t-tests were also conducted to examine gender differences.", [["Independent sample t-tests", "TEST", 0, 26]]], ["No significant difference for any variable was obtained at any time points.", [["significant", "OBSERVATION_MODIFIER", 3, 14], ["difference", "OBSERVATION", 15, 25]]], ["However, subjects with a positive genetic test result had higher HADS Anxiety scores at both T2 and T4.", [["Anxiety", "DISEASE", 70, 77], ["a positive genetic test result", "PROBLEM", 23, 53], ["higher HADS Anxiety scores at both T2 and T4", "PROBLEM", 58, 102], ["T4", "ANATOMY", 100, 102]]], ["We aggregated HNPCC and FAP subjects for subsequent analyses.Correlation of Variables at Time 1 ::: ResultsThe correlation coefficients of variables at T1 are depicted in Table 3 to show the cross-sectional relationship of the variables examined in this study.", [["HNPCC", "DISEASE", 14, 19], ["FAP", "DISEASE", 24, 27], ["HNPCC", "CANCER", 14, 19], ["subsequent analyses", "TEST", 41, 60], ["this study", "TEST", 249, 259]]], ["Hope was related to depression, but not to anxiety.", [["depression", "DISEASE", 20, 30], ["anxiety", "DISEASE", 43, 50], ["depression", "PROBLEM", 20, 30], ["anxiety", "PROBLEM", 43, 50]]], ["Age had no relationship with the three psychological variables investigated in this study.Psychological Outcome Trajectories ::: ResultsThe subjects were classified into different psychological outcome trajectories using the method described previously.", [["this study", "TEST", 79, 89]]], ["The results for HADS Anxiety and HADS Depression are first presented separately.Psychological Outcome Trajectories ::: ResultsHADS Anxiety as an Outcome Indicator - The trajectories for anxiety are illustrated in Figure 2.", [["Anxiety", "DISEASE", 21, 28], ["Depression", "DISEASE", 38, 48], ["Anxiety", "DISEASE", 131, 138], ["anxiety", "DISEASE", 186, 193], ["HADS Anxiety", "PROBLEM", 16, 28], ["HADS Depression", "PROBLEM", 33, 48], ["Anxiety", "PROBLEM", 131, 138], ["anxiety", "PROBLEM", 186, 193]]], ["The most prevalent was resilience, or stable low anxiety across time.", [["low anxiety", "DISEASE", 45, 56], ["stable low anxiety", "PROBLEM", 38, 56], ["most prevalent", "OBSERVATION_MODIFIER", 4, 18], ["stable", "OBSERVATION_MODIFIER", 38, 44]]], ["Approximately two-thirds of our subjects exhibited evidence of this trajectory.", [["subjects", "ORGANISM", 32, 40], ["this trajectory", "PROBLEM", 63, 78]]], ["Delayed reaction, which was characterized by minimal anxiety at T1 and T2 and then a steady increase in the anxiety levels to above the threshold at T4, captured 15.9% of our subjects.", [["Delayed reaction", "DISEASE", 0, 16], ["anxiety", "DISEASE", 53, 60], ["anxiety", "DISEASE", 108, 115], ["Delayed reaction", "PROBLEM", 0, 16], ["minimal anxiety at T1 and T2", "PROBLEM", 45, 73], ["a steady increase in the anxiety levels", "PROBLEM", 83, 122], ["reaction", "OBSERVATION", 8, 16], ["minimal", "OBSERVATION_MODIFIER", 45, 52], ["anxiety", "OBSERVATION", 53, 60], ["steady", "OBSERVATION_MODIFIER", 85, 91], ["increase", "OBSERVATION_MODIFIER", 92, 100]]], ["The percentages of subjects manifesting a chronic dysfunction trajectory (8.7%) or a recovery trajectory (4.3%) were lower.", [["chronic dysfunction", "DISEASE", 42, 61], ["a chronic dysfunction trajectory", "PROBLEM", 40, 72], ["a recovery trajectory", "TEST", 83, 104], ["percentages", "OBSERVATION_MODIFIER", 4, 15], ["chronic", "OBSERVATION_MODIFIER", 42, 49], ["dysfunction", "OBSERVATION", 50, 61]]], ["A small portion of the sample (4.3%) displayed evidence of a variable pattern that could not be categorized into any of the four prototypical patterns.Psychological Outcome Trajectories ::: ResultsHADS Depression as an Outcome Indicator - The outcome trajectories for depression are illustrated in Figure 3.", [["Depression", "DISEASE", 202, 212], ["depression", "DISEASE", 268, 278], ["the sample", "TEST", 19, 29], ["a variable pattern", "PROBLEM", 59, 77], ["Depression", "PROBLEM", 202, 212], ["depression", "PROBLEM", 268, 278], ["small", "OBSERVATION_MODIFIER", 2, 7], ["portion", "OBSERVATION_MODIFIER", 8, 15], ["variable", "OBSERVATION_MODIFIER", 61, 69]]], ["Again, resilience (76.8%) was the most prevalent followed by delayed reaction (13.0%).", [["delayed reaction", "PROBLEM", 61, 77]]], ["Interestingly, none of the subjects exhibited a recovery trajectory when HADS Depression was used as the outcome indicator.", [["Depression", "DISEASE", 78, 88], ["HADS Depression", "PROBLEM", 73, 88]]], ["A relatively small percentage of subjects were classified as having chronic dysfunction (7.2%).", [["chronic dysfunction", "DISEASE", 68, 87], ["subjects", "ORGANISM", 33, 41], ["chronic dysfunction", "PROBLEM", 68, 87], ["relatively", "OBSERVATION_MODIFIER", 2, 12], ["small", "OBSERVATION_MODIFIER", 13, 18], ["percentage", "OBSERVATION_MODIFIER", 19, 29], ["chronic", "OBSERVATION_MODIFIER", 68, 75], ["dysfunction", "OBSERVATION", 76, 87]]], ["A small portion of the sample (2.9%) could not be classified in any of the prototypical trajectories.Hope to Predict Resilience after HCRC Genetic Testing ::: ResultsTwo logistic regressions were then conducted to test whether hope is a reliable predictor of resilience among recipients of HCRC genetic testing.", [["the sample", "TEST", 19, 29], ["HCRC genetic testing", "TEST", 290, 310], ["small", "OBSERVATION_MODIFIER", 2, 7], ["portion", "OBSERVATION_MODIFIER", 8, 15]]], ["Because very few participants exhibited a recovery trajectory (n = 3 for anxiety and n = 0 for depression), this outcome category was excluded from the regression analyses.", [["anxiety", "DISEASE", 73, 80], ["depression", "DISEASE", 95, 105], ["participants", "ORGANISM", 17, 29], ["participants", "SPECIES", 17, 29], ["anxiety", "PROBLEM", 73, 80], ["depression", "PROBLEM", 95, 105], ["the regression analyses", "TEST", 148, 171]]], ["The delayed reaction and chronic dysfunction trajectories were obtained into a single non-resilience outcome trajectory because of the small number of subjects in each of these two categories.", [["The delayed reaction", "PROBLEM", 0, 20], ["chronic dysfunction trajectories", "PROBLEM", 25, 57], ["delayed", "OBSERVATION_MODIFIER", 4, 11], ["reaction", "OBSERVATION", 12, 20], ["chronic", "OBSERVATION_MODIFIER", 25, 32], ["dysfunction", "OBSERVATION", 33, 44], ["small", "OBSERVATION_MODIFIER", 135, 140], ["number", "OBSERVATION_MODIFIER", 141, 147]]], ["The dependent variable was therefore a dichotomous outcome trajectory variable: resilience (coded as \"1\") and non-resilience (coded as \"2\").", [["dependent", "OBSERVATION_MODIFIER", 4, 13], ["variable", "OBSERVATION_MODIFIER", 14, 22]]], ["The first logistic regression equation adopted HADs Anxiety as the criterion variable for categorization of the outcome trajectories, whereas the second used HADS Depression.Hope to Predict Resilience after HCRC Genetic Testing ::: ResultsIn both regression equations, the subject's gender (male or female), syndrome group (FAP versus HNPCC), and genetic test result (positive versus negative) were entered in the first step.", [["Depression", "DISEASE", 163, 173], ["FAP", "DISEASE", 324, 327], ["HNPCC", "DISEASE", 335, 340], ["The first logistic regression equation", "PROBLEM", 0, 38], ["HADs Anxiety", "PROBLEM", 47, 59], ["Depression", "PROBLEM", 163, 173], ["syndrome group (FAP versus HNPCC", "PROBLEM", 308, 340], ["genetic test result", "TEST", 347, 366]]], ["In step 2, either HADS Anxiety or HADS Depression and the Hope Total score at T1 were entered together with the two interaction terms: Hope x Genetic Testing Results and HADS Anxiety or HADS Depression x Genetic Testing Results.", [["Anxiety", "DISEASE", 23, 30], ["Depression", "DISEASE", 39, 49], ["Anxiety", "DISEASE", 175, 182], ["Depression", "DISEASE", 191, 201], ["Anxiety", "PROBLEM", 23, 30], ["HADS Depression", "PROBLEM", 34, 49], ["Genetic Testing", "TEST", 142, 157], ["HADS Anxiety", "PROBLEM", 170, 182], ["HADS Depression", "PROBLEM", 186, 201], ["Genetic Testing", "TEST", 204, 219]]], ["The results of these analyses are presented in Table 4.", [["these analyses", "TEST", 15, 29]]], ["For both logistic regressions, recipients' dispositional hope at pre-disclosure baseline tended to be a significant individual predictor of resilience (Anxiety: \u03b2 = -0.11, p = 0.05; Depression: \u03b2 = -0.25, p < 0.05).", [["Anxiety", "DISEASE", 152, 159], ["Depression", "DISEASE", 182, 192], ["recipients", "ORGANISM", 31, 41], ["Anxiety", "TEST", 152, 159], ["Depression", "PROBLEM", 182, 192]]], ["Hence, dispositional hope may predict the resilience of our HCRC genetic testing recipients after controlling for demographic and medical information as well as for mood status prior to test result disclosure.DiscussionIn this study, we used a longitudinal design to assess HCRC genetic testing recipients prospectively on four occasions over a one year period.", [["HCRC", "CANCER", 60, 64], ["recipients", "ORGANISM", 81, 91], ["recipients", "ORGANISM", 295, 305], ["test result disclosure", "TEST", 186, 208], ["this study", "TEST", 222, 232]]], ["Our results advance our understanding of the psychological consequences of HCRC genetic testing in several ways.", [["HCRC", "CANCER", 75, 79], ["HCRC genetic testing", "TEST", 75, 95]]], ["First, the longitudinal design we employed is relatively uncommon among cancer genetic studies and, to the best of our knowledge, the present study is the first to use a prospective design to investigate psychological outcomes of cancer genetic testing among an Asian population.", [["cancer", "ANATOMY", 72, 78], ["cancer", "ANATOMY", 230, 236], ["cancer", "DISEASE", 72, 78], ["cancer", "DISEASE", 230, 236], ["cancer", "CANCER", 72, 78], ["cancer", "CANCER", 230, 236], ["cancer", "TREATMENT", 230, 236], ["genetic testing", "TEST", 237, 252]]], ["Second, this is the first study to examine the prevalence of different longitudinal outcome trajectories among recipients of HCRC genetic testing.", [["the first study", "TEST", 16, 31], ["HCRC genetic testing", "TEST", 125, 145]]], ["None of the previous studies on HCRC genetic testing has studied outcome trajectories.", [["HCRC", "CANCER", 32, 36], ["the previous studies", "TEST", 8, 28], ["HCRC genetic testing", "TEST", 32, 52]]], ["Our study provides timely data enabling comparison of the experience of HCRC genetic testing recipients with that of subjects affected by other stressful events.", [["HCRC", "CANCER", 72, 76], ["recipients", "ORGANISM", 93, 103], ["Our study", "TEST", 0, 9], ["HCRC genetic testing recipients", "TREATMENT", 72, 103]]], ["This approach is unique among both hope and HCRC genetic testing studies.DiscussionThe prevalence of outcome trajectories observed in the current study showed that a majority of the HCRC genetic testing recipients were psychologically resilient (66.7% for HADS Anxiety and 76.8% for HADS Depression); that is, these individuals exhibited little or no depression and anxiety from pre-disclosure baseline until one year after disclosure.", [["Anxiety", "DISEASE", 261, 268], ["Depression", "DISEASE", 288, 298], ["depression", "DISEASE", 351, 361], ["anxiety", "DISEASE", 366, 373], ["HCRC", "CANCER", 182, 186], ["recipients", "ORGANISM", 203, 213], ["HCRC genetic testing studies", "TEST", 44, 72], ["outcome trajectories", "PROBLEM", 101, 121], ["the current study", "TEST", 134, 151], ["HADS Anxiety", "PROBLEM", 256, 268], ["HADS Depression)", "PROBLEM", 283, 299], ["depression", "PROBLEM", 351, 361], ["anxiety", "PROBLEM", 366, 373]]], ["Our results are consistent with those of other studies showing that predictive genetic testing has no severe psychological impact on its recipients [7,8].", [["recipients", "ORGANISM", 137, 147], ["other studies", "TEST", 41, 54], ["predictive genetic testing", "TEST", 68, 94], ["severe psychological impact", "PROBLEM", 102, 129], ["consistent with", "UNCERTAINTY", 16, 31], ["no", "UNCERTAINTY", 99, 101], ["severe", "OBSERVATION_MODIFIER", 102, 108]]], ["Only a minority of our sample exhibited chronically elevated symptoms (8.7% for HADS Anxiety and 7.2% for HADS Depression).", [["chronically elevated symptoms", "DISEASE", 40, 69], ["Anxiety", "DISEASE", 85, 92], ["Depression", "DISEASE", 111, 121], ["chronically elevated symptoms", "PROBLEM", 40, 69], ["HADS Anxiety", "PROBLEM", 80, 92], ["HADS Depression", "PROBLEM", 106, 121], ["chronically", "OBSERVATION_MODIFIER", 40, 51], ["elevated", "OBSERVATION_MODIFIER", 52, 60]]], ["A prior study reported that the percentage of BRCA1/2 or HNPCC genetic susceptibility testing recipients exhibiting an elevated level of anxiety dropped from 29.3% at two weeks to 14.1% at six months after disclosure of the results [6].", [["HNPCC", "DISEASE", 57, 62], ["anxiety", "DISEASE", 137, 144], ["BRCA1", "GENE_OR_GENE_PRODUCT", 46, 51], ["2", "GENE_OR_GENE_PRODUCT", 52, 53], ["recipients", "ORGANISM", 94, 104], ["BRCA1", "DNA", 46, 51], ["A prior study", "TEST", 0, 13], ["BRCA1/2", "PROBLEM", 46, 53], ["HNPCC genetic susceptibility testing recipients", "PROBLEM", 57, 104], ["an elevated level of anxiety", "PROBLEM", 116, 144], ["BRCA1", "OBSERVATION", 46, 51], ["elevated", "OBSERVATION_MODIFIER", 119, 127]]], ["Our results suggest that the percentage of recipients showing chronic anxiety and depression levels is likely to drop even further to around 7%-9% at 12 months.", [["anxiety", "DISEASE", 70, 77], ["depression", "DISEASE", 82, 92], ["recipients", "ORGANISM", 43, 53], ["chronic anxiety", "PROBLEM", 62, 77], ["depression levels", "PROBLEM", 82, 99], ["chronic", "OBSERVATION_MODIFIER", 62, 69], ["anxiety", "OBSERVATION", 70, 77]]], ["This result is consistent with previous observations in Western countries, where typically only 5% to 10% of people exposed to loss or potential trauma tended to experience chronic psychological dysfunction [41], while the majority of individuals observed in these studies tend to exhibit psychological resilience [33].", [["trauma", "DISEASE", 145, 151], ["chronic psychological dysfunction", "DISEASE", 173, 206], ["people", "ORGANISM", 109, 115], ["individuals", "ORGANISM", 235, 246], ["people", "SPECIES", 109, 115], ["potential trauma", "PROBLEM", 135, 151], ["chronic psychological dysfunction", "PROBLEM", 173, 206], ["these studies", "TEST", 259, 272], ["consistent with", "UNCERTAINTY", 15, 30]]], ["A recent study on outcome trajectories among Hong Kong patients who had recovered from SARS showed that 35% of the sample displayed resilience, and 42% exhibited chronic dysfunction.", [["SARS", "DISEASE", 87, 91], ["chronic dysfunction", "DISEASE", 162, 181], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["A recent study", "TEST", 0, 14], ["SARS", "PROBLEM", 87, 91], ["chronic dysfunction", "PROBLEM", 162, 181], ["chronic", "OBSERVATION_MODIFIER", 162, 169], ["dysfunction", "OBSERVATION", 170, 181]]], ["In comparison with these SARS survivors, our sample of HCRC genetic testing recipients showed a higher prevalence of resilience and a lower prevalence of chronic dysfunction.", [["SARS", "DISEASE", 25, 29], ["chronic dysfunction", "DISEASE", 154, 173], ["HCRC", "CANCER", 55, 59], ["recipients", "ORGANISM", 76, 86], ["our sample", "TEST", 41, 51], ["HCRC genetic testing", "TEST", 55, 75], ["chronic dysfunction", "PROBLEM", 154, 173], ["lower prevalence", "OBSERVATION_MODIFIER", 134, 150], ["chronic", "OBSERVATION_MODIFIER", 154, 161], ["dysfunction", "OBSERVATION", 162, 173]]], ["Previous studies have suggested that the severity of the stressful event is an important factor affecting the prevalence of outcome trajectories: individuals exposed to extremely stressful events exhibited a higher prevalence of psychopathology and a lower prevalence of resilience in comparison with those who were exposed to low-stress levels [31].", [["psychopathology", "DISEASE", 229, 244], ["Previous studies", "TEST", 0, 16], ["the stressful event", "PROBLEM", 53, 72], ["extremely stressful events", "PROBLEM", 169, 195], ["psychopathology", "PROBLEM", 229, 244]]], ["The high prevalence of resilience trajectories and the low prevalence of chronic dysfunction trajectories in our study suggest that HCRC genetic testing induces a milder level of stress in its subjects.DiscussionAnother finding is that 13%-15% of our subjects exhibited a delayed reaction trajectory, i.e. they reported low levels of anxiety and depression initially but their anxiety and distress levels increased beyond the threshold at T3 or T4.", [["chronic dysfunction", "DISEASE", 73, 92], ["anxiety", "DISEASE", 334, 341], ["depression", "DISEASE", 346, 356], ["anxiety", "DISEASE", 377, 384], ["subjects", "ORGANISM", 251, 259], ["resilience trajectories", "PROBLEM", 23, 46], ["chronic dysfunction trajectories", "PROBLEM", 73, 105], ["our study", "TEST", 109, 118], ["HCRC genetic testing", "TEST", 132, 152], ["stress in its subjects", "PROBLEM", 179, 201], ["a delayed reaction trajectory", "PROBLEM", 270, 299], ["anxiety", "PROBLEM", 334, 341], ["depression", "PROBLEM", 346, 356], ["their anxiety", "PROBLEM", 371, 384], ["distress levels", "PROBLEM", 389, 404], ["high prevalence", "OBSERVATION_MODIFIER", 4, 19], ["low prevalence", "OBSERVATION_MODIFIER", 55, 69], ["chronic", "OBSERVATION_MODIFIER", 73, 80], ["dysfunction", "OBSERVATION", 81, 92]]], ["The prevalence of delayed reaction trajectories in this investigation is higher than that observed in previous studies conducted in Western countries (5-10%) but is similar to the 13% reported in a recent study among Hong Kong SARS survivors [30].", [["SARS", "DISEASE", 227, 231], ["Hong Kong SARS", "SPECIES", 217, 231], ["delayed reaction trajectories", "PROBLEM", 18, 47], ["this investigation", "TEST", 51, 69], ["previous studies", "TEST", 102, 118], ["a recent study", "TEST", 196, 210], ["delayed", "OBSERVATION_MODIFIER", 18, 25], ["reaction trajectories", "OBSERVATION", 26, 47], ["higher", "OBSERVATION_MODIFIER", 73, 79]]], ["It is possible that the perception of less support from the Registry on the anniversary of genetic testing may have caused the elevated anxiety level at T4.", [["anxiety", "DISEASE", 136, 143], ["genetic testing", "TEST", 91, 106], ["the elevated anxiety level at T4", "PROBLEM", 123, 155], ["elevated", "OBSERVATION_MODIFIER", 127, 135], ["anxiety", "OBSERVATION", 136, 143]]], ["Similar elevated psychological distress towards discharge after hospitalization has been reported following other clinical procedures such as bone marrow transplantation [42].", [["bone marrow", "ANATOMY", 142, 153], ["elevated psychological distress", "DISEASE", 8, 39], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 142, 153], ["Similar elevated psychological distress", "PROBLEM", 0, 39], ["clinical procedures", "TREATMENT", 114, 133], ["bone marrow transplantation", "TREATMENT", 142, 169], ["elevated", "OBSERVATION_MODIFIER", 8, 16], ["psychological distress", "OBSERVATION", 17, 39]]], ["Another possibility is that the HCRC genetic testing results may have a delayed effect on the recipients.", [["HCRC", "CANCER", 32, 36], ["recipients", "ORGANISM", 94, 104], ["the HCRC genetic testing", "TEST", 28, 52]]], ["For recipients with positive results, the long-term negative consequences of being mutation carriers, such as the inconvenience of regular lifelong medical surveillance and the potential for social discrimination, may only become apparent a few months after result disclosure.", [["mutation carriers", "PROBLEM", 83, 100]]], ["For those with negative testing results, adverse psychological reactions such as feelings of guilt for being a non-carrier in the family and communication issues among family members relating to the testing results may only surface some time after result disclosure [13].", [["adverse psychological reactions", "PROBLEM", 41, 72], ["the testing", "TEST", 195, 206]]], ["However, the supposition that these factors may affect the prevalence of delayed reaction trajectories is tentative and should be investigated in independent studies.DiscussionAnother objective of the present study was to examine the role of hope [43,44] in affecting the psychological outcome trajectories of HCRC genetic testing recipients.", [["HCRC", "CANCER", 310, 314], ["recipients", "ORGANISM", 331, 341], ["delayed reaction trajectories", "PROBLEM", 73, 102], ["the present study", "TEST", 197, 214]]], ["Logistic regression analyses showed that even when the depression and anxiety levels of the subjects at T1 were statistically controlled, hope was still predictive of their resilience trajectories.", [["depression", "DISEASE", 55, 65], ["anxiety", "DISEASE", 70, 77], ["Logistic regression analyses", "TEST", 0, 28], ["the depression", "PROBLEM", 51, 65], ["anxiety levels of the subjects at T1", "PROBLEM", 70, 106]]], ["We believe that high-hope individuals, when confronted with an adverse event such as HCRC genetic testing, are better able to reprioritize their goals in life, better able to generate alternative ideas about how to achieve these goals and have higher levels of motivation to actualize alternative pathways to them[43].", [["an adverse event", "PROBLEM", 60, 76], ["HCRC genetic testing", "TEST", 85, 105], ["high", "OBSERVATION_MODIFIER", 16, 20]]], ["These attributes should be particularly relevant to the adjustment of predictive genetic testing results.DiscussionThe study has several limitations which should be mentioned.", [["predictive genetic testing", "TEST", 70, 96], ["The study", "TEST", 115, 124]]], ["Because our sample size was relatively small, our findings can be generalized only with caution.", [["our sample size", "TEST", 8, 23], ["size", "OBSERVATION_MODIFIER", 19, 23], ["relatively", "OBSERVATION_MODIFIER", 28, 38], ["small", "OBSERVATION_MODIFIER", 39, 44]]], ["More importantly, because we had to combine the delayed reaction and chronic dysfunction groups into a single non-resilience group in the logistic regression analysis, we were prevented from investigating the predictive power of disposition hope for each trajectory path.", [["chronic dysfunction", "DISEASE", 69, 88], ["the delayed reaction", "PROBLEM", 44, 64], ["chronic dysfunction groups", "PROBLEM", 69, 95], ["chronic", "OBSERVATION_MODIFIER", 69, 76], ["dysfunction", "OBSERVATION", 77, 88]]], ["In addition, the unequal group sizes of syndrome type and mutation status also reduced the power of our analyses.", [["syndrome type and mutation status", "PROBLEM", 40, 73], ["our analyses", "TEST", 100, 112], ["unequal", "OBSERVATION_MODIFIER", 17, 24], ["group sizes", "OBSERVATION_MODIFIER", 25, 36]]], ["Furthermore, other personality measures (e.g. neuroticism) and confounding variables not included in the regression analysis may have influenced the results.", [["confounding variables", "PROBLEM", 63, 84], ["the regression analysis", "TEST", 101, 124]]], ["For example, we did not measure life events, and it is possible that the participants' reports on their depression and anxiety levels one year after genetic testing have been affected by other factors in their lives.", [["depression", "DISEASE", 104, 114], ["anxiety", "DISEASE", 119, 126], ["participants", "SPECIES", 73, 85], ["their depression", "PROBLEM", 98, 114], ["anxiety levels", "PROBLEM", 119, 133], ["genetic testing", "TEST", 149, 164]]], ["Independent studies with a larger sample size and a more even distribution of group sizes could be carried out in future to examine whether our present findings can be replicated.ConclusionsIt is possible that high-hope individuals adjust more readily to the results of HCRC genetic testing than their low-hope counterparts.", [["HCRC", "GENE_OR_GENE_PRODUCT", 270, 274], ["Independent studies", "TEST", 0, 19], ["HCRC genetic testing", "TEST", 270, 290], ["size", "OBSERVATION_MODIFIER", 41, 45]]], ["In addition to educating subjects about colorectal cancer and genetic testing, hope-based training can be incorporated into genetic counselling programs for individuals undergoing HCRC genetic testing.", [["colorectal cancer", "ANATOMY", 40, 57], ["colorectal cancer", "DISEASE", 40, 57], ["colorectal cancer", "CANCER", 40, 57], ["colorectal cancer", "PROBLEM", 40, 57], ["genetic testing", "TEST", 62, 77], ["HCRC genetic testing", "TEST", 180, 200], ["colorectal", "ANATOMY", 40, 50], ["cancer", "OBSERVATION", 51, 57]]], ["Systematic outcome studies should be conducted to examine the effectiveness of such hope-based intervention programs which should ideally be provided during the waiting period for genetic testing results.Competing interestsThe authors declare that they have no competing interests.Authors' contributionsSH conceptualized and designed the study.", [["Systematic outcome studies", "TEST", 0, 26], ["such hope-based intervention programs", "TREATMENT", 79, 116], ["genetic testing", "TEST", 180, 195], ["the study", "TEST", 334, 343]]], ["He carried out data analysis; interpretation of the findings as well as wrote the report of this study.", [["data analysis", "TEST", 15, 28], ["this study", "TEST", 92, 102]]], ["JH provided medical advices on the study design and the interpretation of data in this study.", [["the study", "TEST", 31, 40], ["this study", "TEST", 82, 92]]], ["She also supervised subject recruitment in this study.", [["this study", "TEST", 43, 53]]], ["Both AC and EC provided assistance in subject recruitment, data collection and data analysis.", [["EC", "ANATOMY", 12, 14], ["EC", "CELL", 12, 14], ["EC", "CELL_TYPE", 12, 14], ["data collection", "TEST", 59, 74], ["data analysis", "TEST", 79, 92]]], ["All authors read and approved the final manuscript.Pre-publication historyThe pre-publication history for this paper can be accessed here:Pre-publication historyhttp://www.biomedcentral.com/1471-2407/10/279/prepub", [["Pre-publication", "DISEASE", 51, 66], ["pre-publication", "DISEASE", 78, 93], ["Pre-publication", "DISEASE", 138, 153]]]], "9ad2ee4118099bea41cddd13867ad5b134f2f0c4": [["We would like to describe a case of clozapine intoxication as a result of COVID-19 infection.", [["clozapine", "CHEMICAL", 36, 45], ["COVID-19", "CHEMICAL", 74, 82], ["infection", "DISEASE", 83, 92], ["clozapine", "CHEMICAL", 36, 45], ["clozapine", "SIMPLE_CHEMICAL", 36, 45], ["clozapine intoxication", "PROBLEM", 36, 58], ["COVID-19 infection", "PROBLEM", 74, 92], ["infection", "OBSERVATION", 83, 92]]]], "PMC7354372": [["IntroductionDepartment of Health of Taiwan (Department of Health was renamed as the Ministry of Health and Welfare after 2013) promoted the hospital accreditation system in 1978.1 After 40 years of development, the hospital's medical quality, manpower training, hospital management, teaching, and research have made a great progress.", [["manpower training", "TREATMENT", 243, 260], ["hospital management", "TREATMENT", 262, 281]]], ["In 2003, the hospital accreditation reform was carried out and began to focus on patient-centered care and patient safety environment, which had a great impact on medical system of Taiwan.", [["patient", "ORGANISM", 81, 88], ["patient", "ORGANISM", 107, 114], ["patient", "SPECIES", 81, 88], ["patient", "SPECIES", 107, 114]]], ["The contents of hospital accreditation include all medical specialties, hospital management, nursing, pharmacy, radiology, medical rehabilitation, and medical technology, etc. Before dental medicine included in the hospital accreditation, there were only 3 recognized dental specialties (oral and maxillofacial surgery, oral pathology, and orthodontics) to participate in hospital accreditation.", [["oral", "ANATOMY", 288, 292], ["maxillofacial", "ANATOMY", 297, 310], ["oral", "ANATOMY", 320, 324], ["oral", "ORGANISM_SUBDIVISION", 288, 292], ["maxillofacial", "ORGANISM_SUBDIVISION", 297, 310], ["oral", "ORGANISM_SUBDIVISION", 320, 324], ["medical rehabilitation", "TREATMENT", 123, 145], ["oral and maxillofacial surgery", "TREATMENT", 288, 318], ["maxillofacial", "ANATOMY", 297, 310]]], ["Other dental specialties and dental care were excluded from hospital accreditation.2", [["dental care", "TREATMENT", 29, 40]]]], "84171fd20aa8f4e3cd5c185b5187fbc5b8fb149f": [["1 Cardiovascular disease as a risk factor of disease progression in COVID-19: The corrected effect size and forest plot Dear Editor, While the world is in lockdown for months since December of 2019 due to novel coronavirus disease pandemic, a lot of research is in progress to find out various risk factors associated with COVID-19 progression and related mortalities.", [["Cardiovascular", "ANATOMY", 2, 16], ["Cardiovascular disease", "DISEASE", 2, 24], ["coronavirus disease pandemic", "DISEASE", 211, 239], ["coronavirus", "ORGANISM", 211, 222], ["1 Cardiovascular disease", "PROBLEM", 0, 24], ["disease progression", "PROBLEM", 45, 64], ["The corrected effect size", "PROBLEM", 78, 103], ["novel coronavirus disease pandemic", "PROBLEM", 205, 239], ["various risk factors", "PROBLEM", 286, 306], ["COVID", "TEST", 323, 328], ["related mortalities", "PROBLEM", 348, 367], ["Cardiovascular", "ANATOMY", 2, 16], ["disease", "OBSERVATION", 17, 24], ["size", "OBSERVATION_MODIFIER", 99, 103], ["coronavirus disease", "OBSERVATION", 211, 230]]], ["1 We read with great interest, the recent and very informative article by Zheng et al., 2 who performed a meta-analysis to identify various risk factors such as; demographical (male, age, current smoking), comorbidities (diabetes, hypertension, malignancy, respiratory disease and cardiovascular disease), and other laboratory variables for the progression of COVID-19.", [["respiratory", "ANATOMY", 257, 268], ["cardiovascular", "ANATOMY", 281, 295], ["diabetes", "DISEASE", 221, 229], ["hypertension", "DISEASE", 231, 243], ["malignancy", "DISEASE", 245, 255], ["respiratory disease", "DISEASE", 257, 276], ["cardiovascular disease", "DISEASE", 281, 303], ["cardiovascular", "ANATOMICAL_SYSTEM", 281, 295], ["comorbidities (diabetes", "PROBLEM", 206, 229], ["hypertension", "PROBLEM", 231, 243], ["malignancy", "PROBLEM", 245, 255], ["respiratory disease", "PROBLEM", 257, 276], ["cardiovascular disease)", "PROBLEM", 281, 304], ["other laboratory variables", "PROBLEM", 310, 336], ["COVID", "TEST", 360, 365], ["malignancy", "OBSERVATION", 245, 255], ["respiratory disease", "OBSERVATION", 257, 276], ["cardiovascular disease", "OBSERVATION", 281, 303]]]], "54229110e41fcb4ddc86dd46554afd9f3e54096c": [["The system's ability to prevent, detect, and respond to public health emergencies, as well as the ongoing public health challenges facing Canadians have been questioned.", [["Canadians", "ORGANISM", 138, 147]]], ["1,2 A federal/provincial/territorial assessment of public health system capacity reported in 2001 that the system had experienced a loss of resources resulting in widespread concern for the resiliency of the system infrastructure to respond consistently and proactively to the demands placed upon it.", [["a loss of resources", "PROBLEM", 130, 149]]], ["3 The recent experience with SARS has further intensified such concerns.", [["SARS", "DISEASE", 29, 33], ["SARS", "PROBLEM", 29, 33]]]], "7920337e4c64e0914a907b7f1fdcf1de8a813635": [["IntroductionThe 2019 novel coronavirus (2019-nCoV) outbreak is currently bringing challenges to China and the whole world.", [["coronavirus", "ORGANISM", 27, 38]]], ["First reported in December 2019, it has caused over 28 000 cases in around 2 months, among whom at least 3800 have severe illness and more than 550 deaths have been reported (data as of February 5, 2020) [1] .", [["deaths", "DISEASE", 148, 154], ["severe illness", "PROBLEM", 115, 129], ["severe", "OBSERVATION_MODIFIER", 115, 121], ["illness", "OBSERVATION", 122, 129]]], ["Since direct human transmission and asymptomatic infection have been revealed for 2019-nCoV [3] , health authorities in China are facing an enormous challenge on disease management and control.Introduction2019-nCoV is the third highly pathogenic coronavirus emerging in the 21st century, also one of the epidemics or pandemics since the millennium (Fig. 1) .", [["infection", "DISEASE", 49, 58], ["coronavirus", "DISEASE", 246, 257], ["human", "ORGANISM", 13, 18], ["Introduction2019-nCoV", "GENE_OR_GENE_PRODUCT", 193, 214], ["coronavirus", "ORGANISM", 246, 257], ["human", "SPECIES", 13, 18], ["human", "SPECIES", 13, 18], ["asymptomatic infection", "PROBLEM", 36, 58], ["disease management", "TREATMENT", 162, 180], ["the epidemics", "PROBLEM", 300, 313], ["pandemics", "PROBLEM", 317, 326], ["infection", "OBSERVATION", 49, 58], ["pathogenic", "OBSERVATION_MODIFIER", 235, 245], ["coronavirus", "OBSERVATION", 246, 257]]], ["Human coronavirus had been overlooked for a long time before the severe acute respiratory syndrome coronavirus (SARS-CoV) outbreak in 2002, leaving 8096 infections with a mortality rate of nearly 10% [4] .", [["Human coronavirus", "DISEASE", 0, 17], ["acute respiratory syndrome coronavirus", "DISEASE", 72, 110], ["SARS-CoV) outbreak", "DISEASE", 112, 130], ["infections", "DISEASE", 153, 163], ["Human", "ORGANISM", 0, 5], ["coronavirus", "ORGANISM", 6, 17], ["SARS-CoV", "ORGANISM", 112, 120], ["Human", "SPECIES", 0, 5], ["Human coronavirus", "SPECIES", 0, 17], ["severe acute respiratory syndrome coronavirus", "SPECIES", 65, 110], ["SARS-CoV", "SPECIES", 112, 120], ["Human coronavirus", "PROBLEM", 0, 17], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 61, 110], ["a mortality rate", "TEST", 169, 185], ["severe", "OBSERVATION_MODIFIER", 65, 71], ["acute", "OBSERVATION_MODIFIER", 72, 77], ["respiratory syndrome coronavirus", "OBSERVATION", 78, 110]]], ["Fortunately, public health measures, including isolation and quarantine, finally put an end to the SARS pandemic in summer 2003.", [["SARS", "DISEASE", 99, 103], ["public health measures", "TREATMENT", 13, 35], ["isolation", "TREATMENT", 47, 56], ["quarantine", "TREATMENT", 61, 71]]], ["In 2009, the influenza A/H1N1 swept over 200 countries and regions, leaving with more than 18 449 deaths [5] .", [["influenza", "DISEASE", 13, 22], ["deaths", "DISEASE", 98, 104], ["influenza A/H1N1", "ORGANISM", 13, 29]]], ["Subsequently, Middle East respiratory syndrome coronavirus (MERS-CoV), another coronavirus, has posed a continuous threat to global health since 2012.", [["Middle East respiratory syndrome coronavirus", "DISEASE", 14, 58], ["coronavirus", "DISEASE", 79, 90], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 14, 58], ["MERS-CoV", "ORGANISM", 60, 68], ["Middle East respiratory syndrome coronavirus", "SPECIES", 14, 58], ["MERS-CoV", "SPECIES", 60, 68], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 14, 58], ["another coronavirus", "PROBLEM", 71, 90], ["Middle", "ANATOMY_MODIFIER", 14, 20], ["respiratory syndrome", "OBSERVATION", 26, 46]]], ["Considered as a zoonotic virus, MERS-CoV infection is reported occasionally and sometimes in cluster, such as the outbreak in South Korea where one infected traveler back from the Middle East led to 186 infections and 36 deaths in 2015 [6] .", [["MERS-CoV infection", "DISEASE", 32, 50], ["infections", "DISEASE", 203, 213], ["deaths", "DISEASE", 221, 227], ["MERS-CoV", "ORGANISM", 32, 40], ["MERS-CoV", "SPECIES", 32, 40], ["a zoonotic virus", "PROBLEM", 14, 30], ["CoV infection", "PROBLEM", 37, 50], ["zoonotic", "OBSERVATION_MODIFIER", 16, 24], ["virus", "OBSERVATION", 25, 30], ["infection", "OBSERVATION", 41, 50], ["Middle", "ANATOMY_MODIFIER", 180, 186]]], ["By November 2019, MERS-CoV has infected 2494 individuals and caused 858 deaths [7] .", [["deaths", "DISEASE", 72, 78], ["MERS-CoV", "ORGANISM", 18, 26], ["MERS-CoV", "SPECIES", 18, 26]]], ["In addition, Ebola virus outbreak in 2014 and Zika virus outbreak in 2015 both contributed dramatic damage to the affected countries.IntroductionPublic responses to 2019-nCoV outbreak and previous experience Experience from previous epidemics has trained us to perform more positively in the incoming threat.", [["Ebola virus", "DISEASE", 13, 24], ["Ebola virus", "ORGANISM", 13, 24], ["Zika virus", "ORGANISM", 46, 56], ["Ebola virus", "SPECIES", 13, 24], ["Ebola virus", "SPECIES", 13, 24], ["Zika virus", "SPECIES", 46, 56], ["Ebola virus outbreak", "PROBLEM", 13, 33], ["Zika virus outbreak", "PROBLEM", 46, 65], ["Ebola virus", "OBSERVATION", 13, 24], ["dramatic", "OBSERVATION_MODIFIER", 91, 99], ["damage", "OBSERVATION", 100, 106]]], ["For example, the disastrous outbreak of SARS in 2003 promoted the reformation of Chinese Center for Disease Control and Prevention (CCDC), driving the establishment of a better disease surveillance network.", [["SARS", "DISEASE", 40, 44], ["SARS", "PROBLEM", 40, 44], ["Disease Control", "TREATMENT", 100, 115], ["disastrous", "OBSERVATION_MODIFIER", 17, 27]]], ["Realizing the severity of SARS-CoV as a respiratory virus, the detection of pneumonia of unknown origin in 2019-nCoV outbreak enabled relatively early alarm from health authorities and raised awareness for medical staff to equip personal protection methods when dealing with suspected cases.", [["SARS-CoV", "DISEASE", 26, 34], ["pneumonia", "DISEASE", 76, 85], ["SARS-CoV", "ORGANISM", 26, 34], ["SARS-CoV", "SPECIES", 26, 34], ["SARS", "PROBLEM", 26, 30], ["CoV", "PROBLEM", 31, 34], ["a respiratory virus", "PROBLEM", 38, 57], ["pneumonia", "PROBLEM", 76, 85], ["personal protection methods", "TREATMENT", 229, 256], ["respiratory virus", "OBSERVATION", 40, 57], ["pneumonia", "OBSERVATION", 76, 85]]], ["However, material reserve (i.e., gloves, protective suits) for health worker is far from enough with the outbreak evolving, indicating the insufficiency of financial support and emergency practice.IntroductionThe rapid progress in science nowadays has also prepared us for the recent 2019-nCoV outbreak.", [["financial support", "TREATMENT", 156, 173], ["emergency practice", "TREATMENT", 178, 196], ["rapid", "OBSERVATION_MODIFIER", 213, 218]]], ["First, modern biological techniques developed in the last decade have greatly promoted the speed of pathogen detection.", [["pathogen detection", "TEST", 100, 118]]], ["The whole-genome sequencing and isolation of 2019-nCoV strains were accomplished in early January 2020, within two weeks from identifying the outbreak.", [["The whole-genome sequencing", "TREATMENT", 0, 27], ["isolation of 2019-nCoV strains", "TREATMENT", 32, 62]]], ["Second, the more advanced hospital facilities in China, including advanced life support devices (i.e., extracorporeal membrane oxygenation), have improved our ability to manage severe cases, although the equipment is still in shortage in the central disease area.IntroductionThe outbreaks of SARS and MERS informed us about the possibility of highly pathogenic coronavirus, but there are still many unanswered questions.", [["extracorporeal membrane", "ANATOMY", 103, 126], ["SARS", "DISEASE", 292, 296], ["coronavirus", "DISEASE", 361, 372], ["extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 103, 126], ["central disease area", "CANCER", 242, 262], ["coronavirus", "ORGANISM", 361, 372], ["advanced life support devices", "TREATMENT", 66, 95], ["extracorporeal membrane oxygenation", "TREATMENT", 103, 138], ["severe cases", "PROBLEM", 177, 189], ["the central disease area", "PROBLEM", 238, 262], ["highly pathogenic coronavirus", "PROBLEM", 343, 372], ["central", "ANATOMY_MODIFIER", 242, 249], ["disease", "OBSERVATION", 250, 257], ["coronavirus", "OBSERVATION", 361, 372]]], ["Although basic research has generated several promising candidates [9, 10] , we are still not armed with vaccines or specific antiviral drugs against coronaviruses 17 years after SARS and 7 years after MERS outbreak.", [["coronaviruses", "DISEASE", 150, 163], ["SARS", "DISEASE", 179, 183], ["coronaviruses", "ORGANISM", 150, 163], ["vaccines", "TREATMENT", 105, 113], ["specific antiviral drugs", "TREATMENT", 117, 141], ["coronaviruses", "PROBLEM", 150, 163], ["MERS outbreak", "PROBLEM", 202, 215]]], ["The novel coronavirus indeed hit this weakness.", [["coronavirus", "ORGANISM", 10, 21], ["The novel coronavirus", "PROBLEM", 0, 21], ["this weakness", "PROBLEM", 33, 46], ["coronavirus", "OBSERVATION", 10, 21]]], ["As of January 31, the number of confirmed cases for 2019-nCoV has surpassed that of SARS-CoV and the number is still climbing.IntroductionBesides lack of specific antiviral treatments and deficiency in the understanding of novel virus, many other factors have also contributed to the wider transmission of 2019-nCoV, such as increased population density coming with the increased urbanization, easier longdistance travel resulting from improved public transportation, as well as the surge of travelers during the Spring Festival travel rush.", [["SARS", "DISEASE", 84, 88], ["SARS-CoV", "ORGANISM", 84, 92], ["SARS-CoV", "SPECIES", 84, 92], ["IntroductionBesides", "TREATMENT", 126, 145], ["specific antiviral treatments", "TREATMENT", 154, 183], ["deficiency", "PROBLEM", 188, 198], ["novel virus", "PROBLEM", 223, 234], ["increased population density", "PROBLEM", 325, 353], ["the increased urbanization", "PROBLEM", 366, 392], ["antiviral treatments", "OBSERVATION", 163, 183], ["increased", "OBSERVATION_MODIFIER", 325, 334], ["population", "OBSERVATION_MODIFIER", 335, 345], ["density", "OBSERVATION", 346, 353], ["increased", "OBSERVATION_MODIFIER", 370, 379], ["urbanization", "OBSERVATION_MODIFIER", 380, 392]]], ["For example, the more advanced personal terminal equipment such as smartphones facilitates information sharing and real-time epidemic update for disease control.", [["disease control", "TREATMENT", 145, 160]]], ["In addition, onlineordered service including take-out food, online shopping, and fresh product delivery make self-isolation in urban areas relatively possible.IntroductionWe are glad to see that multiple public health measures were taken to prevent the disease transmission.", [["fresh product delivery", "TREATMENT", 81, 103], ["multiple public health measures", "TREATMENT", 195, 226], ["the disease transmission", "PROBLEM", 249, 273], ["disease", "OBSERVATION", 253, 260]]], ["2019-nCoV was identified as Category B infectious disease and managed as Class A on January 20 according to the Law of the People's Republic of China on Prevention and Treatment of Infectious Diseases.", [["infectious disease", "DISEASE", 39, 57], ["Infectious Diseases", "DISEASE", 181, 200], ["People", "SPECIES", 123, 129], ["Prevention", "TREATMENT", 153, 163], ["Infectious Diseases", "PROBLEM", 181, 200], ["infectious", "OBSERVATION", 39, 49], ["Infectious", "OBSERVATION", 181, 191]]], ["At the same time, Chinese community-based governments also adapt receptive measures to propagate the threat brought by 2019-nCoV and recommend personal hygiene in the communities.", [["receptive measures", "TREATMENT", 65, 83]]], ["With the popularity of smartphones, these propagations arrive at almost every family to partially slow down the spread of the disease.", [["the disease", "PROBLEM", 122, 133], ["disease", "OBSERVATION", 126, 133]]], ["As of February 3, a total of 47.0 billion RMB has been applied to disease control and prevention [11] .Preliminary findings in clinical and scientific features of 2019-nCoVThe authorities as well as the scientific community in China have been working diligently to battle against the outbreak.", [["billion RMB", "TREATMENT", 34, 45], ["disease control", "TREATMENT", 66, 81]]], ["After the local authority was informed of the cluster of pneumonia of unknown origin associated with Huanan Seafood Market on December 31, 2019, an expert team of clinicians, epidemiologists, scientists, and officials was dispatched to Wuhan, and suspected cases were soon transferred to a designated hospital (Jinyintan Hospital).", [["pneumonia", "DISEASE", 57, 66], ["pneumonia", "PROBLEM", 57, 66], ["pneumonia", "OBSERVATION", 57, 66]]], ["Several groups have independently isolated a novel pathogen from the lower respiratory tract of the patients in early January 2020.", [["lower respiratory tract", "ANATOMY", 69, 92], ["lower", "ORGANISM_SUBDIVISION", 69, 74], ["respiratory tract", "ORGANISM_SUBDIVISION", 75, 92], ["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108], ["a novel pathogen", "PROBLEM", 43, 59], ["lower", "ANATOMY_MODIFIER", 69, 74], ["respiratory tract", "ANATOMY", 75, 92]]], ["Zhu et al. identified the pathogen as a novel coronavirus (2019-nCoV) by unbiased sequencing and obtained the transmission electron microscopy image [12] .", [["coronavirus", "ORGANISM", 46, 57], ["coronavirus", "SPECIES", 46, 57], ["the pathogen", "PROBLEM", 22, 34], ["a novel coronavirus", "PROBLEM", 38, 57], ["unbiased sequencing", "TEST", 73, 92], ["the transmission electron microscopy image", "TEST", 106, 148], ["pathogen", "OBSERVATION", 26, 34]]], ["This finding was supported by data from other groups and genomic studies showed that 2019-nCoV was closest to a SARS-like coronavirus in bats, and that the receptorbinding domain (RBD) was close to that of SARS-CoV, suggesting ACE2 as the possible receptor [13] [14] [15] [16] .", [["SARS", "DISEASE", 112, 116], ["SARS", "DISEASE", 206, 210], ["2019-nCoV", "GENE_OR_GENE_PRODUCT", 85, 94], ["SARS-like coronavirus", "ORGANISM", 112, 133], ["bats", "ORGANISM", 137, 141], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 206, 214], ["ACE2", "GENE_OR_GENE_PRODUCT", 227, 231], ["[13] [14] [15] [16]", "SIMPLE_CHEMICAL", 257, 276], ["2019-nCoV", "DNA", 85, 94], ["receptorbinding domain", "PROTEIN", 156, 178], ["RBD", "PROTEIN", 180, 183], ["ACE2", "PROTEIN", 227, 231], ["SARS-CoV", "SPECIES", 206, 214], ["genomic studies", "TEST", 57, 72], ["a SARS", "PROBLEM", 110, 116], ["coronavirus", "PROBLEM", 122, 133], ["the receptorbinding domain (RBD", "PROBLEM", 152, 183], ["SARS", "PROBLEM", 206, 210], ["ACE2", "TEST", 227, 231]]], ["However, more studies are needed to fulfill Koch's postulate for 2019-nCoV and identify its cellular receptor.", [["cellular", "ANATOMY", 92, 100], ["cellular", "CELL", 92, 100], ["cellular receptor", "PROTEIN", 92, 109]]], ["Hunting for the animal source of 2019-nCoV is also under way.Preliminary findings in clinical and scientific features of 2019-nCoVApart from the basic science findings, clinicians have worked efficiently to provide first-hand experience with 2019-nCoV patients.", [["patients", "ORGANISM", 252, 260], ["patients", "SPECIES", 252, 260]]], ["Chan et al. reported a case of a family cluster of 2019-nCoV infection, five of whom had travel history to Wuhan but one did not, providing the first evidence that 2019-nCoV was able to transmit from person-to-person [3] .", [["infection", "DISEASE", 61, 70], ["person", "SPECIES", 200, 206], ["person", "SPECIES", 210, 216], ["nCoV infection", "PROBLEM", 56, 70], ["infection", "OBSERVATION", 61, 70]]], ["An epidemiology study conducted by Li et al. also confirmed cluster cases indicating early human transmission [17] .", [["human", "ORGANISM", 91, 96], ["human", "SPECIES", 91, 96], ["human", "SPECIES", 91, 96], ["An epidemiology study", "TEST", 0, 21]]], ["Huang et al. gathered clinical features of the first cohort of 41 laboratory-confirmed cases and found that fever, dry cough, and dyspnea were common symptoms for the new disease [18] .", [["fever", "DISEASE", 108, 113], ["dry cough", "DISEASE", 115, 124], ["dyspnea", "DISEASE", 130, 137], ["fever", "PROBLEM", 108, 113], ["dry cough", "PROBLEM", 115, 124], ["dyspnea", "PROBLEM", 130, 137], ["common symptoms", "PROBLEM", 143, 158], ["the new disease", "PROBLEM", 163, 178], ["fever", "OBSERVATION", 108, 113]]], ["Chen et al. extended the description by gathering another 99 cases and adding details on combined bacterial and fungal coinfections [19] .", [["bacterial and fungal coinfections", "DISEASE", 98, 131], ["combined bacterial and fungal coinfections", "PROBLEM", 89, 131], ["fungal coinfections", "OBSERVATION", 112, 131]]], ["Experience from the front line helped to form a national guideline for the management of the novel coronavirus induced pneumonia patients (now fifth edition) [20] .", [["coronavirus", "DISEASE", 99, 110], ["pneumonia", "DISEASE", 119, 128], ["coronavirus", "ORGANISM", 99, 110], ["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137], ["a national guideline", "TREATMENT", 46, 66], ["the management", "TREATMENT", 71, 85], ["the novel coronavirus induced pneumonia", "PROBLEM", 89, 128], ["pneumonia", "OBSERVATION", 119, 128]]], ["We are expecting good news from Chinese physicians and scientists.ConclusionsIn this era of We Media nowadays, there are more challenges than ever in preventing and controlling infectious diseases.", [["infectious diseases", "DISEASE", 177, 196], ["controlling infectious diseases", "PROBLEM", 165, 196], ["infectious", "OBSERVATION", 177, 187]]], ["There will be less fear when armed with knowledge.ConclusionsThe 2019-nCoV outbreak is an examination for the whole world, and for everyone.", [["an examination", "TEST", 87, 101]]], ["We have accomplished many, and more efforts are needed to better understand the novel virus, with various questions on its source, animal reservoirs, transmission and evolution pattern, pathogenesis, as well as appropriate treatment.Conclusions2019-nCoV is only a quiz but not the final examination, with novel threats around the corner.", [["the novel virus", "PROBLEM", 76, 91], ["pathogenesis", "PROBLEM", 186, 198], ["appropriate treatment", "TREATMENT", 211, 232], ["the final examination", "TEST", 277, 298]]], ["Therefore, a continuous and strengthened emphasis should be put on potential pathogens, such as coronaviruses, that might infect humans and cause epidemic.", [["coronaviruses", "ORGANISM", 96, 109], ["humans", "ORGANISM", 129, 135], ["humans", "SPECIES", 129, 135], ["humans", "SPECIES", 129, 135], ["a continuous and strengthened emphasis", "TREATMENT", 11, 49], ["potential pathogens", "PROBLEM", 67, 86], ["coronaviruses", "PROBLEM", 96, 109], ["epidemic", "PROBLEM", 146, 154]]], ["Financial support, research work, and personal awareness of crisis are not supposed to wane with the departure of a sudden or \"temporary\" threat.", [["crisis", "PROBLEM", 60, 66]]], ["This manuscript is a commentary and does not involve a research protocol requiring approval by the relevant institutional review board or ethics committee.", [["a research protocol", "TREATMENT", 53, 72]]]], "ecba0fc4595e78df6315ca15b0f75c1d10c6202a": []}